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Carbon nanotubes (CNTs) have emerged as promising drug delivery systems due to 
their external functionalizable surface (useful for selective targeting) and their 
hollowed cavity that can encapsulate bioactive molecules inside CNTs and protect 
them from external deactivating agents. 
In this study, we firstly encapsulated cisplatin (CDDP), a FDA-approved 
chemotherapeutic drug, into multi-walled carbon nanotubes (MWCNTs) and further 
sealed their ends to achieve a “carbon nanotube bottle” structure. Cisplatin was 
incorporated into MWCNTs via nano-extraction and/or nano-condensation methods 
to obtain a MWCNT-CDDP complex, and the open ends of MWCNTs were 
subsequently capped with functionalized gold nanoparticles (AuNPs) on the basis of 
physical interaction. High loading of cisplatin was achieved in both uncapped and 
capped MWCNT-CDDP nano-bottles. In comparison with uncapped MWCNT-
CDDP, capped nano-bottles had a prolonged release. In cell viability assay, the IC50 
of capped MWCNT-CDDP (7.74 µM) showed a remarkable improvement in 
comparison to cisplatin alone (11.74 µM) and uncapped CNTs (12.92 µM). 
In addition, an alternative “nano-bottle” strategy was proposed by utilising chemical 
bonds to attach AuNPs to the functional groups at the open ends of MWCNTs, 
instead of merely physical interaction. AuNPs were able to stay at the ends under 
physiological conditions to prevent the release of cisplatin, while the disulfide linkage 
between AuNP and MWCNT was susceptible to reducing agents (1 mM 
dithiothreitol), thus leading to selective release of entrapped cisplatin in cancer cells, 
where are the reductive environment. To assess their selective cytotoxicity against 
 xii 
 
tumor cells, HCT-116 tumor cells and IMR-90 normal cells were treated with the 
disulfide “nano-bottles”; LDH assay suggested that the capped disulfide “nano-bottles” 
exerted stronger cytotoxic effect on HCT-116 than IMR-90 especially at high 
concentrations. Therefore the cleavable “nano-bottles” could attain selective release 
of payload in tumor cells while avoid harmful effects in normal cells. 
An inert and highly hydrophobic platinum(IV) complex was also entrapped within 
MWCNTs. Pt(IV) complex could be stably trapped within MWCNTs without leakage 
in PBS; conversely, upon chemical reduction by ascorbic acid, Pt(IV) complex was 
converted to its cytotoxic and hydrophilic Pt(II) form and released from the carrier, 
via a drastic reversal in hydrophobicity. The analysis of platinum content in A2780 
cells after 8 hours exposure showed that significant platinum levels were detected in 
cells treated with MWCNT–Pt(IV)entrap, in a dose-dependent manner. 
To explore the impact of CNTs on distribution of cisplatin and Pt(IV) complex in vivo, 
cisplatin and Pt(IV) complex were entrapped within various MWCNTs (i.e. pristine, 
carboxylated, amidated), and then injected intravenously into mice. The results 
showed that the distribution of elemental platinum in organs remarkably altered when 
they were delivered through MWCNTs, and the extent of accumulation was 
correlated with functionalities onto MWCNTs. Moreover, there were no additional 
immune or histopathological responses in mice after the treatment with MWCNT-
drug complexes. 
Overall, this study provides a proof-of-concept on MWCNTs capable of entrapping 
platinum-based derivatives with high drug loading, and selectively releasing them 
under pathological conditions. Furthermore, MWCNT-assisted delivery could have an 
impact on tissue distribution, thus probably exerting an improved pharmacological 
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1.1 Nanotechnology and nanomaterials 
1.1.1 Overview of nanotechnology 
Much research in recent years has been focusing on nanotechnology, as distinct and 
excellent performances were found in materials [1, 2] or devices [3-5] with 
dimensions at the nanoscale. Nanotechnology is attracting widespread interest in 
fields such as consumer goods [6], energy [7], environment [8], heavy industry [9], 
information and communication [10, 11], etc. The utilisation of nanofibers in textiles 
could make clothes stain-repellent or wrinkle-free [12], as well as the infusion of 
nanotechnological finish in trousers and socks will extend their life-span and keep 
comfortable temperature for the wearers [13]. Another example is the addition of 
titanium oxide (TiO2) nanoparticles in sunscreen, which achieves long-term stability 
in comparison with traditional chemical ultraviolet (UV) protection approach [14]. 
The application of nanotechnology in sports leads to innovation of products, e.g., 
reinforced tennis balls and golf balls to be more durable [15], lighter athletic shoes to 
promote the performance of athletes, as well as antimicrobial textiles to prevent from 
illness [16, 17]. Nanotechnology, moreover, is closely related to energy saving; for 
example, a strong reduction of energy consumption for illumination could be reached 
by the use of light-emitting diodes (LEDs) [18] or quantum caged atoms (QCAs) [19]. 
On the aspect of environment, nanoporous membranes are applicable for 
nanofiltration or ultrafiltration to purify water [20] or separate fluids [21], and 
magnetic nanoparticles are used for waste-water treatment with high efficiency to 
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remove heavy metal contaminants [22] or toxic substances [23]. In the development 
of heavy industry, lighter nanomaterials with higher strength and durability [24, 25] 
are of extensive use in manufacturing, TiO2 nanoparticles are introduced in the glass 
industry and coating techniques to break down organic pollutants [26] and bacterial 
membranes [27, 28], and moreover, nanotechnology and nanomaterials used by the 
construction industry produce high-performance building materials comprising 
nanoscale admixtures to settle fatigue issues (e.g., the use of nanoparticles in cement 
composites to enhance mechanical strength and durability) [9, 29]. Apart from that, 
the development of nanoscale integrated circuits [30] and electronic devices [31, 32] 
in the field of information and communication plays a key role in the fabrication of 
high-speed central processing units (CPUs) and larger-capacity memory storage 
systems while reducing their costs [33]. 
 
1.1.2 Nanotechnology in medicine 
The field of medicine also takes advantage of nanotechnology to develop new 
diagnostic and therapeutic techniques (e.g., contrast agents, analytical tools, physical 
therapy applications and drug delivery systems) [34-37], offering some exciting 
possibilities. The nanoscale medical agents or devices are less invasive and can be 
implanted inside the body with improved patient compliance; moreover, their unique 
physicochemical or biomedical properties enable better instrumental detection or 
biological analysis by allowing them to target diseased sites [38-40]. Biomedical 
nanotechnology has exploited the outstanding properties of nanomaterials for a wide 
range of applications; for example, nanomaterials are suitable for both in vivo and in 
vitro biomedical research [41-43], since the size of nanomaterials is similar to that of 
most biological molecules and structures. 
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One of their most common applications in nanomedicine is represented by the 
antimicrobial nanomaterials for the treatment of wounds [44, 45]. Bandages are 
infused with silver nanoparticles to heal cuts faster [46]. A nanoparticle cream 
containing nitric oxide gas, which is able to spoil bacteria, could significantly reduce 
the infection by releasing nitric oxide gas at the site of staph abscesses [47, 48]. Burn 
dressing coated with antibiotics nanocapsules released the encapsulated antibiotics 
once an infection occurred in the wound [49], allowing much quicker cure for 
infection and reduced frequency of changing dressing. 
Nanomedicine also seeks to develop diagnostic and imaging techniques for quick 
identification of diseases and accurate location of cancer tumors. On the basis of 
proteins and other biomarkers that are left behind by cancer cells, sensor test chips 
containing thousands of nanowires are designed for the detection and diagnosis of 
cancer in the early stages from a few drops of a patient’s blood [50, 51]. Gold 
nanoparticles (AuNPs) linked with antibodies can provide quick diagnosis of 
influenza virus [52]; furthermore, AuNPs tagged with short segments of DNA, can be 
used for detection of genetic sequences in biological samples [53, 54]. Iron oxide 
nanoparticles, coated with peptides that bind to cancer tumors, could provide better 
images of cancer tumors detected by magnetic resonance imaging (MRI) techniques, 
since the magnetic property of iron oxide enhances the imaging quality of the MRI 
scan [55]. Quantum dots can also produce higher contrast MRI images for locating 
cancer tumors in patients; in addition, surgeons can see the glowing tumor under UV 
light following the infusion of quantum dots into tumor sites, thus improving the 
accuracy of tumor excision [56, 57]. 
Some new therapeutic techniques currently also involve applications of nanomaterials 
to block the spreading pathway of pathogenesis at the diseased sites or heat the tumor 
area via external irradiation. In the treatment of allergic reactions, fullerenes or 
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buckyballs (an isoform of carbon with diameter of about 1 nm) have shown the ability 
to trap free radicals and block the inflammation [58]. In photodynamic therapy, 
nanoshells coated with gold can be heated sufficiently to destroy cancer cells by 
irradiating the area of the tumor with an infrared light [59, 60]; the nanoshells can 
also target cancer cells by conjugating antibodies or peptides, thus circumventing 
healthy tissues or organs without heating them [61]. 
In addition, tissue engineering, which makes use of artificially stimulated cell 
proliferation caused by suitable nanomaterial-based scaffolds and growth factors, is 
another field where nanomedicine can help to reproduce or repair damaged tissue [62, 
63]. 
 
1.1.3 Nanotechnology in drug delivery 
The application of nanoscale drug delivery systems is currently playing a crucial role 
in the development of nanomedicine, as the small size of nano-carriers endows them 
with properties that can be very useful for the treatment of several diseases, especially 
cancer cure. In view of the fact that tumor vessels are poorly-aligned defective 
endothelial cells with wide fenestrations, as well as tumor tissues lack an effective 
lymphatic drainage system, the enhanced permeability and retention (EPR) effect [64, 
65] allows certain sizes of molecules (typically in nano-dimensions, including 
liposomes, nanoparticles, and macromolecular drugs) to preferentially accumulate at 
the tumor sites compared with the chance to locate in normal tissues [66-68]. 
Nevertheless, one main concern in drug delivery is the bioavailability, i.e. the 
measure of the rate and extent to which a drug reaches the systemic circulation. 
Nanotechnology is able to improve drug bioavailability by using nanoscale vehicles 
to prolong circulation time of drug in the body. Nano-carriers (liposome, micelle, 
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nanoparticle, etc.) can be strategically designed to avoid the body’s defense 
mechanisms and alter the pharmacokinetics and biodistribution of drugs [69-72]. 
Thus far, much research has focused on the conjugation of nanoparticles with 
polyethylene glycol (PEG) molecules to deliver therapeutic drugs [73]; it is generally 
accepted that PEG molecules can prevent white blood cells from recognizing the 
nanoparticles as foreign materials, allowing them to circulate over a long period of 
time in the bloodstream to reach the disease sites in high concentration [74]. 
In addition, poor biodistribution of drugs can affect normal tissues, therefore much 
effort has been made in the field of nanotechnology to enhance drug accumulation at 
specific places in the body, thus helping to lower the volume of distribution and 
reduce any unwanted effect at nontarget tissues. For example, drug with poor 
solubility could been capsulated in nanoparticles, which are composed of amphiphilic 
molecules, to improve the solubility; delivery through nanoparticles can also regulate 
drug release so as to relieve non-target tissue damage; in regard to the problem of 
quick clearance from the body, nanoparticles are also used to alter the 
pharmacokinetics of drugs, instead of using high doses for patients [75-77]. 
Another advantage of nano-carriers for drug delivery involves their high surface area 
to volume ratio, which allows the attachment of many functional groups or 
antibodies/peptides to their surface, thus helping to actively target the receptor 
molecules and deliver drugs with high precision inside the cells of interest [78, 79]. It 
has been reported that the attachment of epidermal growth factor receptor (EGFR) 
targeted Cetuximab to nanoparticles, which were loaded with hydrophobic paclitaxel, 
could lead to much better therapeutic effects against tumors with radiation and, most 
importantly, the healthy tissue suffered less toxicity than in the case of nontargeted 
therapy [80]. 
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The nanotechnology of drug delivery presents numerous merits that could lead 
renovation of conventional drugs with more useful properties and lower side effects. 
However, several limitations still hamper the current research, including low 
encapsulation efficiency of drugs, intrinsic toxicity of nanomaterials, low stability and 
degradability [81-84], etc. Nowadays, there is a lot of effort underway to develop 
novel nano-carriers with more advantages for drug delivery by using a variety of 
nanomaterials. 
Indeed, the use of chemotherapeutic drugs in cancer therapy is often compromised by 
their systemic toxicity caused by problems with administration, such as limited 
solubility, poor biodistribution, lack of selectivity, and inability of drugs to cross 
cellular barriers [85]. Therefore, the development of suitable vehicles, which are 
capable of carrying drugs into cells or diseased sites, is required to improve the 
cellular penetration of many small molecules and macromolecules including proteins 
and nucleic acids [86], as well as avoid or lessen the harmful side effects. Towards 
that purpose, the interest of this thesis is focused on the use of a particular type of 
nanomaterial, namely carbon nanotubes (CNTs), as a vehicle for drug delivery, based 
on the great progress of research on carbon nanotubes in the fields of chemistry and 
biology. 
 
1.2 Carbon nanotubes 
1.2.1 Background and general applications of carbon nanotubes 
Carbon nanotubes have received considerable attention since their first evidence in 
the 1950s and especially after Iijima discovered them in the carbon soot of graphite 
electrodes during an arc discharge in 1991 [87]. CNTs are well-ordered allotropes of 
carbon with a cylindrical nano-structure, having an extremely large length-to-
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diameter ratio. There are many variables in the structure of CNTs, including diameter, 
length, chirality and layers. Typically, CNTs are classified as single-walled carbon 
nanotubes (SWCNTs) and multi-walled carbon nanotubes (MWCNTs) in light of 
layer construct (Fig. 1.1). SWCNTs have diameters close to 1 nm, and they can be 
thought of as wrapping a one-atom-thick layer of graphene sheet into a seamless 
cylinder; conversely, MWCNTs have dimensions ranging from 1 nm up to 50 nm, 
which can be conceptualized by rolling up many layers of graphene sheets [88-91]. 
 
Fig. 1.1 Schematic illustration of (a) single-walled carbon nanotube, and (b) multi-
walled carbon nanotube. 
 
These CNTs have prominent properties, for example, extraordinary mechanical 
properties (high stiffness, strength and tenacity) [92] and thermal conductivity [93], 
plus their electrical conductivity renders them interesting materials as either metals or 
semiconductors [94, 95]. These properties have attracted much attention to the 
application of CNTs in electronics [96-98], energy storage [99-102], information 
technology and communications [103, 104], materials science and technology [105-
110], etc. 
Besides, a large amount of effort has been focused on the development of CNTs in 
the biomedical field to use them as scaffolds for tissue engineering, due to their 
strength and biocompatibility. For instance, it has been found that bones can be 
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regrown efficiently on carbon nanotube scaffolds, which offer the additional 
advantage of providing strong mechanical support [111, 112]. Porous ultra-short 
MWCNTs reinforced polymer nanocomposite scaffolds exhibited favorable hard and 
soft tissue responses, with much greater bone tissue ingrowth in comparison with 
polymer scaffolds alone [113]. The film of PEGylated MWCNTs was used as 
scaffolds to accelerate the differentiation of human mesenchymal stem cells into 
osteoblasts by providing a more viable microenvironment [114]. Furthermore, the 
research on CNTs biosensors for proteins or DNA detection, on the basis of their 
electrochemical properties, is paving the way for lab-on-a-chip systems. For example, 
a non-enzymatic CNTs sensor, which was functionalized with boronic acid receptors 
integrated in a microfluidic channel, showed high sensitivity to glucose [115]; a label-
free DNA sensor based on CNTs, on which both redox and DNA probes were grafted, 
was able to discriminate a single mismatched DNA sequence from the 
complementary one [116]; a design of DNA-functionalized SWCNT-Au sensor was 
ultrasensitive to DNA detection [117]. 
 
1.2.2 Carbon nanotubes in drug delivery 
The unique properties of CNTs, such as ultrahigh surface area, needle-like structure, 
intrinsic stability, etc., have triggered much interest for their applications in 
nanomedicine as novel carrier for drug delivery [118]. These properties impart some 
features in favor of transporting drugs; for example, large surface area brings about 
the potential to carry multiple moieties at high density, high aspect ratio gives rise to 
superior flow dynamics compared with spherical nanoparticles, as well as an 
enhanced capacity to penetrate cell plasma membranes through nano-penetration [119] 
or clathrin-dependent endocytosis [120]. Nano-penetration is an energy-independent 
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passive process, which is similar to passive diffusion of nano-needles from 
extracellular to intracellular space. This process enables CNTs to behave similarly to 
cell penetrating peptides, facilitating the diffusion across the cellular membrane [121]. 
On the other hand, most studies have suggested endocytic internalizations of CNTs 
via clathrin-dependent endocytosis through the formation of clathrin-coated pits on 
the cell membrane [122-124]. Hong et al. presented the first 3D tracking of individual 
SWCNTs, and revealed the nanotube entry pathway to be clathrin-dependent 
endocytosis [125], which was activated with the formation of a vesicle wrapping 
around the surfactant-coated nanotube via clathrin-associated invagination of the 
plasma membrane, followed by vesicle pinching-off and clathrin uncoating to 
undergo the endocytic pathway [126]. Besides, it is worth noting that CNTs, capable 
of linking specific peptides or ligands at their surface to recognize receptors on the 
cell surface, could carry therapeutic drugs more safely and effectively into the cells 
[127]. 
So far, a great number of studies have reported the novel CNT-based nano-carrier, 
generally comprising three parts (namely, functionalized CNTs, targeting ligands, and 
therapeutic agents), for the delivery of various drugs, such as anticancer, antibacterial 
or antiviral agents. For example, Feazell et al. designed a “longboat delivery system”, 
in which SWCNTs were first wrapped with macromolecules consisting of 
phospholipid and PEG through noncovalent adsorption to solubilize the SWCNTs 
and then Pt(IV) complex c,c,t-[Pt(NH3)2Cl2(OEt)(O2CCH2CH2CO2H)] was tethered to 
the surface of soluble SWCNTs [128]. The SWCNT-tethered Pt(IV) complex 
displayed a significantly enhanced cytotoxicity profile in comparison to the fact the 
free Pt(IV) complex is nearly nontoxic to testicular cancer cells. Fluorescence 
microscopy images suggested that the delivery of soluble SWCNT-Pt(IV) complex 
increased the cellular uptake through endocytosis, providing 6-fold higher 
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intracellular concentration of platinum molecule than that obtained following 
exposure to the untethered Pt(IV) complex, as confirmed by atomic absorption 
spectroscopy (AAS). Wu et al. found that the antibiotic amphotericin B linked to 
MWCNTs via covalent binding was efficiently taken up by mammalian cells without 
toxic effects in comparison with the antibiotic drug incubated alone [129]. Moreover, 
the conjugation with nanotubes preserved high antifungal activity of amphotericin B 
against a broad range of pathogens, including Candida albicans, Cryptococcus 
neoformans and Candida parapsilosis. 
The current research on CNT-based drug delivery has established a variety of loading 
strategies, mainly including (a) chemical binding to external surface, (b) π-π stacking 
on both internal and external surface, (c) encapsulation into inner cavity, etc., based 
on the physicochemical properties of nanotubes. Herein we present these main 
strategies of drug loading and the effects of CNT-based carriers on therapeutic agents 
in the studies of drug delivery. 
 
1.2.2.1 CNT-based drug delivery system through chemistry attachment 
The functionalization of CNTs by means of several strategies enables the attachment 
of many molecules to the nanotubes. The chemotherapeutic agents are covalently 
attached to functionalized water-soluble CNTs to produce a cell-penetrating 
conjugate, which offers a solution to a few problems, including limited solubility, 
poor distribution, inability to cross cellular barriers, etc. 
A large amount of therapeutic agents and biomolecules have been covalently attached 
to nanotubes in the studies of CNTs as drug carrier. The attachment of streptavidin 
(SA), a protein with clinical applications in anticancer therapies, to SWCNTs was 
described by Kamet al. in 2004, showing that nanotubes were able to transport 
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macromolecules SA (MW ≈ 60 kD) into human promyelocytic leukemia (HL60) cells, 
in contrast with the inability of SA to transverse the cell membrane alone, as 
confirmed by confocal microscopy and flow cytometry [130]. The SWCNT-SA 
conjugate was found to cause extensive cell death of HL60, while no toxicity was 
observed after cells were incubated even in highly concentrated solutions of SA. In 
addition, the SWCNTs themselves exhibited little toxicity to HL60 cells, suggesting 
SWCNTs could act as a safe vehicle to carry SA into cells with high efficiency. 
A controlled drug delivery system was developed based on SWCNTs coated with 
doxorubicin (DOX) through hydrazone bond, which is sensitive to mildly acidic 
tumor microenvironments [131]. The SWCNT-DOX conjugate showed a dramatic 
pH-responsive drug release behavior and was stable at physiological conditions. MTT 
assay and confocal microscope observations revealed that the cellular uptake of DOX 
by human hepatocellular carcinoma cells (HepG2) was efficiently increased by 
attachment to SWCNTs, and DOX was released intracellularly, thus significantly 
improving its cytotoxicity against HepG2 cells. 
Moreover, hydrophilic polymers are used as spacer, which combines drug molecules 
with nanotubes, to increase the biocompatibility and water-solubility of conjugates. 
Paclitaxel (PTX), a widely used anticancer chemotherapy drug with poor aqueous 
solubility, has been covalently linked to polymer-functionalized CNTs via ester 
linkage [132, 133]. Sobhani et al. functionalized MWCNTs with hyperbranched poly 
citric acid (PCA) to improve their hydrophilicity, and then paclitaxel was tethered to 
the carboxyl functional groups of PCA to obtain a MWCNT-PCA-PTX conjugate 
[132]. Paclitaxel showed a faster release from the MWNT-PCA-PTX conjugate at pH 
6.8 and 5.0 than at pH 7.4, suggesting the favorable drug release in tumor tissues and 
tumor cells. In vitro cytotoxicity assays demonstrated that MWCNT-PCA without 
paclitaxel had an insignificant cytotoxic effect on the A549 lung cancer cells and 
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SKOV3 ovary cancer cells; moreover, MWCNT-PCA-PTX exhibited a higher 
cytotoxic effect on both cell lines in comparison to the free paclitaxel, likely owing to 
increased cell penetration. Liu et al. synthesized a water-soluble SWCNT-PEG-PTX 
conjugate, which was connected using branched polyethylene glycol chains as the 
spacer between nanotube and paclitaxel [133]. SWCNT-PEG-PTX conjugate 
afforded markedly improved efficacy in suppressing tumor growth than clinical Taxol 
in a murine 4T1 breast cancer model, which was confirmed by tumor staining that 
revealed significant apoptotic cells and few proliferation active cells in the SWCNT-
PEG-PTX-treated tumor. The higher tumor suppression efficacy is associated with a 
10-fold higher tumor paclitaxel uptake by SWCNT delivery that results from 
prolonged blood circulation and EPR effects. A water-soluble MWCNT-based drug 
delivery system was developed by covalently combining nanotubes with the 
antitumor agent 10-hydroxycamptothecin (HCPT) using hydrophilic 
diaminotriethylene glycol as the spacer between nanotubes and drug moieties [134]. 
MWCNT-HCPT conjugate exhibited significantly improved cytotoxicity against 
human gastric carcinoma MKN-28 cells with respect to HCPT injection at equal 
HCPT concentrations, which may be associated with the enhanced cellular uptake of 
the drug by conjugation to nanotubes, as revealed by the confocal microscopy. The in 
vivo tumor inhibition experiments confirmed the superior antitumor effect of the 
conjugate in comparison to clinical HCPT formulation and low toxicity towards 
healthy mice. In vivo single photon emission computed tomography (SPECT) 
imaging and ex vivo gamma scintillation counting analyses suggested that the 
superior antitumor effect of the MWCNT-HCPT conjugate is due to the enhanced 
cellular uptake efficiency, prolonged blood circulation, and multivalent presentation 
of HCPT molecules on a single nanotube. 
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The tumor-targeted delivery of anticancer agent taxoid by CNTs was achieved by 
attachment of targeting ligands to nanotubes. Chen et al. tethered taxoid and tumor-
recognition module biotin to SWCNTs [127]. Confocal fluorescence microscopy 
(CFM) analysis revealed that the SWCNT-taxoid-biotin conjugate was internalised 
into murine leukemia L1210 cells via biotin receptor mediated endocytosis, and the 
drug was efficiently released and bound to the target microtubules; moreover, it was 
found that the mass drug delivery into the cytosol of the cancer cells using this 
targeted conjugate is superior to the simple extracellular exposure of the drug itself. 
MTT assay showed the specificity and cytotoxicity of SWCNT-taxoid-biotin 
conjugate against L1210 cells, which overexpress biotin receptors at their surface, 
and the cytotoxicity of the conjugate is solely ascribed to the released taxoid 
molecules inside the cancer cells. 
The development of CNT functionalization through the covalent attachment of 
functional ligands to the external walls of nanotubes has paved the way for interesting 
uses of CNTs as suitable drug delivery systems. However, the conjugated molecules, 
which are bound to the nanotubes’ surface for drug delivery, are not prevented from 
the interaction with external reactive species in physiological environment; moreover, 
the chemical conjugation of some drug molecules with nanotubes may cause loss of 
their activities. As regards this last aspect, a number of studies have paid attention to 
the use of nanotubes’ surface and/or inner cavity to load therapeutic molecules 
through physical interaction instead of chemical binding. 
 
1.2.2.2 CNT-based drug delivery system through π-π stacking interactions 
CNTs are intact graphitic regions interspersed with sp2-hybridized carbon containing 
carboxyl, hydroxyl, and epoxide functional groups [135]. The large π-conjugated 
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structure can allow supramolecular binding of aromatic molecules by π-π stacking of 
those molecules onto the polyaromatic surface of nanotubes. Therefore, the anticancer 
drug doxorubicin (DOX) with aromatic structure could be easily loaded on the CNTs 
by the π-π stacking interaction between its quinine part and nanotubes’ graphitic 
surface. 
DOX will detach from the carrier in an acidic environment upon internalization into 
cells, due to the pH-dependent π-π stacking interaction between DOX and nanotubes. 
In order to track drug release from CNTs in living cells, the nanotubes were marked 
with fluorophore or AuNPs prior to drug loading. Branched AuNPs were grown on 
oxidised MWCNTs to obtain CNT/AuNP hybrids, which displayed a broad 
absorption band in the red and near-infrared regions allowing their use for imaging 
applications [136]. In vitro cellular tests showed that the CNT/AuNP hybrids could 
efficiently transport and deliver DOX inside A549 lung cancer cells. Kang et al. 
investigated the process of drug release from fluorescein isothiocyanate (FITC) 
functionalized SWCNTs (FITC-SWCNT) by monitoring the fluorescence of DOX 
(red) and FITC-SWCNT (green) under a confocal microscope, which showed that 
DOX detached from FITC-SWCNT inside the lysosomes to yield free molecules and 
escaped into the cytoplasm and finally into the nucleus, while the vehicle FITC-
SWCNT were trapped inside the lysosomes, without entering the nucleus [137]. 
To obtain higher dispersibility and biocompatibility, the CNTs for delivery of DOX 
were modified with solubilizing agents. DOX was reported to be loaded onto the 
soluble SWCNT, which was noncovalently modified with Polyoxyl 35 Castor Oil 
(CrEL), via π-π stacking interactions [138]. Liu et al. evaluated the in vivo efficacy 
and loco-regional distribution of this CrEL-SWCNT-DOX conjugate in a solid tumor 
model, which was obtained by injecting mouse sarcoma 180 cells into the thighs of 
ICR mice. The biodistribution studies demonstrated that intratumoral injection of 
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CrEL-SWCNT-DOX resulted in longer drug retention time and higher drug level 
(27.6-fold than that of free DOX) in tumor, as well as less accumulation in other solid 
tissues, especially in heart. Furthermore, in vivo antitumor activity results showed that 
CrEL-SWCNT-DOX could effectively inhibit the tumor growth over free DOX and 
the saline control, due to its enhanced intratumoral DOX level. The histopathological 
findings revealed that the CrEL-SWCNT was a safe vehicle for topical drug delivery 
systems. 
Besides, targeting ligands were combined with the π-conjugated drug delivery system, 
allowing the nano-carriers to target tumor cells. Folic acid (FA) is one of the 
commonly used ligands in the tumor-targeted study. In the investigation reported by 
Huang et al., who tethered DOX to CNT surface and then decorated CNTs with 
folate-conjugated chitosan to obtain targeted SWCNT-DOX-CHI-FA, the in vitro 
release behavior of SWCNT-DOX-CHI-FA and SWCNT-DOX was compared in 
different pH conditions [139]. SWCNT-DOX-CHI-FA and SWCNT-DOX both had a 
significantly higher drug release at pH 5.3 (7% versus 12%) than at pH 7.4 (36% 
versus 61%), attributed to partial dissociation of hydrogen bonding interaction 
between DOX and SWCNT at acidic pH. Moreover, the relatively superior controlled 
release from SWCNT-DOX-CHI-FA in contrast to SWCNT-DOX is ascribable to (a) 
degradation of chitosan and diffusion through the chitosan shell and (b) folate-DOX 
hydrogen bonding. Furthermore, Zhang et al. investigated the anticancer effect 
against human cervical carcinoma HeLa cells, demonstrating that folate-decorated 
SWCNTs selectively delivered DOX into the lysosomes of HeLa cells with much 
higher efficiency than free DOX. The DOX released from the modified nanotubes has 
been shown to migrate into nucleus to damage DNA and inhibit the cell proliferation 
[140]. The antibody of P-glycoprotein (anti-P-gp) was also used as tumor-targeting 
ligand in the study described by Li et al., who evaluated the anticancer activity of 
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anti-P-gp functionalized SWCNT (Ap-SWCNT) loaded with DOX against the 
multidrug resistance (MDR) of K562 human leukemia cells [141]. It has been shown 
that Ap-SWCNTs could not only specifically recognize the drug-resistant K562R 
cells, which was confirmed by flow cytometry (FCM) and confocal laser scanning 
microscopy (CLSM), but also demonstrate the effective loading and controllable 
release performance for DOX toward the target K562R cells by exposing to near-
infrared (NIR) radiation. The binding affinity of Ap-SWCNTs toward K562R cells 
was 23-fold higher than that toward drug-sensitive K562S cells. Moreover, the 
composite of DOX and Ap-SWCNTs exerted 2.4-fold higher cytotoxicity and 
exhibited the significant cell proliferation suppression toward K562R leukemia cells 
(p< 0.05) as compared with free DOX. Angiopep-2 (TFFYGGSRGKRNNFKTEEY), 
a ligand of the low-density lipoprotein receptor-related protein (LRP) receptor 
overexpressed on the blood brain barrier (BBB) and glioma cells[142, 143], was used 
for modifying nano-carriers to target brain glioma. PEGylated oxidised MWCNTs 
were modified with angiopep-2 to obtain targeted O-MWCNTs-PEG-ANG, which 
were then loaded with DOX via π-π stacking [144]. The DOX-loaded O-MWCNTs-
PEG-ANG (DOX-O-MWCNTs-PEG-ANG) showed higher cytotoxicity against C6 
glioma cells than DOX, and DOX-O-MWCNTs-PEG as a vehicle proved its good 
biocompatibility and low toxicity in cytotoxicity, hematology, and 
immunohistochemical analyses. Fluorescence imaging in vivo indicated that DOX-O-
MWCNTs-PEG could distribute into brain and glioma more efficiently than DOX, 
and that the brain distribution and the capability of glioma targeting could be 
furthermore enhanced by DOX-O-MWCNTs-PEG-ANG, possibly due to the receptor 
mediated endocytosis (RME) mechanism of angiopep-2 interaction with LRP 
receptor. The survival of the mice bearing intracranial C6 glioma suggested that 
DOX-O-MWCNTs-PEG-ANG significantly prolonged the median survival time 
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(MST) compared to DOX. In addition, DOX-O-MWCNTs-PEG-ANG exhibited a 
lower cardiac toxicity than DOX, as evaluated by histopathological analysis. 
The π-π stacking interaction, ascribed as a non-covalent type of functionalization, 
provides a facile method for attaching therapeutic agents to CNTs, allowing 
nanotubes to stably preserve drugs at physiological conditions and achieve controlled 
release at acidic conditions. However, this strategy is limited to only aromatic drugs, 
and is not applicable to all cases, therefore it is not employed as commonly as the 
other two strategies. 
 
1.2.2.3 CNT-based drug delivery system through incorporation into inner 
cavity 
There is a huge space in the inner cavity of CNTs, whose interior surface exhibits a 
more favorable binding energy towards molecules’ adsorption compared with their 
external surface [145-147]. Therefore, a variety of studies have shown that the 
incorporation of exogenous molecules into the hollow space of CNTs is valuable in 
compound synthesis [148, 149], materials storage [150, 151], etc. Here, we introduce 
the research on CNTs acting as nano-capsules, which load drug molecules and 
efficiently transfer them into cells, to enhance the therapeutic efficacy of these drugs. 
The CNT-based encapsulation method mainly has several advantages superior to 
traditional systems (e.g., nanoparticles, micelles, liposomes, etc.). Firstly, the huge 
hollow space of CNTs provides a scaffold for high loading capacity, while the drug 
loading of polymeric nano-carriers is relatively lower. Secondly, the facile chemical 
functionalization allows introducing various functionalities into CNTs, being much 
easier than the modification of traditional drug delivery systems. Thirdly, the size of 
CNT-based nano-carriers is completely dependent on the CNTs. Unlike the polymeric 
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drug delivery systems (such as nanoparticles and liposomes) that are assembled from 
nanomaterials and generally require great efforts to control the resulting nano-carriers’ 
size, therapeutic agents could be directly entrapped within CNTs with a certain size. 
Therefore, encapsulation of drugs inside CNTs is able to exploit them as good vessel 
for drug delivery. 
Cox et al. first investigated the nature of the suction force and proposed a strategy to 
determine whether the suction force for a particular configuration would allow the 
particle to be sucked completely into the nanotube; this strategy was used to predict 
the feasibility for C60 fullerene, which was considered as drug model, to be accepted 
into the interior of CNTs by van der Waals forces alone, and figured out the radius of 
the nanotubes that provided the maximum suction or uptake of the drug molecule 
[152]. The C60 encapsulation has been reported into both SWCNTs and MWCNTs 
using solvents, and the presence of C60 in the interior of nanotubes was demonstrated 
by high-resolution transmission electron microscopy (HR-TEM), X-ray 
diffractometry, and Raman spectroscopy [153-155]. HR-TEM showed that C60 tends 
to form zigzag chains in nanotubes with diameters of about 2 nm, while irregular 
arrangements of C60 is observed at larger diameters (> 3 nm) [153]. It was found that 
the C60 incorporation efficiency was optimal at diameters of 1~2 nm, while no C60 
incorporation occurred in nanotubes with diameters less than 1 nm [155]. The release 
of C60 from CNTs was confirmed in dichlorobenzene and toluene, and the release 
efficiency reached its maximum at diameters of 3~5 nm [154, 155]. 
Cisplatin (CDDP) is one of the first drugs incorporated into the interior of CNTs or 
carbon nanohorns (CNHs).The encapsulation modelling of CDDP was established by 
Hilder et al. based on the evaluation of interatomic interaction energy, revealing that 
the nanotube radius must be greater than 4.785 Å to allow CDDP to enter its interior, 
and the maximum suction energy occurs in nanotube with radius of 5.27 Å [156, 157]. 
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In 2005, Ajima et al. first reported the entrapment of CDDP within oxidised single-
walled carbon nanohorns (SWCNHox), finding that the CDDP clusters were 
maintained inside the SWCNHs and that the CDDP was slowly released from the 
SWCNHs in aqueous environments [158]. Cytotoxicity assays showed that the CDDP 
released from SWCNH-CDDP conjugate exhibited dose-dependent anticancer effects 
against human lung cancer cells NCI-H460, while SWCNHox itself had no 
discernible effect on cancer cell growth. Similar findings were obtained by 
Tripisciano et al. in the research on SWCNT-based drug delivery [159]. The presence 
of CDDP on the nanotubes’ interior side was supported by FT-IR, Raman scattering, 
and HR-TEM analyses. In vitro simulated release suggested that the discharge of 
CDDP from SWCNT started after 24 h of immersion in physiological solution, and it 
reached the maximum release (68%) after 72 h. The SWCNT-CDDP conjugate was 
effective in inhibiting the viability of prostate cancer cells (PC3 and DU145), which 
decreased with the increase of the conjugates concentration. In addition, Ajima et al. 
improved on the incorporation method and eventually increased the incorporated 
CDDP quantity from 15% to 46% in 2008 [160]. The high-loading SWCNT-CDDP 
conjugate exhibited 4~6 times greater anticancer efficiency in vitro against NCI-H460 
cells over intact CDDP. In vivo, the conjugate, which was intratumorally injected to 
transplanted tumors of mice, was more effective in suppressing the tumor growth than 
the intact CDDP and was found to stay in the tumor tissues for a considerable period 
up to 25 days, which was in favor of the higher anticancer efficiency. 
The factors that may influence the performance of nanotubes in CDDP delivery were 
investigated by Ajima et al., who found that functional groups at hole edges and the 
hole-opening condition have an impact on the CDDP incorporation and release. 
Firstly, oxygen-containing functional groups at the hole edges (SWCNHox) were 
found to greatly hamper the release of incorporated CDDP from nanohorns compared 
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with hydrogen-terminated edges (SWCNHh); the quantity of CDDP released from 
SWCNHh in PBS was 70%, while only 15% was released from SWCNHox [161]. 
The difficulty in CDDP release from SWCNHox was due to the plug effect; that is, 
conjugation of Na+ with oxygen-containing functional groups at the hole edges 
decreased the practical hole size, and sterically hindered the CDDP passing through 
the holes. Secondly, the optimum target temperature, to which the SWCNHs were 
heated from room temperature, to open the holes of nanohorns was found to be 
500 °C, in terms of the least amount of CDDP deposited outside the SWCNHs. The 
incorporated CDDP was slowly released from these SWCNHs in PBS for a period of 
50 h, and eventually the released quantity was 80% [162], which was greatly 
improved from the previous value of 15% [161]. 
In order to improve the biocompatibility and drug delivery efficiency, nanotubes were 
functionalized with biocompatible solubilizing agents or targeting ligands. Guven et 
al. encapsulated CDDP into ultrashort SWCNTs (US-tubes), and then wrapped the 
CDDP@US-tubes with Pluronic-F108 surfactant [163]. The in vitro release study 
showed that CDDP release from CDDP@US-tubes in PBS was remarkably slowed 
down by wrapping the CDDP@US-tubes with Pluronic-F108 surfactant. The 
anticancer activity assay was performed against two different breast cancer cell lines 
(MCF-7 and MDA-MB-231), showing that pluronic-wrapped CDDP@US-tubes 
exhibited greater cytotoxicity in comparison to free CDDP after 24 h. Matsumura et 
al. non-covalently modified SWCNH, which entrapped CDDP within its interior, 
using a conjugate composed of PEG and a peptide aptamer (NHBP-1) to obtain 
CDDP@SWCNH/PEG-NHBP conjugate, which exhibited a good dispersibility under 
aqueous conditions [164]. The cytotoxicity assay showed that 
CDDP@SWCNH/PEG-NHBP conjugate exerted potent cytotoxic effect against NCI-
H460 cells in a dose-dependent manner; while SWCNH/PEG-NHBP complex itself 
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had no effect on cell proliferation, suggesting that the released CDDP elicited the 
cytotoxicity. 
Moreover, dexamethasone (DEX), an anti-inflammatory glucocorticoid, was also 
involved in the study of nano-capsules. DEX was entrapped into SWCNH and its 
oxidised form SWCNHox, respectively; the incorporated DEX quantity in 
SWCNHox was 6-fold larger than that obtained for SWCNH [165]. SWCNHox-DEX 
conjugate exhibited sustained release of DEX in PBS as well as in mammalian cells 
without significant side effects. The biological integrity of the released DEX was 
confirmed by activation of glucocorticoid response element-driven transcription in 
mouse bone marrow stromal ST2 cells and induction of alkaline phosphatase in 
mouse osteoblastic MC3T3-E1 cells. Luo et al. designed CNT drug nanoreserviors, 
composed of CNTs with DEX loaded in their inner cavity and polypyrrole (PPy) 
coatings that seal the ends of CNTs, obtaining effective drug loading and release in a 
controlled manner under electrical stimulation [166]. The bioactivity assay revealed 
that the released DEX was able to reduce lipopolysaccharide induced microglia 
activation in highly aggressively proliferating immortalized (HAPI) cells to the same 
degree as the intact DEX. The effective inhibition of microglia activation by released 
DEX indicated that the drug molecules retained their bioactivity after the loading and 
stimulated release. 
In addition to the simple drug molecules, CNTs drug delivery system was 
successfully filled with hydrogel-drug complex. Wu et al. describe a “Trojan-Horse” 
nanotube by incorporating a temperature-sensitive hydrogel mixed with paclitaxel 
and C6-ceramide into CNTs; the hydrogel-drug payload remained stably within the 
CNTs until their release by inductive heating, which caused the temperature-sensitive 
hydrogel to undergo a gel-sol phase transformation and discharge into the 
surrounding fluid, where the concomitant drug release occurred [167]. The paclitaxel 
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and C6-ceramide released from CNT-hydrogel-drug conjugate by inductive heating 
exerted a potent cytotoxic effect against multidrug resistant pancreatic cancer L3.6 
cells; the CNT-hydrogel-drug conjugate allowed the drugs to act at a 100-fold lower 
concentration compared to exogenous treatment with free drugs, achieving over 70% 
cancer cell death. In contrast, without inductive heating the drugs were safely 
confined to the CNTs, showing no toxicity in cell viability tests. 
In these studies, the CNT-based carrier is engineered to be energetically favorable for 
encapsulation of drug molecules, and then once internalised inside the cells, this drug 
delivery system is engineered to become energetically favorable to discharge drug 
molecules from the nanotube in response to a trigger such as changed environmental 
conditions. These drug molecules could retain their integrity after encapsulation and 
subsequent release, thus preserving the bioactivity towards diseased cells. 
Furthermore, the transport capacity of CNTs efficiently increased the cellular uptake 
of drug molecules, whose therapeutic efficacy could therefore be significantly 
enhanced. In view of these successful examples and to the possibility of preserving 
drug molecules from a premature inactivation once in contact with the external 
environment in physiological systems, we will follow the encapsulation strategy to 
design a “carbon nano-bottle” drug delivery system. 
 
1.3 The biocompatibility of carbon nanotubes in drug 
delivery 
1.3.1 Toxicity issues of carbon nanotubes towards biological systems 
Within the research on drug delivery systems, CNTs are emerging as a new vehicle 
for transporting and translocating therapeutic molecules, since their high aspect ratio 
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facilitates the penetration through cell membranes like needles as well as ultrahigh 
surface area that permits efficient loading of therapeutic molecules alongside the 
CNTs’ walls. Nevertheless, toxicity is still a great dilemma regarding the usage of 
CNTs in biological systems. Despite these inherent advantages in favor of delivering 
drugs, there has been a great concern about the toxicity of pristine CNTs to biological 
systems, especially at high concentrations. Mitigation of toxicity and loading of drug 
molecules are hence two main topics in the application of CNTs as carriers for drug 
delivery, thus enabling CNTs to be biocompatible drug delivery system with high 
efficiency. 
There are numerous studies in recent years investigating the toxicity of CNTs both in 
vitro and in vivo, although many results reported in the literature are not consistent. 
The comparison between those contradictory findings suggests that the lack of 
toxicity is likely associated with relatively low concentrations (most of the 
cytotoxicity studies were performed within the range of 7~30 μg/mL) and high purity 
of CNTs used for the studies; in contrast, those reports on high toxicity were mostly 
carried out at higher concentrations of CNTs and, moreover, used pristine or non-
functionalized CNTs with lower purity. 
 
1.3.1.1 Purity of carbon nanotubes 
High purity CNTs were found nontoxic or low-toxic at certain range of doses. 
Chlopek et al. examined viability of fibroblasts and osteoblasts on polysulfone films 
covered with MWCNTs, as well as the amount of collagen type I, pro-inflammatory 
cytokine IL-6 and oxygen free radicals, confirming high level of cells viability and a 
good biocompatibility of MWCNTs [168]. Cherukuri et al. found the active ingestion 
of SWCNTs by murine peritoneal macrophages without any sign of cytotoxicity at a 
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dose of 7.3 μg/mL [169]. Erythrocytes and thymocytes were incubated in the 
presence of MWCNTs for 24 h, and the viability of cells indicated that MWCNTs do 
not have toxic effects on erythrocytes and thymocytes at concentrations up to 25 
μg/mL [170]. Vittorio et al. investigated the cell viability of human neuroblastoma 
cell line (SH-SY5Y) following 3 days exposure to three types of CNTs (99% purity, 
97% purity, and 97% purity acid-treated) at the concentrations up to 10 μg/mL, and 
the data indicated that SH-SY5Y cells maintained their growth rate and showed 
normal mitochondrial activity and metabolism; moreover, apoptosis and oxidative 
stress were not induced in the SH-SY5Y cells [171]. Davoren et al. conducted 
cytotoxicity assays (i.e. alamar blue, neutral red and MTT) of SWCNTs on A549 
human lung cells, revealing the SWCNTs to have very low acute toxicity to the A549 
cells (24 h EC50 values exceeded 800 μg/mL), which retained the main properties of 
alveolar epithelial type II (AE2) cells following SWCNTs exposure [172]. 3D tissue-
mimetic models for the cytotoxicity assessment of purified (p-) and oxidised (o-) 
SWCNTs showed that there were no significant cytotoxic response or cell stress, as 
well as no notable changes in pro-inflammatory cytokines IL-6 and TNF-α secretion 
detected in 3D cell aggregates following a 24 h exposure to p- and o-SWCNTs, and 
interestingly, cell death had a random distribution within SWCNT-treated 3D 
aggregates instead of localization to the areas where cells were in direct contact with 
the SWCNTs [173]. 
To date, a few studies suggest CNTs to be nontoxic in vivo as well. In the experiment 
on intravenous (i.v.) injection of SWCNTs, no significant toxic effects on specimens 
were observed at the concentration of about 20 μg/kg body weight after a 24 h period 
[174]. It was demonstrated that small aggregates of SWCNTs (< 10 μm) can be 
engulfed by phagocytes without granuloma formation [175]. Huczko et al. reported 
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that non-purified CNTs did not induce significant signs of lung toxicity 4 weeks after 
a single intratracheal administration in guinea pigs [176]. 
To explore the reasons for low toxicity of CNTs, several postulates have been 
proposed on the basis of biological protecting mechanisms. It is possible that the 
surrounding of proteins outside CNTs efficiently reduced their toxicity. It has been 
found that the inherent cytotoxicity of CNTs was attenuated by the adsorption of 
serum proteins on CNTs, and the extent of toxicity attenuation increased with higher 
surface coverage of CNTs by serum proteins [177]. The low toxicity of intravenously 
administered SWCNTs might stem from the active protecting mechanism, which is 
dependent on reticuloendothelial system (RES) uptake of nanotubes post-i.v. injection 
and determines the restriction of the SWCNTs within certain cells. The opsonin 
regulated RES capture protects parenchyma cells from the interaction with SWCNTs 
and restricts the toxicity to certain cells, such as Kupffer cells (KC) and alveolar 
macrophages (AM) [178]. These isolated SWCNTs, which are trapped in AM and KC, 
could be eliminated from the lungs via mucus through mucociliary transport [179] or 
excreted via bile [180], respectively. In addition, an increase of AE2 cells expressing 
cytoplasmic lamellar bodies was observed following exposure to SWCNTs via 
pharyngeal aspiration [181]. The lamellar bodies conduct exocytosis of their contents 
[172], and are recognised as storage vessels for pulmonary surfactant, which is a 
surface-active lipoprotein complex (phospholipoprotein) formed by AE2 cells; the 
proteins and lipids that comprise the surfactant are released into the alveolus [182] 
and involved in the regulation of surface tension in the lungs [183]. It is therefore 
postulated that the increased presence of these lamellar bodies and the concurrent 
surfactant secretion may play an important role in a protective response of the lung 
cells to reduce the cytotoxic effects of SWCNTs [172]. 
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1.3.1.2 Toxicity reports on carbon nanotubes 
1.3.1.2.1 In vitro toxicity study on carbon nanotubes 
Despite these findings on lack of toxicity or low toxicity of CNTs and a few 
hypotheses correlated to detoxification that have been put forward in the previous 
paragraph, the majority of the studies on the biocompatibility of this material indicate 
that CNTs display some toxicity both in vitro and in vivo. Many cytotoxicity assays 
have shown that cell cultures are remarkably influenced by exposure to CNTs and the 
cells viability significantly declines. For example, a considerable cytotoxic response 
of human monocytic leukemia THP-1 cells was detected following exposure to p- and 
o-SWCNTs, regardless of purity grade or the reactive groups on the surface [173]. 
Cells viability assays of A549 human pneumocytes showed significant cell death after 
48 h incubation with MWCNTs at the concentration of 100 μg/mL, which led to 
maximum cell death rate of 75% in MTT assay, 40% in lactate dehydrogenase (LDH) 
assay and 10% in 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) 
carbonyl] (XTT) assay [184]. The toxicity of SWCNTs to neurons and glial cells was 
evaluated by Belyanskaya et al., showing significant decrease of the overall DNA 
content related with agglomeration [185]. When rat erythrocytes and thymocytes 
were exposed to MWCNTs at a concentration of 50 μg/mL, the negative effects of 
MWCNTs caused the acceleration of erythrocyte hemolysis, decrease of viable 
thymocytes by 32% and inhibition of the mitochondrial electron-transporting chain 
[170]. 
 
1.3.1.2.2 In vivo toxicity study on carbon nanotubes 
Aside from cytotoxic studies on various cell lines, a large amount of in vivo 
toxicology studies have revealed the CNT-related toxicity in multiple organ systems, 
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including pulmonary lesions, adverse cardiovascular effects, skin irritation, etc. 
Concerns over CNTs respiratory exposure with consequent pulmonary toxicity have 
attracted the most attention. Thus inhalation is the most relevant method for 
determining the effects of lung exposure to CNTs, simulating more accurate 
deposition and pathologic responses to “real world” exposure scenarios [186]. Erdely 
et al. investigated the toxic effects of CNTs on mice by pharyngeal aspiration, finding 
that CNT exposure induced up-regulation of more than half of the tested genes in the 
lungs related to inflammation, oxidative stress, coagulation, and remodeling [187]. 
Besides, intratracheal instillation is generally regarded as a suitable method for 
characterizing the in vivo toxicity of fibers and particles, and lung responses induced 
with this route of administration are very similar to those observed after inhalation 
exposure [188]. It has been noted that the lungs of all the mice intratracheally instilled 
with high doses (0.5 mg) of CNTs had prominent granulomas, which were located 
beneath the bronchial epithelium and were present throughout most of the 
microscopic fields of lung tissue [189]. Warheit et al. observed the formation of lung 
granulomas and mortality in about 15% of rats following intratracheal instillation of 
SWCNTs in the lungs of rats [190]. 
Furthermore, it has also been demonstrated that a systemic circulation response is 
activated after CNT deposition in the lungs. Fraczek et al. stated that smaller 
aggregates formed of SWCNTs were easily dispersed in the tissue environment and 
were subsequently transported to the local lymph nodes by macrophages [191]. The 
authors assumed that the transport of SWCNTs from the implant sites to the lymph 
nodes may determine undesirable effects related with cytotoxicity. Kolosnjaj-Tabiet 
al. proved that intraperitoneal (i.p.) administration of high doses (50~100 mg/kg body 
weight) of CNTs allowed a large dose of small aggregates and well individualized 
nanotubes to reach the systemic circulation and subsequently tissues (and a variety of 
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cells) through the lymphatic system, which was verified by electron microscopy 
imaging [175]. 
Adverse cardiovascular outcomes were simultaneously caused by exposure to CNTs. 
Simeonova et al. demonstrated that SWCNT-related pulmonary response was 
associated with adverse cardiovascular effects including distressed aortic 
mitochondrial homeostasis, a prerequisite of vascular dysfunction in wild-type mice, 
and accelerated atherogenesis in mice model of atherosclerosis [192]. 
Skin contact with CNTs may also induce dermal toxicity, causing an inflammatory 
response. The inflammation may be ascribed to metal impurities of CNTs, which 
interact with the skin, initiate oxidative stress, and induce redox-sensitive 
transcription factors [186]. Exposure of mice to unpurified CNTs generally causes 
oxidative stress, depletion of glutathione (GSH), an increase in dermal cell number, 
localized alopecia and skin thickening [193, 194]. 
 
1.3.1.2.3 Elimination of carbon nanotubes from biological systems 
Another aspect of safety concerns is the elimination of CNTs following ingestion by 
biological systems. The biopersistence of an ingested particulate strongly determines 
its toxicity, since the clearance of xenobiotics and occurrence of disease are closely 
linked with the biopersistence of a substance in the body. 
An early study reported long persistence of non-functionalized MWCNTs coated with 
Tween 80 after intratracheal instillation [195]. Li et al. demonstrated that a persistent 
accumulation of CNTs aggregates in the lungs resulted from the intratracheal or 
pharyngeal instillation of SWCNTs suspension in mice [196]; this observation is in 
accordance with the findings that pristine SWCNTs were found in mice for 3 months 
after intravenous exposure [197]. An in vivo study of SWCNTs in Swiss mice showed 
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that small aggregates of SWCNTs persisted inside cells for up to 5 months after 
administration, while short (< 300 nm) well-individualized SWCNTs could be 
eliminated through the kidney and bile ducts [175]. 
On the other hand, a decrease in the MWCNT quantity after respiratory exposure was 
presented in reports on pulmonary biopersistence of MWCNTs. Elgrabli et al. 
determined the accumulation of bovine serum albumin (BSA) dispersed MWCNTs in 
the lungs after intratracheal instillation in rats, finding that only 37% of the MWCNTs 
remained within the lungs after 3 months and only 16% remained after 6 months; 
moreover, there were no MWCNTs detected in various systemic organs during the 
period between three and six months, suggesting the elimination rather than a 
translocation of MWCNTs from the lungs [198]. Muller et al. also observed that 18% 
of instilled MWCNTs that accumulated in the lungs were eliminated after 60 days 
[195]. In a more detailed study of inhaled MWCNTs in rats, Oyabu et al. reported 
that the amount of retained MWCNTs in the lungs declined exponentially until 3 
months after the inhalation; the biological half clearance time of MWCNTs was 
calculated to be around 50 days [199]. These results suggest that SWCNTs and 
MWCNTs can be eliminated from lung and body within a certain period. 
In addition, carboxylated CNTs have been found degradable in the presence of 
enzyme in vitro. For example, several peroxidase and hemo-proteins, such as 
lactoperoxidase, eosinophil peroxidase, thyroid peroxidase, prostaglandin synthase, 
hemoglobin and myoglobin, showed the ability to degrade carbonaceous 
nanomaterials via the generation of highly oxidising reactive intermediates [200]. It 
was reported that the human neutrophil enzyme myeloperoxidase (MPO), due to its 
ability to produce hypochlorite, catalyses the biodegradation of SWCNTs in 
neutrophils and, to a less degree, in macrophages [201]; lactoperoxidase (LPO) was 
able to produce hypobromite, which also played an important role in the degradation 
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of CNTs [202]. Liu et al. investigated the biodurability of SWCNTs using an in vitro 
assay simulating the phagolysosome, and the results indicated that SWCNTs with 
carboxylated surfaces are unique in their ability to undergo 90-day degradation in 
vitro in an artificial phagolysosomal stimulant fluid leading to length reduction and 
accumulation of ultrafine solid carbonaceous debris [203]. 
 
1.3.1.2.4 Correlation between toxicity and administrated dose as well as 
exposure time 
A number of toxicology studies furthermore revealed the toxicity of CNTs to be dose- 
and/or time-dependent. Toxicity of CNTs is related to their concentration and the 
dose to which cells or organisms are exposed [204]. Jia observed prominent dose-
dependent cytotoxicity of SWCNTs in alveolar macrophages isolated from guinea 
pigs, which showed characteristic features of apoptosis at different dosages [205]. 
Monteiro-Riviere et al. investigated the cytotoxic response of human epithelial 
keratinocytes (HEK) following exposure to purified MWCNTs, and their findings 
indicated an increase in the concentration of the irritation marker, IL-8, in a time- and 
dose-dependent manner [206]. 
This correlation was also observed in the in vivo toxicity studies of CNTs. Shvedova 
et al. reported that purified SWCNTs induced a dose-dependent increase in the 
concentration of biomarkers for inflammation and oxidative stress, as well as a rapid, 
dose-dependent and progressive development of fibrotic granulomas at the site of 
SWCNT aggregates deposition in addition to interstitial fibrosis in pulmonary regions 
distant from these sites [181]. Significant changes in serum biochemical parameters 
were identified by Schipper et al. who reported a dose-dependent increase in the 
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alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of mice 
exposed to pristine SWCNTs [207]. 
 
1.3.1.3 Toxicity-related factors of carbon nanotubes 
1.3.1.3.1 Metal impurities 
The reasons for the toxicity of CNTs are explored to identify the main adverse factors 
and further attenuate the toxic response of biological systems exposed to CNTs. The 
residual catalytic transition metals from the manufacturing process of CNTs are 
considered to play a key role in the toxic effects of CNTs, since these metal catalysts, 
such as iron and nickel, have been shown to contribute to increased toxicity through 
induction of oxidative stress, thereby leading to inflammation [186, 189, 208]. For 
example, the iron-based catalyst residue can react with the superoxide to form highly 
reactive hydroxyl (OH-) radicals, causing the resulting oxidative damage to cell 
proteins, lipids and DNA [121]. The role of metal catalyst in reactive oxygen species 
(ROS) formation was confirmed by Pulskamp et al. using rat macrophages NR8383 
and human A549 lung cell lines [209]. In the in vitro studies of unpurified SWCNTs 
containing iron or cobalt impurities, SWCNTs rich in 30 wt% iron resulted in 
oxidative stress and loss of cell viability in human epidermal keratinocytes (HaCaTs) 
[210]; a significant loss of intracellular glutathione and accumulation of lipid 
hydroperoxides in murine macrophages arose from exposure to 26 wt% iron-rich 
SWCNTs [211]; a notable chromosome damage has been observed following 
exposure to CNTs with residual cobalt at 4 μg/mL [212]. Therefore, the first 
conclusion is that high-purity samples are required to reduce the cytotoxic effects of 
the residual catalyst and/or surface oxidation when the dose increases to high 
concentration [171]. 
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In the in vivo toxicity studies of metal impurities in CNTs, Lam et al. observed a 
mortality rate of about 50% of the animals within 7 days after exposure to a dose of 
0.5 mg/mouse of CNTs (sonicated suspension) containing 26% nickel and 5% yttrium, 
presuming that nickel released during ultrasonication caused the deaths [213]. In 
contrast, reports on dermal toxicity showed that highly pure and clean CNTs 
implanted in mice did not cause any skin hair loss, suggesting that purification is an 
effective way to improve the biocompatibility of CNTs [186]. 
On the other hand, although metal impurities seem to significantly affect the toxicity 
of CNTs, recent studies manifested that the principal cause of toxic effects is 
attributable to CNTs themselves rather than the catalysts [214]. For example, 
Shvedova et al. found that highly purified CNTs (0.23% iron) manufactured by HiPco 
process induced a dose-dependent increase in biomarkers associated with 
inflammation and oxidative stress in the lungs, which were attributed to the other 
features of CNTs [181]. 
 
1.3.1.3.2 Carbon nanotubes’ structure 
Indeed, it has been well documented that the intrinsic properties of the CNTs material, 
such as their structure (SWCNTs versus MWCNTs), length, aspect ratio, surface area, 
degree of aggregation, extent of oxidation, surface chemistry, and bound functional 
groups, are closely related with the toxicity [204]. 
A large amount of studies have investigated the influence of CNTs structure on their 
toxicity, indicating that SWCNTs seem to be typically more toxic than MWCNTs 
[205, 215, 216]. Moreover, Kang et al. found that both SWCNTs and MWCNTs 
alone caused death of bacteria, interpreting their diverse mechanism of toxicity: 
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SWCNTs appear to exert direct damage on cell walls [217, 218], while MWCNTs 
cause toxicity via oxidative stress [219, 220]. 
 
1.3.1.3.3 Carbon nanotubes’ length 
The possibility of length-related toxicity has also been examined by many 
laboratories, since it is considered that the length and shape of the CNTs influence 
their ability to traverse the membrane of macrophages and determine the resulting 
immunologic response [221, 222]; however, results of these studies are controversial. 
On the one hand, some studies come to the conclusion of length-dependent toxicity. 
Shorter CNTs (~0.22 μm in length) were found to have higher degree of 
internalization into macrophages and phagocytes than did the longer (> 0.8 μm) 
CNTs. It was also found that the degree of inflammatory response in subcutaneous 
tissue in rats exposed to MWCNTs was length-dependent [223]. Poland et al. 
investigated the influence of length on toxicity by injecting non-functionalized 
MWCNTs of different lengths into mice intraperitoneally, finding that MWCNTs 
longer than 20 μm induced significantly more accumulation of MWCNTs in the 
diaphragmatic mesothelium and remarkably higher degree of subsequent granuloma 
lesion formation compared with low-aspect-ratio, tangled nanotube aggregates, 
presumably because macrophages could not completely engulf longer fibers [224]. 
On the other hand, distinct results indicated that CNTs do not have length-dependent 
toxicity. Simon-Deckers et al. demonstrated the cytotoxicity of MWCNTs by increase 
in LDH release from cells, which suggests increased cell membrane damage due to 
MWCNTs, noticing that LDH release was not correlated with the length of CNTs 
[184]. MWCNTs were found to slightly enhance tumor necrosis factor-α levels, 
whereas this induction did not depend on the length of the nanotubes [223]. Muller et 
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al. reported that inflammation and fibrosis of lung tissue caused by intratracheal 
instillation of long (6 μm) and short (0.7 μm) MWCNTs did not have significant 
length-dependent differences [195]. Therefore, the second conclusion is that long and 
short CNTs samples have almost the same proportions of CNTs that are too long for 
the cells to engulf, and such CNTs that cannot be engulfed by cells cause similar 
effects irrespective of the length [186]. Due to contrasting evidence associated with 
length of CNTs and toxicity, it is necessary to carry out more specific and thorough 
studies. 
 
1.3.1.3.4 Carbon nanotubes’ aspect ratio 
The high aspect ratio of CNTs, a property shared with asbestos fibers, might enable 
CNTs to behave like asbestos and other pathogenic fibers, which have toxicity 
associated with their needle-like shape [208]. It is reasonable to expect that 
macrophages would have some difficulties in safely engulfing fibrous CNT structures, 
especially if some of them can conduct electrons; the electronically active CNTs, can 
potentially perforate cell membranes and could disturb cellular functions, resulting in 
toxicity and even cell death [189]. 
The pathogenic properties of individual CNTs and assembled nanotube bundles, 
which resemble those of certain asbestos fibers, have been reported in recent studies 
[225]. It seems that the toxic effect of CNTs increases with decreasing diameter and 
increasing aspect ratio [204]. Kolosnjaj-Tabi et al. observed a granulomatous reaction 
in mice following exposure to high doses of even ultrashort CNTs through i.p. 
injection on account of the fact that small compact bundles of ultrashort nanotubes 
can coalesce inside the body to form large fiberlike structures [175]; this is in line 
with the findings that nanotube aggregates exhibit fiberlike structures sufficiently 
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large to trigger granuloma formation likely through a so-called frustrated 
phagocytosis mechanism [224]. These results are supported by the observation that 
CNTs retained in the lungs clearly showed the fibrous structures [190, 213]. Thereby 
the third conclusion is that the key physical property of CNTs that may be associated 
with potential granuloma induction is not only their length but also their capacity to 
aggregate as fiberlike structures [175]. 
 
1.3.1.3.5 Carbon nanotubes’ diameter 
The diameter of CNTs is inevitably considered as an important parameter in the 
toxicological assessment of CNTs. Fenoglio et al. compared MWCNTs of different 
diameter (9.4 versus 70 nm) on a mass-dose basis, finding that small-diameter 
MWCNTs exhibited markedly higher toxicity than large-diameter ones both in vitro 
and in vivo [226]. When tested toward murine alveolar macrophages (MH-S) in vitro, 
MWCNT9.4 elicited a dose-dependent cytotoxic effect, which presented LDH leakage, 
a substantial production of intracellular ROS and a decrease of intracellular GSH; 
conversely, MWCNT70 appeared non-cytotoxic and did not induce any cellular 
alteration at the equivalent mass dose. The in vivo experiments on rats following a 24 
h exposure also revealed the difference of biological reactivity: the results showed 
that only rats administered with MWCNT9.4 developed an inflammatory reaction, 
which was measured by LDH activity and protein content in broncho-alveolar lavage 
fluid as well as by the recruitment of neutrophils, eosinophils, and lymphocytes in the 
alveoli. It is therefore speculated that the observed differences in toxicity might 
derive from their difference in diameter. 
 
Chapter 1 Introduction 
36 
 
1.3.1.3.6 Carbon nanotubes’ surface properties 
The surface properties, including surface area and surface chemistry, are also 
important variables that affect the potential toxicity of CNTs. The size of CNTs 
provides great surface area for physical contact, hence it influences their toxicity, not 
only in terms of deposition in the respiratory tract, but also in the interaction with the 
target cells [227].Media depletion experiments were conducted to examine the 
toxicity of SWCNTs, showing that SWCNTs of greater surface area produced by 
HiPco chemical vapor deposition process were more toxic compared with SWCNTs 
of smaller surface area produced by arc discharge method [216, 228, 229]. Fenoglio 
et al. investigated MWCNTs of markedly different specific surface area (60 versus 
240 m2/g) and found that the toxicity seems to increase with surface area [226]. 
In addition, CNTs are known to possess unique surface chemistry; it has been noted 
that their unusual chemical and electronic properties could contribute to the toxicity 
of CNTs [213]. It is conceivable that CNTs may remove electrons from or shift 
electrons around the cells, thus taking part in oxidative and peroxidative reactions and 
leading to the generation of ROS [189]. Shvedova et al. detected robust acute 
inflammation in the lungs induced by even highly purified CNTs, suggesting that the 
observed toxicity is very likely derived from the electron transport property of CNTs 
[181]. Furthermore, purification procedures, such as strong acid treatment, can lead to 
some imperfections of the carbon framework [192]; these surface defects are often 
composed of carboxyl and hydroxyl groups [230], which increase their surface 
reactivity. The toxicity of MWCNTs therefore highly depends also on their surface 
chemistry. 
 
Chapter 1 Introduction 
37 
 
1.3.1.3.7 Carbon nanotubes’ charge 
The toxicity of CNTs is correlated with the local and overall charge as well. It has 
been estimated that CNTs are comprised mainly of hexagonal rings and 1% to 3% of 
non-hexagonal (seven- or five-membered) rings randomly distributed along the 
surface [231]. These odd-membered rings could generate either deficit or excess of 
charge, thus eliciting deviations from neutrality. Singh et al. have proven that the type 
of charge and charge density on functionalized nanotubes can affect cellular 
interaction [232, 233]. Pagona et al. found that CNTs’ charge density played an 
important role in the attachment of DNA strands onto CNTs, having an impact on the 
amount of bound DNA and their binding strength [234]. 
 
Overall, it seems that CNTs with low catalytic content, short length, large diameter, 
high functionalization, lower reactivity at surface, are the most promising materials 
for biomedical applications. In view of the concern about toxicity, an effective 
approach to the attenuation of toxicity is extremely necessary to the development of 
CNTs in drug delivery or bioengineering. To date, studies of biocompatible CNTs 
manufacturing mainly focus on the “decoration” strategy, including chemical 
functionalization and physical interaction, to alter the surface properties as well as the 
shape and size of CNTs according to the cause of toxicity. The studies of modified 
CNTs are therefore expected to remedy the drawbacks of CNTs and propel their 
application in biological fields and in nanomedicine. 
 
1.3.2 Biocompatibility improvement of carbon nanotubes 
There has been a great effort to exploit the merits of CNTs in biological field. 
However, a major concern in their development is how to improve their 
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biocompatibility and reduce the toxicity to an acceptable level. Thus far, much 
attention has been paid to the modification of CNTs, namely non-covalent coating 
and covalent binding that depend on physical interaction and chemical 
functionalization, respectively. The modification methods could help to solubilize 
CNTs and attenuate their toxicity by generating variations in their physicochemical 
properties, including an increase in purity, a decrease in length, enhancement of 
surface hydrophilicity, etc. Therefore, biocompatible CNTs could be produced by 
coating and/or linking them with biocompatible polymers or macromolecules. 
 
1.3.2.1 Non-covalent coating 
Non-covalent coating is a facile way to increase the dispersibility and 
biocompatibility of CNTs through nonspecific binding between nanotubes and 
coating materials (e.g. biopolymers, lipids, proteins, etc.), but will not cause defects 
on the structures of nanotubes or compromise their basic properties. 
In the studies of non-covalent coating, a variety of polymers were utilised to generate 
a hydrophilic surface of nanotubes. Liu et al. reported a non-destroyable surface 
decoration of CNTs with chitosan biopolymer via a controlled surface-deposition and 
crosslinking process [235]. Ren et al. non-covalently functionalized oxidised 
MWCNTs with PEG (O-MWCNTs-PEG) and PEG-angiopep-2 (O-MWCNTs-PEG-
ANG), and evaluated their cytotoxicity to brain capillary endothelial cells (BCEC) 
and C6 glioma cells: cells viabilities of BCEC and C6 remained above 90% following 
exposure to O-MWCNTs-PEG and O-MWCNTs-PEG-ANG at the concentrations up 
to 100 μg/mL, which suggested that both complexes exhibited low toxicity and good 
biocompatibility due to the PEG coating [144]. 
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Lipids have also been used for non-covalent coating on account of the amphiphilic 
property. Water-soluble SWCNTs, which were coated with lysophophatidylcholine 
(LPC), were fed to the planktonic crustaceans Daphnia magna, and no mortality was 
observed at concentrations up to 5 mg/L; the results also suggested that Daphnia 
magna could digest the LPC portion of the LPC-SWCNTs supramolecular complex, 
in which the digested lipid was used as a food source and non-coated SWCNTs were 
egested below the threshold concentration of toxicity [236]. Liu et al. treated mice 
with SWCNTs non-covalently covered by phospholipids bearing long and more 
branched PEG, observing longer blood circulation time and lower uptake by the 
reticuloendothelial system, which are beneficial to targeted imaging or therapeutic 
applications [180]. 
Some studies have also exploited multi-domain peptides as biocompatible 
solubilizing agents; the hydrophobic amino acid residues are immobilized on CNTs 
sidewalls, while the hydrophilic residues interact primarily with water to solubilize 
CNTs in an aqueous solution. Bakota et al. compared SWCNTs non-covalently 
coated with a series of short, multi-domain peptides, finding that charged residues on 
the peptide termini markedly affected compatibility of peptide-wrapped SWCNTs 
with biological systems, i.e. a tendency to aggregate in the culture medium occurred 
when SWCNTs were coated with peptides bearing the positively charged residue 
lysine in the charged domain, while no visible aggregates were detected when lysine 
was replaced by the negatively charged glutamic acid, which was confirmed by 
atomic force microscopy (AFM) images and NIR fluorescence spectra. It was 
postulated that the positive charge of lysine residues was neutralized by negatively 
charged phosphate ions in the cell culture medium; thereby the individual peptides 
lost their capacity to repel one another and self-assembled into aggregates. The 
authors also measured cell viability of NIH 3T3 mouse fibroblasts exposed to these 
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peptide coatings, concluding that there is no evidence for synergistic toxicity effects 
involving SWCNTs and peptide surfactants, at least at the concentrations between 
150 and 300 μM. After 48 h, cells were imaged with a NIR fluorescence microscope, 
and the results showed that significant amounts of nanotubes still remained in 
solution, as well as interactions between SWCNTs and 3T3 cells were detectable 
[237]. 
In addition, CNTs were solubilized by non-covalent coating with DNA through 
electrostatic interactions. DNA is classified as a natural polymer with interesting 
solubilizing properties of numerous materials [238]. It was suggested that both DNA 
chain flexibility and backbone charge might have contributed to high dispersion 
efficiency. Zheng et al. in 2003 first described the interaction between CNTs and 
DNA [239]. It was demonstrated that nucleic acids could easily adhere to the surface 
of CNTs on the basis of a π-stacking interaction that dispersed the bundles into 
individual tubes, while exposing the sugar-phosphate groups to water. This was 
confirmed by electronic adsorption and NIR fluorescence. Cathcart et al. carried out 
an extensive study on the time dependence of DNA wrapping in SWCNT dispersions 
[240]. SWCNTs were dispersed in water with salmon testes DNA and monitored over 
a three-month period. HR-TEM images of the DNA-SWCNT hybrids clearly showed 
the progressive formation of a coating of DNA on the walls of the nanotubes over 
time. It was found using HR-TEM and circular dichroism (CD) spectroscopy that the 
improvement in both the NIR photoluminescence (PL) intensity and the van Hove 
absorption peaks corresponded to the completion of a monolayer coating of DNA on 
the SWCNT walls. Eventually, HR-TEM images of the DNA-SWCNT hybrids with 
complete coating showed the DNA wrapping helically around the SWCNTs in a 
surprisingly ordered fashion. Interestingly, the solubilizing capacity of DNA is 
reversible; polyaromatic molecules, such as rhodamine 6G (R6G) and methylene blue 
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(MeB), were found capable of precipitating DNA-solubilized SWCNTs from solution 
through a competitive binding mechanism whereby DNA is displaced from the 
nanotube surface, allowing the nanotubes to rebundle [241]. Moreover, R6G and 
MeB, both positively charged molecules due to the presence of amino and imino 
moieties, are able to shield the negative charges on the DNA backbone and allow the 
SWCNTs to approach each other, in essence acting as an electrostatic glue. Similarly, 
this delamination of DNA also occurred when complementary oligonucleotides were 
used to hybridize to the DNA coating on the nanotubes, essentially peeling it off the 
SWCNTs. 
 
1.3.2.2 Covalent binding 
The covalent functionalization of CNTs is considered to achieve a greater 
biocompatibility of functionalized CNTs (f-CNTs) with physiological systems. 
Chemical functionalization could increase the solubility of f-CNTs in physiological 
conditions and hence lead to a decrease in their toxicity, which is correlated with the 
degree of sidewall functionalization [242, 243]; furthermore, in vivo studies on 
elimination of CNTs from the body have revealed higher urinary excretion rates when 
f-CNTs are individualized rather than aggregated in the bloodstream [244, 245]. A 
comparison between the toxicity of covalently functionalized and non-covalently 
coated CNTs indicated that f-CNTs exhibited lower toxicity than non-covalently 
coated CNTs and pristine CNTs [204]. 
Carboxylated CNTs processed by strong acid treatment are more water-soluble than 
pristine CNTs, since carboxylation in strong acids cuts nanotubes into smaller 
fragments and generates surface defects comprised of hydrophilic carboxyl 
functionalities, making them shorter and more suspensible. Moreover, the oxidation 
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process is able to purify CNTs by reducing the amount of metal catalyst. A large 
amount of studies have shown that carboxylated CNTs have lower toxicity and better 
biocompatibility. Human promyelocytic leukemia HL60 cells were incubated with 
carboxylated SWCNTs at the concentration of 50 μg/mL for 1 h; observation after 24 
and 48 h indicated that carboxylated SWNCTs exhibited little toxicity to HL60 cells 
[130]. Zhang et al. found that carboxylation provided more stable dispersions than 
pristine MWCNTs, and carboxylated MWCNTs exhibited lower cytotoxicity to RAW 
264.7 mouse macrophages, although inflammatory responses were induced by 
carboxylated MWCNTs; meanwhile, higher internalization of carboxylated 
MWCNTs inside cells was observed after 24 h incubation compared with pristine 
MWCNTs [246]. This observation is consistent with the findings that carboxylated 
surfaces enhance cellular uptake, and the amount of nanotube uptake could be 
correlated to the degree of functionalization [247]. Such phenomena might be 
attributed to favorable interactions between the cells and the negatively charged 
coating. 
The carboxyl functionalities of CNTs are available for further modification via 
covalent linkage with other molecules. Carboxylated CNTs have been functionalized 
with PEG through formation of ester bonds other than non-covalent coating. It has 
been reported that PEGylation improved hydrophilicity and dispersion ability of 
MWCNTs, and PEGylated MWCNTs were less toxic to osteoblasts than raw 
MWCNTs [248]. A comparison study of cytotoxic and inflammatory responses of 
pristine and functionalized MWCNTs in macrophages showed that PEG-MWCNTs 
were less cytotoxic than pristine and carboxylated MWCNTs, and were less effective 
for induction of pro-inflammatory cytokines compared with carboxylated MWCNTs 
[246]. Moreover, cellular uptake showed that few PEG-MWCNTs were located in the 
cellular interior after 24 h incubation, suggesting that PEG-MWCNTs in solutions 
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lack the ability to traverse across cell membranes by themselves. Such a decrease in 
cellular uptake is due to PEGylation, which is able to reduce the interaction of 
nanotubes with cells via the formation of a hydrophilic stealth coating around the 
particles [249]. Besides, the serum biochemical parameters assessments were carried 
out to evaluate the in vivo toxicity of PEGylated SWCNTs, showing that the ALT and 
AST levels of mice exposed to PEG-SWCNTs remained unchanged in comparison 
with a dose-dependent increase caused by pristine SWCNTs; therefore PEG-
SWCNTs were less toxic than pristine SWCNTs [207]. Bhirde et al. synthesized 
highly aqueous dispersible PEG-SWCNTs through covalent attachment of PEG onto 
SWCNTs, as well as investigated their adverse reactions, distribution and clearance in 
athymic mice after intravenous administration [250]. In this in vivo study, no 
inflammatory responses were detected in the lungs or elsewhere following 24 h 
exposure to PEG-SWCNTs. Raman analysis of vital organs and fecal material from 
mice treated with PEG-SWCNTs suggested slower clearance of SWCNTs in vivo 
through a biliary/renal pathway of excretion compared with non-PEG-SWCNTs. 
Many other functionality species have also been demonstrated in the studies of 
covalent functionalization to improve the biocompatibility of CNTs with 
physiological systems. Phospholipid-modified MWCNTs were prepared by covalent 
functionalization with 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and 
the DSPE-MWCNTs showed enhanced dispersibility not only in nonpolar solvent 
CHCl3 but also in an aqueous solution [251]. The lysine-modified MWCNTs (Lys-
MWCNTs) exhibited a much higher dispersibility in water under a wide range of pH 
values (5~14) and maintained stable concentration as high as 10 mg/mL, which was 
nearly 2 orders of magnitude higher than that obtained from carboxylated MWCNTs 
[252]. Furthermore, the dispersibility of Lys-MWCNTs was pH-sensitive and 
reversible; precipitation appeared quickly below pH 5, and disappeared when pH was 
Chapter 1 Introduction 
44 
 
adjusted back to the range of pH 5~14. Says et al. found that the covalently 
functionalized SWCNT-phenyl-SO3H and SWCNT-phenyl-SO3Na caused 
insignificant damage to cells even at high concentrations (> 2 mg/mL); moreover, it 
has been observed that SWCNT-phenyl-SO3H and SWCNT-phenyl-(COOH)2 
exhibited lower cytotoxicity than SWCNTs non-covalently coated with Pluronic F108 
[242]. The polyamidoamine-MWCNT (PAMAM-MWCNT) hybrids, which were 
prepared by covalent linkage approach, exhibited good dispersibility and stability in 
aqueous solution [253]. It was observed, using EM analysis, that lots of PAMAM-
MWCNT hybrids bound to HeLa cellular surface; moreover, PAMAM-MWCNT 
hybrids penetrated into HeLa cells and most of them were in the cytoplasm while 
some others into or near the nucleus, suggesting that PAMAM-MWCNT hybrids had 
good affinity for HeLa cells; this is likely due to the interaction between the 
positively charged PAMAM-MWCNT hybrids and the negatively charged cellular 
membrane. Qin et al. found that PAMAM-MWCNT hybrids could immobilize 
plasmid DNA of enhanced green fluorescence protein (pEGFP-N1) and efficiently 
deliver GFP gene into cultured HeLa cells [254]. The transfection efficiency of 
PAMAM-MWCNT hybrids (7.9%) was about 3.4 and 1.9 times as large as that of 
carboxylated MWCNTs (2.3%) and pure PAMAM dendrimers (4.1%), respectively. 
High cell viability of HeLa cells was observed after incubation with PAMAM-
MWCNT hybrids at concentrations below 15 μg/mL over 24 h, and morphological 
studies showed that HeLa cells, which were incubated with PAMAM-MWCNT 
hybrids at different concentrations, lived better than those incubated with pure 
PAMAM. Therefore, the surface modification of MWCNTs could be a feasible 
strategy to develop non-viral gene carriers with good biocompatibility and delivery 
performance. 
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These great efforts to modify CNTs have efficiently enhanced their biocompatibility 
and lessened concerns about toxicity of CNTs towards physiological systems. In 
addition, the carboxyl functionalities of oxidised CNTs and other reactive sites of 
modified CNTs are favorable for the attachment of various drugs and targeting agents. 
Therefore the functionalization of CNTs is rapidly advancing the development of 
CNTs as potential carrier in drug delivery. 
 
  




The impact of nanotechnology is rapidly growing everywhere, including building 
industry, daily consumables, heavy industry, information technology, medicine, 
textile industry, etc. Nanomedicine has been established on the basis of 
nanotechnology to enhance therapeutic effects and relieve patients’ discomfort during 
the treatment process. Besides the infusion of nanotechnology into medical 
instruments, nanomaterials are used to develop novel drug delivery systems, which 
are aimed to efficiently reach the desired target with minimal side effects. Carbon 
nanotubes, emerging carbonaceous nanomaterials, have shown potential as carriers 
for drug delivery in view of their unique properties, such as needle-like structure, 
large surface area, high aspect ratio, facile modification, etc. Although toxicity of 
CNTs is a great concern that may hamper their use in physiological systems, a large 
amount of efforts have been made to improve the biocompatibility of CNTs and 
further optimize their capability to work in physiological conditions. Indeed, it has 
been extensively demonstrated that appropriate modification of CNTs (such as 
purification, physical coating, chemical functionalization, attachment of targeting-
ligands, etc.) could even enable high-performance delivery, improve recognition at 
the diseased sites, and circumvent normal tissues, so as to achieve selective transport 
of therapeutic molecules. 
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Chapter 2 Hypothesis and Objectives 
 
 
2.1 Thesis rationale and hypothesis 
Carbon nanotubes (CNTs) as an emerging nanomaterial have generated considerable 
recent research interest, due to their unique properties that render them suitable for 
several applications not only in material science and electronics, but also in biology 
and even in medicine. These characteristics include needle-like structure (which 
enables them to pierce cells without causing disruption of the cellular membrane), 
ultrahigh surface area (which affords the capability to carry multiple moieties at high 
density), huge interior volume (which provides large space for drugs storage and 
protects the entrapped drugs from external environment), intrinsic stability (which 
ensures a stable and safe delivery in harsh environments), facile functionalization 
(which allows the attachment of many functional groups, therapeutic agents or 
antibodies/peptides to their surface), etc. These features suggest their use as a novel 
nano-carrier to transport drugs into cells, thus providing a solution to insoluble drug 
molecules or macromolecules incapable of penetrating cells. 
The studies presented in this thesis were based on the following hypotheses: 
(1) By adopting different strategies on CNTs (namely nano-extraction and/or nano-
condensation), anticancer chemotherapeutic drugs like cisplatin could be 
successfully encapsulated into the interior of multi-walled CNTs (MWCNTs) 
with high loading efficiency and, due to the MWCNTs’ ability to penetrate cells, 
the drug’s cytotoxic effect could be enhanced against tumor cells in comparison 
with the drug alone. 
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(2) The drug (cisplatin) release from CNT-based carrier could be controlled by 
corking the open-tips of nanotubes with “caps” after drug encapsulation, forming 
a “carbon nano-bottle” structure. 
(3) Platinum(IV) prodrugs could be entrapped within MWCNTs to construct a 
controlled-release drug delivery system on the basis of a drastic reversal in 
hydrophobicity of encapsulated platinum(IV) complexes. The platinum(IV) 
prodrugs could be stably preserved inside the nanotubes, while release will be 
activated under reducing conditions, which could elicit their conversion to 
hydrophilic platinum(II) species. Therefore this strategy could exhibit selective 
cytotoxic effect against tumor cells, which are characterized by a higher 
intracellular reducing environment. 
(4) Due to the intrinsic ability of CNTs to accumulate in some organs/tissues, drug 
delivery with MWCNTs will be able to alter the distribution of drugs in vivo. 
Different nanotubes (i.e. pristine MWCNTs, oxidised MWCNTs, amidated 
MWCNTs) will have various effects on the biodistribution due to their variations 
in the properties, such as length, charge, surface hydrophilicity, etc. 
 
2.2 Objectives 
To prove these hypotheses, we propose the following specific objectives: 
(1) The incorporation of cisplatin into MWCNTs through nano-extraction and/or 
nano-condensation methods will be optimized using a variety of solvents to 
achieve high loading efficiency in the interior and the least amount of cisplatin 
deposited on the external surface. 
(2) One “nano-bottle” design is to co-encapsulate another material, which is smaller 
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than the diameter of nanotubes, at the open ends of nanotubes to slow down the 
release rate of the encapsulated drug. This method could prolong the period of 
drug release and avoid initial burst release as well as premature release in bodily 
fluid, obtaining improved cellular uptake of cisplatin by tumor cells and 
attenuation of side effects on healthy cells. 
To achieve this purpose, the open-tips of nanotubes will be blocked through 
suction of small AuNPs into the inner cavity after encapsulation of cisplatin. The 
in vitro release behavior of cisplatin from “nano-bottles” and cell viability assay 
of tumor cells following the treatment with “nano-bottles” will be carried out to 
assess the efficacy of “caps”. 
(3) The other “nano-bottle” design is to completely seal the open-tips from the 
external environment by attaching the “caps” material, whose size is larger than 
the nanotubes’ diameter, to the functional groups at the ends through the 
formation of cleavable bonds. This method could safely retain drug molecules 
inside nanotubes and prevent the release under physiological conditions, while 
specific conditions will trigger the release upon the dissociation of cleavable bond 
in pathological environment, hence achieving selective cytotoxicity to tumor 
cells. 
Towards this purpose, large AuNPs will be tethered to the open ends to seal the 
nanotubes loaded with cisplatin. Different conditions will be designed to 
investigate the controlled release in vitro. Cell viabilities of tumor cells and 
normal cells exposed to “nano-bottles” will be compared to confirm the selective 
killing of tumor cells. 
(4) Platinum(IV) prodrug will be entrapped within MWCNTs and its release under 
reducing conditions will be confirmed. The activity of release platinum species 
will be examined by conjugation with dGMP as a DNA model, and cellular 
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uptake of elemental platinum in tumor cells treated with the MWCNT-Pt(IV) 
complexes will be analysed to evaluate the transportation of platinum(IV) 
prodrug into cells using nanotube as a carrier. 
(5) Cisplatin and platinum(IV) prodrug will be entrapped within pristine, oxidised, 
and amidated MWCNTs. These MWCNT-drug complexes will be intravenously 
injected into mice to investigate the distribution of elemental platinum in vivo. 
The immune-response and histopathological analyses will evaluate the 
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The information contained in this chapter has been collated in the following 
article: 
 Li Jian et al., Carbon nanotube bottles for incorporation, release and 
enhanced cytotoxic effect of cisplatin. Carbon, 2012. 50(4): 1625-1634. 
 
3.1 Introduction 
3.1.1 Anticancer drug cisplatin 
Cisplatin (cis-diamminedichloroplatinum(II), CDDP, Fig. 3.1) is a chemotherapy 
drug that acts as an alkylating agent, although it has no alkyl groups and is unable to 
carry out alkylating reactions [255]. It is the first member of platinum-containing 
anticancer drugs, which now also include carboplatin and oxaliplatin, and was 
approved by FDA in 1978. Cisplatin is widely used alone or with other drugs to treat 
a wide spectrum of cancers, including bladder cancer, cervical cancer, germ cell 
cancer, lymphomas, malignant mesothelioma, non-small cell lung cancer, squamous 
cell carcinoma of head and neck, and testicular cancer [256, 257]. 
 
Fig. 3.1 Structure of cisplatin. 
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In the treatment of carcinoma following administration of cisplatin, the drug 
molecules undergo an aquation process, in which one of the chloride ligands is slowly 
displaced by water (an aqua ligand). The aqua ligand in the resulting 
[PtCl(H2O)(NH3)2]
+ is itself easily displaced, thus the platinum atom in the labile 
compound is able to bind to bases, resulting in the formation of monofunctional DNA 
adducts [258]. Guanine and adenine, among the bases in DNA, are preferentially 
combined with the [PtCl(H2O)(NH3)2]
+, since the N7 atoms of the imidazole rings of 
guanine and adenine located in the major groove of the double helix are the most 
accessible and reactive nucleophilic sites for platinum binding to DNA [259]. 
Following the formation of [PtCl(guanine-DNA)(NH3)2]
+, the other chloride ligand is 
further displaced typically by another guanine to produce irreversible interstrand or 
intrastrand cross-links of DNA, which then block replication and/or prevent 
transcription [260]. Cisplatin cross-links DNA in several different ways, thus causing 
interference with cell division by mitosis. The 1,2-intrastrand cross-links 
with purine bases generally occur following the treatment of cisplatin. It has been 
found that 60~65% of adducts formed by cisplatin are 1,2-intrastrand d(GpG) cross-
links, and 1,2-intrastrand d(ApG) cross-links are responsible for 20~25% of the 
adducts. 1,3-intrastrand d(GpXpG) cross-links take place but are unstable, since they 
are readily excised by the nucleotide excision repair (NER). Minor adducts, each 
accounting for a small percentage, include inter-strand cross-links and nonfunctional 
adducts that have been postulated to contribute to cisplatin’s activity [261]. As a 
result, the cross-links cause damage to DNA and subsequently elicit DNA repair 
mechanisms; the resulting DNA damage triggers cell cycle arrest at either the G1, S, 
or G2 phase, therefore apoptosis will be induced when repair proves impossible [262-
264]. 
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Despite the efficacy in therapy of cancers, a number of side effects also occur 
following the treatment with cisplatin, thus limiting its use. These side effects include 
nephrotoxicity (kidney damage) that is a major concern, neurotoxicity (nerve 
damage), nausea and vomiting, ototoxicity (hearing loss), electrolyte disturbance, 
myelotoxicity, as well as a temporary drop in the number of blood cells produced in 
bone marrow (low white blood cell count with increased risk of infection, low platelet 
count with increased risk of bleeding, low red blood cell count, which can cause 
fatigue, dizziness, or breathlessness) [265-269]. Therefore, administration of cisplatin 
needs effective drug delivery systems to enhance the drug content in tumors and 
avoid or lessen the accumulation in normal tissues, in order to eliminate or relieve 
side effects. In this study, we encapsulated cisplatin into multi-walled carbon 
nanotubes (MWCNTs) through nano-extraction and nano-condensation methods. 
Cisplatin was successfully entrapped within the inner cavity of MWCNTs, and a 
higher loading of drug molecules was obtained compared with results reported in 
literature [158, 159]. 
 
3.1.2 Rationale of nano-extraction and nano-condensation [270] 
The CNTs’ interior has a more favorable binding energy towards molecules’ 
adsorption compared with their external surface [145-147], and the huge hollow space 
seems to be suitable for entrapment of other molecules. Yudasaka et al. described two 
methods for incorporating guest molecules into the inner cavity of CNTs. These two 
strategies were defined as nano-extraction and nano-condensation, respectively, since 
the incorporation mechanisms of these methods are similar to those of two 
conventional methods widely used in chemistry, namely extraction and condensation. 




Fig. 3.2 Schematic illustration of nano-extraction and nano-condensation. The 
relative affinities among the guest molecules, solvents, and CNTs needed to carry out 
nano-extraction and nano-condensation are shown on the triangles. Modified from 
“Nano-extraction and nano-condensation for C60 incorporation into single-wall 
carbon nanotubes in liquid phases,” by Yudasaka, M., et al., 2003, Chemical Physics 
Letters, 380(1-2), p. 42-46. 
 
In nano-extraction, guest molecules must have poor affinity for the solvent but strong 
affinity for the CNTs; also, the solvent must have poor affinity for CNTs (Fig. 3.2). 
Indeed, to achieve nano-extraction, the solvent inside the tube walls needs to be 
replaced by guest molecules. For this purpose, the attractive forces among the three 
agents (namely, CNTs, guest molecule, and solvent) must be appropriately balanced 
(Fig. 3.2): the attractive force between the guest molecules and the graphene-sheets of 
CNTs must be greater than that between the guest molecules and solvent molecules 
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and that between the solvent molecules and CNT graphene-sheets. If these conditions 
are satisfied, guest molecules will be deposited within the CNTs, since CNT’s interior 
is the most stable site for deposition and subsequently guest molecules will gather 
there [271, 272]. Yudasaka et al. demonstrated nano-extraction through incorporation 
of fullerene C60 into SWCNTs in ethanol. They put C60 crystallites (1 mg) into 
ethanol (10 mL), ultrasonicated the solution for 3 min, added SWCNTs (1 mg), and 
left this SWCNT-C60-ethanol mixture for 1 day at room temperature (Fig. 3.2). 
Transmission electron microscopy (TEM) observation showed that C60 molecules 
were incorporated inside the SWCNTs through nano-extraction, in contrast to the 
empty SWCNTs prior to incorporation. One the other hand, when toluene was used 
instead of ethanol, the nano-extraction did not work, probably because the C60-
SWCNT interaction was unable to compete with C60-toluene and/or SWCNT-toluene 
interactions. 
If the solvents have strong affinity for the guest molecules and CNTs, nano-extraction 
is unable to incorporate guest molecules into CNTs. Instead, Yudasaka et al. adopted 
nano-condensation to incorporate C60 into SWCNTs in toluene. They dropped about 
10 μL of C60-toluene saturated solution (2.8 mg/mL) onto SWCNTs placed on a grid 
disk laid on filtration paper. TEM observation verified the deposition of C60 
molecules inside SWCNTs. 
In nano-condensation, competing processes are the adsorption of solvent molecules 
onto the tube walls, evaporation of solvent molecules, segregation or self-
crystallization of guest molecules, and deposition of guest molecules inside the tube 
walls. Yudasaka et al. tentatively interpreted the mechanism as follows: in the C60-
toluene-SWCNT cases, the C60-toluene solution remained on the SWCNT surfaces 
after the solution was absorbed by the filtration paper, and toluene formed thin layers 
covering the inside and outside of the tube walls (Fig. 3.2). The C60 molecules were 
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bound to the thin toluene layers and to the SWCNT walls via van der Waals forces; 
they migrated through the thin toluene layers, and eventually deposited themselves 
inside the tubes, which represent the most stable sites for C60 molecules.  
 
3.1.3 Selective washing of CNTs with guest molecules [273] 
In the process of incorporation, a certain amount of material is inevitably deposited 
onto external walls of the CNTs, no matter whether they are prepared through either 
nano-extraction or nano-condensation [274]. To achieve exclusive filling of CNTs, Fu 
et al. proposed a simple strategy as illustrated in Fig. 3.3 [273]. In step I, open CNTs 
are impregnated with excess of the precursor solutions to ensure that most of the 
tubes can be filled by the impregnating solution. In step II, a suitable washing 
medium is used to dissolve the solution sticking onto the external walls of CNTs but 
keep the solution stable in the internal cavity. 
 
Fig. 3.3 Scheme of the selective filling of carbon nanotubes: (I) filling of CNTs via 
impregnation and (II) selective washing. Modified from “Selective filling of carbon 
nanotubes with metals by selective washing,” by Fu, Q., et al., 2008, New Carbon 
Materials, 23(1), p. 17-20. 
 
The impregnation of solution is dependent on the capillarity energy ∆Ecapillarity, and 
the dissolution of the impregnating solution into the washing medium (step II in Fig. 
3.3) is driven by the solvation energy ∆Esolvation. From the thermodynamic point of 
view, the dissolution of the impregnating solution, which sticks to external walls of 
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CNTs, into the washing medium necessitates the condition of ∆Esolvation < 0. On the 
other hand, ∆Ecapillarity < ∆Esolvation is required to ensure that the solution is stable in the 
internal cavity of CNTs; otherwise, it may dissolve into the outside washing medium. 
In summary, to achieve the selective washing shown in Fig. 3.3, the following 
inequality is needed: ∆Ecapillarity < ∆Esolvation < 0. 
Therefore, the key point in this strategy is to find suitable impregnating solutions and 
washing medium. The above inequality suggests that impregnating solution should 
present limited solubility in the washing medium, in order to enable the dissolution of 
the impregnating solution bound to the external walls of CNTs into the washing 
medium but keep it unchanged in the internal cavity. 
 
3.2 Hypothesis and objectives 
In this chapter, we put forward a hypothesis that, by encapsulating the anticancer drug 
cisplatin inside the nanotubes’ interior via nano-extraction and/or nano-condensation 
methods, MWCNTs could act as an efficient carrier that affords great drug loading, 
and potentially improve the delivery performance of encapsulated drug. Towards that 
purpose: 
(1) Cisplatin will be incorporated into MWCNTs through nano-extraction and nano-
condensation methods to achieve high loading efficiency. 
(2) We will estimate the effect of MWCNTs on the in vitro release profile of 
cisplatin: the resulting MWCNT-CDDP complex will be dialysed in neutral and 
mildly acidic media, respectively; the acidic conditions are aimed to simulate 
cisplatin release in tumoral environment. 
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3.3 Materials and methods 
3.3.1 Chemicals and reagents 
cis-Diammineplatinum(II) dichloride (cisplatin) and ultrapure nitric acid (≥ 65%, for 
ultratrace analysis) were purchased from Sigma Aldrich. Dimethylsulfoxide (DMSO) 
was purchased from Merck. Dimethylformamide (DMF) was purchased from Fisher 
Scientific. Tetrahydrofuran (THF) was purchased from Reagent Chemical Industry 
Ltd. All other solvents were obtained from Tedia. Ultrapure water was obtained from 
Sartious-Stedim biotech atrium® 611 system (18.2 MΩ-cm resistivity). Spectra Por 
dialysis membrane (12,000~14,000 MWCO) was used in the drug release experiment. 
Fluoropore hydrophobic PTFE membranes (0.22 µm) were purchased from Millipore. 
Commercial MWCNTs with diameters of ≤ 10 nm, length of 1~2 μm, and a purity of 
≥ 95% (code S.MWNTs-10), were purchased from NTP (Shenzhen Nanotech Port Co. 
Ltd, China). Ultrapure MWCNTs were kindly provided by Professor Ramaprabhu 
(Nano-Functional Materials Technology Centre (NFMTC), Indian Institute of 
Technology, Chennai, India): the outer and inner diameters of ultrapure MWCNTs 
(purity > 95%) are 30~40 nm and approximately 10 nm, respectively; their length 
ranged from a few hundred nanometers to several microns. 
 
3.3.2 Instruments 
TEM was carried out using JEM 2010F HR-TEM (JEOL). Scanning Electron 
Microscopy Energy Dispersive X-ray (SEM-EDX) analysis was carried out using 
JSM-6700 Field Emission Scanning Electron Microscope. Thermogravimetric 
analysis (TGA) using TGA-SDT 2960 Simultaneous DTA-TGA and Inductively 
Coupled Plasma Optical Emission Spectrometry (ICP-OES) using Perkin Elmer 
Chapter 3 Carbon Nanotubes for Incorporation, Storage and Release of Cisplatin 
59 
 
Dual-view Optima 5300 DV Inductively Coupled Plasma Optical Emission 
Spectrometer were performed by CMMAC (NUS). 
 
3.3.3 Methods 
3.3.3.1 Entrapment of CDDP within MWCNTs via nano-extraction and nano-
condensation methods 
3.3.3.1.1 Dispersibility test of carbon nanotubes 
Commercial pristine MWCNTs and oxidised MWCNTs (MWCNTox, obtained 
following the procedure reported by Nayak et al. [275]) were dispersed in water, 
DMF, and DMSO to investigate their dispersibility in polar solvents. The 
dispersibility test of ultrapure pristine MWCNTs, which were provided by Professor 
Ramaprabhu’s research group, was performed in these polar solvents and some non-
polar organic solvents as well. 
In the dispersibility test, nanotubes (30 μg, 60 μg, 100 µg, 1 mg) were weighed and 
suspended in solvents (0.5~1.5 mL) under sonication, after which the stability of 
nanotubes in the solvents was examined by centrifugation at 7,000 rpm for 20~30 s. 
The volume of solvent was increased until no observable solid remained in the 
solution after the pulse centrifugation. 
 
3.3.3.1.2 Solubility test of CDDP 
A wide range of solvents (e.g. acetone, diethyl ether, ethanol, ethyl acetate, methanol, 
water, etc.) was used to investigate the solubility of CDDP. 
CDDP (300 μg, 400 μg, 700 μg) was weighed and dispersed in solvents (0.5~1.5 mL) 
under sonication, after which centrifugation at 7,000 rpm for 20~30 s was performed 
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to determine the presence of solid remaining in the solution. The volume of solvent 
was increased until no observable solid remained in the solution, and this 
concentration was considered as the solubility of the CDDP in a certain solvent. 
 
3.3.3.1.3 Screening of “washing solvent” 
There was a portion of CDDP remaining in the solvent or sticking onto the external 
walls of nanotubes in the process of encapsulation. Therefore, an exhaustive study of 
solvents’ miscibility and dissolving capacity was carried out to identify a “washing 
solvent” able to remove the un-capsulated CDDP and keep the CDDP in the internal 
cavity unchanged. To explore the suitable “washing solvent”, ethyl acetate, ethanol, 
and water were mixed by adjusting their proportions until the 3 solvents became 
miscible. The dissolving capacity of this mixture was also evaluated by solubility test. 
 
3.3.3.1.4 Encapsulation of CDDP in MWCNTs 
3.3.3.1.4.1 Nano-extraction method [270] 
The choice of solvents for nano-extraction and nano-condensation methods was based 
on the results of solubility test, which are described below. CDDP was dispersed in 
various solvents (acetone, ethanol, ethyl acetate, methanol, etc.) at a concentration of 
2.5 mg/mL under sonication. Ultrapure MWCNTs (4 mg) were added to the 
suspension of CDDP (4 mL), followed by 15 min of sonication. The mixture of 
CDDP and MWCNTs was stirred at room temperature for 24 h in the dark. The 
MWCNTs were filtered through a 0.22 µm hydrophobic PTFE membrane (Millipore) 
to yield MWCNT-CDDP complex, followed by an extensive washing with ethyl 
acetate:ethanol:water (2.6:1:1 v/v) to remove CDDP bound to the MWCNTs’ external 
surface. The remaining solid was then dried under vacuum. 
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3.3.3.1.4.2 Nano-condensation method [270] 
CDDP was dissolved in deionized water (0.6 mL) at a concentration of 3.5 mg/mL. 
Ultrapure MWCNTs (0.4 mg) were added to the CDDP aqueous solution, followed 
by 15 min of sonication. The mixture was stirred at room temperature for 24 hours in 
the dark. The MWCNTs were dried to yield raw MWCNT-CDDP and then 
extensively washed with ethyl acetate:ethanol:water (2.6:1:1 v/v) to remove the 
eventual CDDP bound to the MWCNTs’ external surface. The remaining solid was 
then dried under vacuum. 
 
These as-prepared MWCNT-CDDP complexes were analysed using TEM and SEM-
EDX. CDDP content in MWCNT-CDDP complexes was evaluated using TGA and 
ICP-OES. 
 
3.3.3.2 Characterization of MWCNT-CDDP 
3.3.3.2.1 Transmission Electron Microscopy (TEM) 
TEM imaging was carried out using JEOL JEM 2010F Microscope with an 
accelerating voltage of 200 keV. The samples were prepared by placing a drop of 
MWCNTs aqueous suspension (10 μg/mL) on 300 mesh copper grids coated with 
carbon and by drying it at room temperature. Micrographs at various positions were 
taken and the size of the preferentially present tubes or particles was determined by 
examination of several (≥ 10) micrographs. 
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3.3.3.2.2 Quantification of encapsulated CDDP using TGA and ICP-OES 
Thermal studies were carried out using TGA-SDT 2960 Simultaneous DTA-TGA. 
The samples were heated in air at a heating rate of 10 °C/min until a final temperature 
of 1000 °C was reached. The residue remaining after TGA was dissolved in aqua 
regia and diluted with 2% HNO3 for ICP-OES determination of platinum levels. 
 
3.3.3.3 In vitro release of CDDP from MWCNT-CDDP complex 
In vitro release was evaluated using a dialysis bag diffusion technique. The dialysis 
membranes were kept overnight in deionized water before dialysis to ensure the 
thorough wetting of the membrane. 
To study the release profile of CDDP from MWCNT-CDDP in phosphate-buffered 
saline (PBS), MWCNT-CDDP (containing 0.5 mg of CDDP) was dispersed in 
deionized water (200 µL), transferred to a dialysis button with 12,000~14,000 Da cut-
off (which allowed the free exchange of CDDP and release media) and immersed into 
PBS (pH 7.4) as release medium (400 mL). An aliquot (2 mL) of sample was 
collected from the release medium at regular intervals (i.e. every 5 min in the first 
half an hour, every one hour within 1~6 h, and subsequently 8 h, 12 h, 24 h, 36 h, 48 
h, 96 h) and their platinum contents were determined using ICP-OES to evaluate the 
CDDP released from MWCNTs. 
The in vitro release experiment was also carried out in phosphate buffer at pH 5.5 as 
release medium to mimic a typical cancerous environment that is mildly acidic. 
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3.4 Results and discussion 
3.4.1 Dispersibility of carbon nanotubes 
The dispersibility tests were performed to choose suitable CNTs, which had good 
dispersion in water, as vehicles for encapsulation of CDDP among 3 available kinds 
of MWCNTs. 
 
Table 3.1 Dispersibility of CNTs in polar protic, polar aprotic, and non-polar solvents. 
 












Ethanol > 2.8 mg/mL  —  — 
Methanol < 205 µg/mL  —  — 
Water > 4.9 mg/mL  10~26 µg/mL  40~50 µg/mL 
       
Polar 
aprotic 
Acetone < 105 µg/mL  —  — 
Acetonitrile 300~400 µg/mL  —  — 
Dioxane < 160 µg/mL  —  — 
DMF > 10 mg/mL  > 20 mg/mL  ≤ 225 µg/mL 
DMSO > 10 mg/mL  > 10 mg/mL  — 





< 180 µg/mL  —  — 
 
aCommercial MWCNTox was prepared from commercial pristine MWCNTs 
purchased from NTP through the oxidation procedure reported by Nayak et al [275]. 
 
As reported in Table 3.1, the dispersibility of commercial pristine MWCNTs was 
very limited in water. The commercial pristine MWCNTs were stable in water for 
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more than 12 h at the concentration below 10 µg/mL, but their stability decreased 
with the rise of concentration. Oxidised MWCNTs (MWCNTox) showed improved 
dispersibility compared with pristine MWCNTs, attributed to a shorter length and the 
additional ionizable carboxylic acid groups, which allowed MWCNTox to be stable 
in water up to the concentration of 40~50 µg/mL. However, such degree of dispersion 
was not adequate for delivery of therapeutic molecules in aqueous conditions. In the 
special case of ultrapure pristine MWCNTs, their suspension in water could be stable 
for a long period, with a concentration up to 4.9 mg/mL. Taking into account the 
excellent dispersibility and stability of this batch of nanotubes, ultrapure MWCNTs 
were identified as the best vehicle for drug delivery and selected for the following 
experiments reported in this study. 
In addition, based on the principles of nano-extraction and nano-condensation 
methods, the solvents that are used for encapsulation should have specific affinities 
towards ultrapure MWCNTs. Suspensions of ultrapure MWCNTs were not stable in 
most organic solvents, with the exception of polar solvents like ethanol, DMF, and 
DMSO. DMF and DMSO had very strong capacity to disperse MWCNTs and 
maintain good dispersion for a long period of time. Compared with these polar aprotic 
solvents, ethanol, a polar protic solvent, did not have such an excellent dissolving 
capacity, but the MWCNTs ethanolic suspension could still be stable for more than 
24 h at the concentration of 2.8 mg/mL. The dispersibility study of MWCNTs in a 
variety of solvents suggested that acetone, acetonitrile, dioxane, ethyl acetate, and 
methanol could be candidates for nano-extraction method due to their weak affinities 
for MWCNTs, while the strong affinity of DMF and DMSO for MWCNTs could be 
favorable to the nano-condensation method. 
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3.4.2 Solubility of CDDP 
Taking into account the principles of nano-extraction and nano-condensation methods, 
the solvents that were used for encapsulation also required to have specific affinities 
for the guest molecules, therefore solubility of CDDP in various solvents were 
evaluated. Results from the solubility of CDDP in different solvents have been 
summarised in Table 3.2. 
 
Table 3.2 Solubility of CDDP in polar protic, polar aprotic, and non-polar solvents. 
 
Solvents Solubility of CDDP 
Polar protic 
Ethanol < 192 µg/mL 
Methanol < 205 µg/mL 
Water 3.65~4.87 mg/mL 
   
Polar aprotic 
Acetone < 347 µg/mL 
Acetonitrile < 320 µg/mL 
Dioxane < 171 µg/mL 
   
Non-polar 
Dichloromethane < 257 µg/mL 
Diethyl ether < 136 µg/mL 
Ethyl acetate < 265 µg/mL 
Petroleum ether < 273 µg/mL 
 
The solubility tests showed that CDDP was almost insoluble in most organic solvents 
except for water, DMF and DMSO, which were reported to have very good 
dissolving capacity. In this work, the solubility of CDDP in water was higher than 2 
mg/mL as reported in literature [276], so it is possible that a part of the CDDP 




+ due to displacement of chloride ligand by water 
during the test. 
Among all the solvents investigated in this study, DMF, DMSO, and water, which 
have strong affinity for CDDP, could be used for the encapsulation of CDDP through 
the nano-condensation method, while the solvents having weak affinity for CDDP, 
such as acetone, dioxane, and ethyl acetate, could be suitable for the nano-extraction 
method. 
 
3.4.3 Screening of “washing solvent” for selective cleaning of MWCNT-
CDDP 
The filling process in both nano-extraction and nano-condensation methods makes 
use of the principle of capillarity exerted by CNTs. However, this procedure 
inevitably results in the deposition of a certain amount of material onto external walls 
of the CNTs [274]. In this study, solvents’ miscibility and dissolving capacity were 
investigated to screen a suitable “washing solvent” (Table 3.3). Based on the 
physicochemical properties of CDDP and solvation phenomenon of liquids, a mixture 
of ethyl acetate:ethanol:water (2.6:1:1 v/v) was chosen as the “washing solvent” due 
to its miscibility and dissolving capacity. 
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Table 3.3 “Washing solvents” screening for CDDP (“√” miscible, “×” immiscible) 
 
Mixture Solubility 
EA:EtOH:water (v/v)  Miscibility 
(2.7~8):1:1  × — 
2.6:1:1  √ 0.78 mg/ml 
(2~2.5):1:1  √ —a 
16.5:4:3  × — 
16:4:3  √ < 0.41 mg/ml 
(8~15.5):4:3  √ —a 
(20~60):5:3  √ —a 
 
aSolubility of CDDP was not tested in this mixture, since this washing solvent with 
good solvation is not favorable to keep impregnating solution stable in the inner 
cavity, in terms of the principle of selective washing as mentioned in Section 3.3.3. 
 
3.4.4 Characterization of MWCNT-CDDP 
3.4.4.1 TEM imaging of MWCNT-CDDP 
As a confirmation of encapsulation, CDDP, ultrapure pristine MWCNTs and 
MWCNT-CDDP were evaluated under TEM. 
CDDP (Fig. 3.4) clustered as particles with size of about 1~2 nm. Ultrapure pristine 
MWCNTs (Fig. 3.5) had cavities with the diameter of 10~15 nm, and very neat walls 
with the thickness of 10~15 nm in comparison with normal pristine MWCNTs, 
although impurity (Fig. 3.5b, white circles) still existed at a few regions along the 
multi-layered walls. Fig. 3.5a showed that the tips of ultrapure pristine MWCNTs 
were already removed, hence the tubes were open. 




Fig. 3.4 TEM image of CDDP. 
 
TEM images of MWCNT-CDDP (Fig. 3.6) suggested that CDDP clusters were 
distributed along the MWCNTs. When acetone was used as filling solvent in the 
process of encapsulation, CDDP clusters appeared in the cavities (Fig. 3.6a) and to a 
higher extent adsorbed on the walls of MWCNTs (Fig. 3.6b). The appearance of 
CDDP clusters on the sidewalls was also observed in CDDP-loaded SWCNTs [159]. 
It is most likely that the tiny CDDP molecules (0.4×0.6 nm with 0.1 nm of thickness) 
[161] were entrapped within the defective sites. Moreover, Fig. 3.6a showed the 
leakage of CDDP clusters from the defective sidewalls, which were highlighted with 
black circles. Conversely, when the nano-extraction encapsulation was performed 
with ethyl acetate, a more uniform distribution was observed inside the hollow space 
of MWCNTs and on the sidewalls, suggesting a better encapsulation performance 
with this solvent (Fig. 3.6c and Fig. 3.6d). In nano-condensation method carried out 
with water, the amount of entrapped CDDP (Fig. 3.6e and Fig. 3.6f) was not as large 
as that in nano-extraction method, which was confirmed by ICP-OES (data not 
shown). 




Fig. 3.5 TEM images of ultrapure pristine MWCNTs at (a) low magnification and (b) 
high magnification. 
 
In view of the fact that (a) nano-condensation method used CDDP saturated solution, 
which required larger amount of CDDP compared with nano-extraction method, (b) it 
was difficult to condense those solvents (water, DMF, DMSO) and (c) CDDP content 
entrapped within MWCNTs was not as much as with nano-extraction method, we 
eventually chose nano-extraction method to encapsulate CDDP into MWCNTs. 




Fig. 3.6 TEM images of MWCNT-CDDP. MWCNT-CDDP using acetone as filling 
solvent at (a) low magnification and (b) high magnification; MWCNT-CDDP using 
ethyl acetate as filling solvent at (c) low magnification and (d) high magnification; 
MWCNT-CDDP using water as filling solvent at (e) low magnification and (f) high 
magnification. 
 
Chapter 3 Carbon Nanotubes for Incorporation, Storage and Release of Cisplatin 
71 
 
3.4.4.2 Quantification of CDDP entrapped within MWCNTs using TGA and 
ICP-OES 
The loading of CDDP in MWCNTs was evaluated using TGA and ICP-OES. TGA is 
a thermal analysis technique that measures the weight change in a material as a 
function of temperature and time, in a controlled environment. With the increase of 
temperature, the functionalization of CNTs degrades or combusts first, while the 
metal components remain as residue, thus allowing the quantification of drug loaded. 
First, MWCNT-CDDP was combusted by TGA, and the remaining residue was 
dissolved in 2% HNO3 and analysed by ICP-OES to determine the amount of 
elemental platinum. For example, 10 mg of MWCNT-CDDP were used for the 
analysis, and subsequently 4.04 mg of elemental platinum (AW=195.08) was 
quantified using ICP-OES, which corresponded to approximately 621 µg CDDP 
(MW=300.05) within 1 mg MWCNT-CDDP. 
TGA graphs of ultrapure pristine MWCNTs (Fig. 3.7a) and pure CDDP (Fig. 3.7b) 
were compared with that of MWCNT-CDDP (Fig. 3.7c and Fig. 3.7d). In the analysis 
of ultrapure pristine MWCNTs alone, the residue collected after heating up to 
1000 °C was 4.1% of initial weight (Fig. 3.7a). At 1000 °C, the carbon atoms would 
be completely combusted and thus the residue was most likely due to metal catalyst 
impurities present in the MWCNTs during their production. This was in agreement 
with the residue found in other samples used by our group [114]. Notably, no 
elemental platinum was present in the starting material, which has been proven by 
ICP-OES measurement, as shown previously [275]. 
In TGA analysis of pure CDDP, degradation occurred at about 320 °C (Fig 3.7b). The 
amino and chloride groups were combusted leaving behind platinum residue, which 
was 67% w/w of initial weight. This value is comparable to the theoretical platinum 
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content in CDDP. Indeed, based on the atomic weight of platinum and the molecular 
weight of CDDP, the theoretical platinum content in CDDP is 65% w/w. 
In contrast, the residue obtained from MWCNT-CDDP, which was prepared using 
ethyl acetate as filling solvent, was 41.3% w/w of its initial weight. In its TGA graph, 
the first weight loss at about 320 °C corresponded to CDDP degradation while the 
second weight loss corresponded to MWCNT decomposition (Fig. 3.7c). Taking into 
account that the ultrapure MWCNTs in our study contained about 4.1% w/w of metal 
catalyst impurities (Fig. 3.7b), the platinum content in our formulation and as 
obtained from ICP-OES measurements was 43.9% w/w, thus corresponding to 0.621 
mg of CDDP for each 1 mg of MWCNT-CDDP sample (i.e. 62.1% w/w). When the 
encapsulation was performed with acetone, more metal residue was obtained 
following combustion, however, such residue might include a large portion of 
platinum from CDDP bound to the external surface due to a less effective side-walls 
washing, as shown in Fig. 3.6a and Fig. 3.6b. Therefore in this study ethyl acetate 
was finally selected to encapsulate CDDP through the nano-extraction method. In 
another report, Tripisciano et al. encapsulated CDDP into MWCNTs with a main 
diameter of about 13 nm, via nano-extraction of CDDP from DMF for 3 days. 
However, their final product only contained 21% w/w of CDDP [159]. In comparison, 
our method successfully encapsulated a significantly greater amount of CDDP (62.1% 
w/w) in a shorter period of time (24 h). In addition, TGA graphs showed that the 
decomposition temperature of MWCNTs shifted forward in the presence of CDDP, 
which was probably attributed to the platinum as catalyst for the combustion of 
MWCNTs [161]. 




Fig. 3.7 Thermogravimetry (red solid lines) and differential thermogravimetry (blue 
dashed lines) curves. (a) ultrapure pristine MWCNTs (b) CDDP powder (c) 
MWCNT-CDDP using ethyl acetate as filling solvent (d) MWCNT-CDDP using 
acetone as filling solvent. 
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3.4.4.3 SEM-EDX characterization of MWCNT-CDDP 
TEM imaging and ICP-OES could evaluate only the total platinum amount in 
MWCNT-CDDP complex, but were not able to distinguish CDDP entrapped within 
cavities from that bound to the external surface. In order to examine the surface 
condition of MWCNT-CDDP, SEM was performed on both pristine MWCNTs and 
MWCNT-CDDP. SEM images showed no remarkable differences between pristine 
MWCNTs (Fig. 3.8a) and MWCNT-CDDP (Fig. 3.8b), suggesting that there was not 
a large amount of CDDP present on the surface of the MWCNT-CDDP. Besides, the 
EDX analysis on the surface of MWCNT-CDDP (Fig. 3.8d) detected very little 
elemental platinum (3.45% w/w), which was much lower than the total platinum 
content determined using ICP-OES, indicating that the proportion of CDDP bound to 
the external surface was indeed very low in comparison with that entrapped within 
the nanotubes’ inner cavities. 
 
  




Fig. 3.8 SEM images (30 keV) of (a) ultrapure pristine MWCNTs and (b) MWCNT-
CDDP; EDX spectrum of (c) MWCNTs showing C (93.36%) peak, while the other 
peaks are assigned to O (6.47%), and Si (0.17%) peaks; EDX spectrum of (d) 
MWCNT-CDDP showing C (71.52%), Cl (1.24%), Pt (3.45%), the other peaks are 
assigned to O (21.13%), and Si (2.57%) peaks; all the elements were measured by 
weight. 
 
3.4.5 In vitro release of CDDP from MWCNT-CDDP in neutral and weakly 
acidic conditions 
Cancer needs an acidic and oxygen-poor environment to survive and flourish within. 
Therefore, the tumor environment has a remarkably lower pH in comparison to 
physiological conditions: for example, the lumen of recycling endosomes and trans-
Golgi network in MCF-7 human breast cancer cell line has a pH of 6.0~6.3 and that 
of the lysosomes is as low as 4.9 [277]. The release profile of CDDP from MWCNT-
CDDP was therefore quantified in pH environments mimicking tumoral (pH=5.5) and 
physiological (pH=7.4) conditions, and observed to be comparable. Rapid release of 
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the encapsulated drug occurred mainly within the first hour (Fig. 3.9). Approximately 
89% and 93% of encapsulated CDDP were released following 6 h immersion in 
media at pH 7.4 and pH 5.5, respectively. This was in agreement with Tripisciano et 
al. who reported that 95% of encapsulated CDDP was recovered from their 
formulation, although their drug release mainly occurred after 48 h [159]. The fast 
and almost complete release of CDDP from MWCNTs suggested that there was no 
significant interaction between encapsulated CDDP and the walls of MWCNTs. By 
contrast, as reported by Ajima et al. [158], it took more than 20 h to release half 
amount of CDDP from single-walled carbon nanohorns with a diameter of 2~5 nm. 
Such small diameter could make water molecules slowly enter the narrow portal of 
nanohorns and carry CDDP out of tubes, whereas the larger hole size (10~15 nm 
diameter) of MWCNTs in our study was not able to hinder the passage of water and 
CDDP molecules so as to limit the release rate. This result was corroborated by the 
findings that the release quantity and rate of the material incorporated inside 
nanohorns would be controlled by chemically modifying the functional groups 
attached to the hole edges of nanohorns [161]. As the formulation was immersed in 
aqueous environment, water could enter and exit the MWCNTs freely. CDDP, being 
soluble in water and having higher affinity for water molecules as compared to 
MWCNTs, could be displaced from MWCNTs as it would prefer to exist in an 
aqueous environment as opposed to being enclosed inside hydrophobic MWCNTs. 
On account of the fact that unselective and fast release of CDDP was associated with 
the large size of MWCNTs’ open ends, a possible strategy for controlling or slowing 
down the release of CDDP is to modify the open ends of MWCNTs. 




Fig. 3.9 Release of [Pt] from MWCNT-CDDP as assayed by ICP-OES; MWCNT-
CDDP in PBS at pH 7.4 (black line); MWCNT-CDDP in phosphate buffer at pH 5.5 
(red line); measurements are taken in triplicates. 
 
3.5 Conclusion 
In this chapter, we encapsulated the anticancer drug CDDP inside MWCNTs via 
nano-extraction and nano-condensation methods. The characterization of MWCNT-
CDDP samples, which were prepared with various solvents, suggested that 
encapsulation performed with ethyl acetate via nano-extraction was the optimal 
procedure for high-loading CDDP that could selectively fill the nanotubes’ cavity. In 
vitro release of CDDP showed comparable and fast release in media at pH 7.4 and pH 
5.5, indicating that MWCNT-CDDP conjugate was not able to achieve a pH-
responsive release. Since the size of MWCNTs’ open ends was associated with the 
fast release of CDDP, a possible strategy for controlling or slowing down the release 
of CDDP is to seal the open ends of MWCNTs using suitable materials. 
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The information contained in this chapter has been collated in the following 
articles: 
 Li Jian et al., Carbon nanotube bottles for incorporation, release and 
enhanced cytotoxic effect of cisplatin. Carbon, 2012. 50(4): 1625-1634. 
 Li Jian et al, Incorporation and delivery of bioactive molecules from 
smart carbon nano-devices. Asian Chemistry Letters, 2011. 16(1): 1-8. 
 
4.1 Introduction 
4.1.1 “Carbon nano-bottle” structure for drug storage [278] 
Numerous studies have established that carbon nanotubes (CNTs) could be exploited 
as a carrier for drug delivery. CNTs’ inner hollow space, which favors molecules 
adsorption due to its strong binding affinity, could be utilised to incorporate drug 
molecules, provided that the nanotubes’ ends are opened in order to make this cavity 
accessible to the drugs. However, a drawback is present in the use of CNTs as drug 
delivery system, since the open ends are incapable of stably retaining encapsulated 
drug molecules inside CNTs. Therefore, the performance of CNTs has to be 
ameliorated to achieve stable storage and controlled release of deposited drug 
molecules. 
Recently, our group has presented a “carbon nano-bottle” structure and demonstrated 
that, by adopting nano-extraction procedure, it is possible to load CNTs with a 
bioactive molecule and finally to seal the nanotubes again, with the purpose of 
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protecting the drug from any eventual degradation occurring in the external 
environment. In our specific case, it was employed hexamethylmelamine (HMM), 
which is an antitumor drug particularly valuable in ovarian cancer but whose poor 
water solubility (lower than 0.09 mg/mL) and the frequently reported gastrointestinal 
effects after oral administration have limited its clinical use to refractory malignancy 
[279-282]. 
 
Scheme 4.1 Preparation of ‘‘carbon nano-bottles’’ loaded with antitumor agents and 
C60 using a controlled nano-extraction strategy. C60 filled at the extremities of CNTs 
can act as ‘‘cap’’ to seal the CNTs. Reprinted from “Incorporation of 
hexamethylmelamine inside capped carbon nanotubes,” by Ren, Y., et al., 2008, 
Advanced Materials, 20(11), p. 2031-2036. 
 
A two-step nano-extraction was used to incorporate two species of compounds in 
sequence (Scheme 4.1). First, opened CNTs were incubated with a saturated HMM 
aqueous solution and, due to the poor affinity of HMM for water, the dispersed HMM 
molecules could be successfully extracted by CNTs [283]. In the second step of the 
“carbon nano-bottle” preparation, the as-prepared CNTs loaded with HMM were 
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suspended in a saturated C60/ethanol solution. Since HMM had already been 
incorporated inside the CNTs in the previous step, C60 could only fill the remaining 
vacant space at the extremities of the CNTs. As a result, C60 behaved like “caps’’ able 
to plug the openings of CNTs. In addition, to remove the drug that was un-
specifically adsorbed on the external surface of the nanotubes, an extensive washing 
using ethanol was carried out; however, due to the low solubility of C60 in ethanol, the 
nanotubes were preserved from the removal of the caps and loss of encapsulated 
HMM. Therefore the sealed nanotubes could act as occlusive ‘‘nano-bottles’’ for the 
storage of guest molecules. 
Moreover, Shao et al. sealed up the openings of SWNCTs, which were filled with 
uranyl acetate or potassium iodide, by simply using C60 to enter and block the ends 
[284]. HR-TEM observation confirmed the presence of uranyl acetate or KI crystals 
inside the nanotubes sealed by C60 after washing in water, while no uranyl acetate or 
KI could be detected in the filled SWCNTs without C60 as “cork”, suggesting that C60 
molecules were able to plug the ends of open nanotubes and prevent the loss of 
encapsulated compounds at the washing step, which could remove the excess of 
external soluble materials used in the filling experiment. Luksirikul et al. further used 
dimethylamino-functionalized fullerenes (pf-C60), which are soluble in acidic 
conditions, as removable ‘‘corks’’ at the openings of copper acetate or uranyl acetate 
filled SWCNTs [285]. The pf-C60 “corks” allowed the removal of the large amount of 
external acetate present after the filling step and a pH-triggered discharge of the 
encapsulated materials, resulting in the selective release of payload by lowering the 
pH (6 M HCl) of the aqueous solution. However, fullerenes exhibited toxicity to 
physiological systems and their tiny size (~1 nm in diameter) could not efficiently 
plug the large tubular structure of MWCNTs; therefore, in this study, we attempted to 
Chapter 4 Carbon Nano-bottles Capped by Gold Nanoparticles for 
Controlled Release and Enhanced Cytotoxic Effect of Cisplatin 
81 
 
use gold nanoparticles (AuNPs) as “caps” by co-entrapment within the inner cavity of 
CNTs following the encapsulation of anticancer drug CDDP. 
 
4.1.2 Use of gold nanoparticles as “caps” 
AuNPs are the colloidal suspension of sub-micrometer-sized particles of gold. A wide 
range of chemical approaches has been established to synthesize AuNPs, and these 
methods are mainly based on the reduction of chloroauric acid (HAuCl4) in the 
presence of a stabilizing agent. AuNPs are generally produced by the citrate synthesis 
method, in which the formation of AuNPs stems from the reduction of chloroauric 
acid using trisodium citrate [286]. 
Properties and applications of AuNPs depend on shape (spherical, rod-like, etc.) and 
size that could be controlled under various synthetic conditions. Spherical particles, 
the most common shape in the synthesis of AuNPs, are beneficial to the incorporation 
into the inner cavity of CNTs. Besides, particle size is readily adjusted by varying the 
gold ion:reducing agent ratio or gold ion:stabilizer ratio; i.e. particle sizes increases 
while monodispersion typically decreases with larger ratios [287]. In 1981, Schmid et 
al. obtained extremely small (1.4±0.4 nm diameter) phosphine-stabilized AuNPs from 
the reduction of chloro(triphenylphosphine)gold(I) (PPh3AuCl) by diborane in 
benzene [288]. In early 1990s, Brust method, involving the reaction of chlorauric acid 
with anti-coagulant tetraoctylammonium bromide solution in toluene and reducing 
agent sodium borohydride, was discovered to prepare AuNPs around 5~6 nm in 
diameter [289]. Turkevich method, the simplest one available, is generally used to 
produce modestly monodispersed spherical AuNPs around 10~20 nm in diameter 
[290, 291]. In 2009, Perrault method, which could produce particles of at least 
30~250 nm in diameter, was developed using hydroquinone to reduce HAuCl4 in an 
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aqueous solution that contains AuNPs seeds typically obtained from citrate method 
[292]. Therefore, the manufacturing technique of AuNPs is capable of accurately 
controlling their spherical shape and particle size, providing various particles that 
could act as “caps”. 
On account of easy quality control in fabrication and their special properties 
stemming from nano-size, AuNPs are widely used in the biomedical research, such as 
probe [293, 294], bioactive molecules’ carrier [295, 296], cancer radiation therapy 
[59, 60], etc. For example, Luo et al. synthesized highly luminescent Au(0)@Au(I)-
thiolate core-shell nanoclusters (NCs) by inducing the controlled aggregation of 
Au(I)-thiolate complexes on in situ generated Au(0) cores [297]. The common 
thiolate ligands glutathione could be replaced by custom-designed peptides (e.g. Am-
Cys-Am), thus making these luminescent Au-thiolate NCs highly effective as 
luminescence probes with ultrafine size, low toxicity, and good biocompatibility, in 
various biosettings. The gold core is biologically inert, therefore AuNPs are 
considered relatively less cytotoxic and they are extensively used for various 
applications including drug and gene delivery [286, 298, 299]. However, it was found 
that AuNPs induced size-dependent cellular response [300]. When the gold core size 
is very small (< 2 nm diameter), AuNPs are able to penetrate cells and cellular 
compartments (such as the nucleus) and could generate particle surface of unusual 
chemical reactivity, exhibiting extreme toxicity [301]. For example, it was found that 
spherical AuNPs (1.4 nm in diameter) exerted significant toxicity, such as necrosis, 
mitochondrial damage, and DNA interactions, to various cell lines via oxidative stress 
mechanism, which may be associated with AuNPs’ well-known catalytic activity at 
these sizes [302, 303]. Provided that AuNPs could target malignant or diseased 
tissues via their further functionalization with ligands, these tiny nanoparticles of high 
toxicity could be utilised in clinical therapies to selectively kill cancer cells. On the 
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other hand, the toxicity of AuNPs decreases with larger sizes. Generally, surface 
reactivity of AuNPs drops to a very low level when the dimensions are larger than 10 
nm. Pan et al. found that large AuNPs of 15 nm in diameter were completely 
nontoxic to all four tested cell lines (Hela, SK-Mel-28, L929, J774A1) at the 
concentration up to 6300 μM [300]. 
For biomedical applications, AuNPs surface is modified with functional moieties to 
increase their affinity for biological compartments, thus allowing them to target 
specific areas and selectively interact with diseased cells or biomolecules [304]. 
Surface functionalization with targeting moieties and bioactive molecules is generally 
achieved by attachment of the ligand to the gold surface through the conjugation of 
thiol group with gold atom. The coating strategies in biomedical research are mainly 
based on the use of any one or a combination of the biochemical species such as 
oligo- or polyethylene glycol [305-307], bovine serum albumin [308], oligo- or 
polypeptides [309-311], oligonucleotides [312, 313], antisense or sense RNA 
molecules [314], antibodies [315-317], etc. In addition, other non-biochemical 
compounds with a thiol group on one terminus could also be readily immobilized on 
the surface of AuNPs, giving rise to the variation in surface properties. 
In our study, the facile control of particle size and surface properties could allow 
spherical AuNPs to be entrapped within the inner cavity of MWCNTs and 
accordingly plug the main space at open ends. The CNTs have interior hollow space 
of approximately 10 nm in diameter, thereby it is possible to incorporate spherical 
AuNPs smaller than 10 nm into the inner cavity through the circular edge in order to 
form “nano-bottle” structure. Therefore we speculated that AuNPs could be used as 
inert and biocompatible “caps” for “nano-bottles” in this study. 
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4.2 Hypothesis and objectives 
In this chapter, we hypothesized that, by using an engineered “carbon nano-bottle” as 
drug delivery system, it is possible to control the release behavior of the encapsulated 
anticancer drug cisplatin and enhance its cytotoxicity to tumor cells. The design of 
such a system relies on a “capping” strategy to delay the release rate of encapsulated 
cisplatin from “nano-bottles”, thus allowing more drug molecules to enter malignant 
cells rather than diffusing into culture medium and undergoing an aquation process 
before being taken up by cells.  
Towards that purpose: 
(1) MWCNTs will be loaded with cisplatin via nano-extraction method. 
(2) The biocompatible AuNPs, which have smaller size in comparison with the 
hollow space of MWCNTs, will be modified with thiol agent to be applicable for 
“caps”. 
(3) The modified AuNPs will be located at the open ends of nanotubes after the 
entrapment of cisplatin, forming the “carbon nano-bottle” system. 
 
4.3 Materials and methods 
4.3.1 Chemicals and reagents 
Spherical gold nanoparticles (4 nm diameter) were purchased from NanopartzTM. 1-
octadecanethiol (ODT), cis-diammineplatinum(II) dichloride (cisplatin) and ultrapure 
nitric acid (≥ 65%, for ultratrace analysis) were purchased from Sigma Aldrich. 
Organic solvents were obtained from Fischer Scientific. Ultrapure water was obtained 
from Sartious-Stedim biotech atrium® 611 system (18.2 MΩ-cm resistivity). Spectra 
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Por dialysis membrane (12,000~14,000 MWCO) was used in the drug release 
experiment. Fluoropore hydrophobic PTFE membranes (0.22 µm) were purchased 
from Millipore. Ultrapure MWCNTs were kindly provided by Professor Ramaprabhu 
(Nano-Functional Materials Technology Centre (NFMTC), Indian Institute of 
Technology, Chennai, India). 
 
4.3.2 Instruments 
TEM was carried out using JEM 2010F HR-TEM (JEOL) and TEM-EDX analysis 
using JEM 3010 HR-TEM & EDX 300KV LaB6 (JEOL). IR spectra were recorded 
on a Spectrum 100 FT-IR (PerkinElmer) and UV-vis spectra on a BioSpec-nano 
(SHIMADZU). TGA using TGA-SDT 2960 Simultaneous DTA-TGA and ICP-OES 
using Perkin Elmer Dual-view Optima 5300 DV Inductively Coupled Plasma Optical 
Emission Spectrometer were performed by CMMAC (NUS). 
 
4.3.3 Methods 
4.3.3.1 Functionalization of AuNPs with 1-octadecanethiol 
Coating of bare AuNPs by ODT was carried out using different stoichiometric ratios 
of reagents; only optimized coating conditions are reported. Briefly, 1.044 mg of bare 
AuNPs were pre-concentrated to a volume of 3.2 mL using Vivaspin 20 PES 3K 
MWCO (Stedim Biotech), and 1.044 mg (1044 µL of 1 mg/mL of ODT in EtOH) of 
ODT were added. The mixture was stirred for 24 h and subjected to 4 cycles of 
washing to remove unbound ODT, comprising centrifugation at 10,000 g for 20 min, 
removal of supernatant and addition of fresh EtOH for each washing cycle. After the 
last washing cycle, EtOH was removed and ODT functionalized AuNPs (ODT-f-
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AuNPs) were re-dispersed in suitable solvents for subsequent characterization 
through TEM, IR and UV-vis analysis. 
To determine a suitable medium for nano-extraction, the ODT-f-AuNPs were 
dispersed in various organic solvents, namely dichloromethane, EtOH, ethyl acetate, 
hexane, DMSO, and toluene. Thus ODT-f-AuNPs, equivalent to 0.2 mg of bare GNPs, 
were dispersed in the mentioned organic solvents (0.5~1.5 mL) and their 
suspensibility as well as stability were qualitatively evaluated after 24 h. 
 
4.3.3.2 Capping MWCNT-CDDP with ODT-f-AuNPs 
Encapsulation of CDDP into MWCNTs was based on the principles of nano-
extraction [270], for which ethyl acetate was selected as the encapsulation medium. 
Ultrapure MWCNTs (5 mg) and CDDP (14 mg) were mixed in ethyl acetate (4.5 mL) 
and ultrasonicated for 30 min. After stirring for 40 h in the dark, the MWCNTs were 
filtered through 0.22 µm hydrophobic PTFE membrane (Millipore) and extensively 
washed with a solvent mixture EA:EtOH:water (2.6:1:1 v/v, as optimized previously 
in chapter 3) to remove un-encapsulated CDDP molecules. Dry MWCNTs containing 
encapsulated CDDP (MWCNT-CDDP) were recovered from the membrane and 
analysed using TEM and TEM-EDX. Platinum levels encapsulated in MWCNTs 
were evaluated using TGA and ICP-OES. The sample was heated in air at a rate of 
10 °C/min until a final temperature of 1000 °C was reached. The residue remaining 
after TGA was dissolved in aqua regia, diluted with 2% HNO3 (10 mL) and analysed 
by ICP-OES to determine the amount of elemental platinum. 
Based on the stability of ODT-f-AuNPs in various organic solvents, ethyl acetate was 
chosen for incorporation of ODT-f-AuNPs into MWCNT-CDDP through nano-
extraction. MWCNT-CDDP (1 mg) and ODT-f-AuNPs (equivalent to 1 mg of bare 
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AuNPs) were mixed in ethyl acetate (1 mL). The mixture was ultrasonicated for 30 
min and stirred in the dark for about 60 h. Ethyl acetate was evaporated to leave a 
mixture of free ODT-f-AuNPs and capped MWCNT-CDDP. EtOH was used to 
separate the two components since capped MWCNT-CDDP was dispersible in EtOH 
while free ODT-f-AuNPs kept sticking to the wall of reaction flask due to their 
insolubility in EtOH. The capped MWCNT-CDDP was characterised using TEM, to 
assess the presence of ODT-f-AuNPs inside the MWCNTs. 
 
4.3.3.3 In vitro release of CDDP from capped MWCNT-CDDP 
In vitro release of CDDP from capped MWCNT-CDDP was evaluated using a 
dialysis bag diffusion method. The procedure was the same as described in Chapter 3. 
In brief, capped MWCNT-CDDP was dispersed in deionized water (200 µL), 
transferred to a dialysis button with 12,000~14,000 Da cut-off and immersed into 
PBS as release medium (400 mL). An aliquot (2 mL) of sample was collected from 
the release medium at regular intervals (i.e. every 5 min in the first half an hour, and 
subsequently 1 h, 2 h, 4 h, 8 h, 12 h, 24 h, 36 h, 48 h, 96 h) and their platinum levels 
were determined using ICP-OES. 
 
4.3.3.4 Cell viability assays of CDDP, pristine MWCNTs, uncapped MWCNT-
CDDP, and capped MWCNT-CDDP on MCF-7cells 
4.3.3.4.1 Cell culture 
Human mammary gland adenocarcinoma epithelial cells (MCF-7) were obtained 
courtesy of Prof. Victor Yu (NUS). 
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Breast cancer cells MCF-7 were chosen as a common prototype of cancer cells, since 
CDDP is a FDA approved drug for the treatment of solid malignancies. In particular, 
it has shown an important role as a front-line therapy for metastatic breast cancer 
[318]. 
MCF-7 cells were cultured in DMEM medium (Invitrogen) supplemented with 10% 
FBS (HyClone) and 1% Penicillin-Streptomycin (Invitrogen). 
 
4.3.3.4.2 MTT cell viability assay 
In order to compare the efficacy of encapsulated CDDP against the free drug, nine 
concentrations (between 0.1 and 80 M) of free CDDP were initially chosen for the 
MTT assay [319, 320] involving MCF-7 cells. The corresponding concentrations of 
uncapped MWCNT-CDDP, capped MWCNT-CDDP, and pristine MWCNTs were 
calculated based on our results that CDDP content in MWCNT-CDDP were 62.1% 
w/w and 44.4% w/w for uncapped MWCNT-CDDP and capped MWCNT-CDDP, 
respectively. The negative control consisting of pristine MWCNTs was included to 
demonstrate that the cytotoxic effects of both MWCNT-CDDP samples specifically 
stemmed from the CDDP encapsulated. Thus, the assays were carried out with 
pristine MWCNTs that were in the same amount as capped MWCNT-CDDP, as the 
amount of MWCNTs present in that sample was greater than uncapped MWCNT-
CDDP due to difference in CDDP content. Table 4.1 summarises the concentrations 
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Table 4.1 Concentrations of CDDP, MWCNT-CDDP, and pristine MWCNTs used 















0.1 0.03 0.05 0.07 0.07 
1 0.3 0.48 0.68 0.68 
2 0.6 0.97 1.35 1.35 
5 1.5 2.42 3.38 3.38 
10 3 4.83 6.75 6.75 
15 4.5 7.25 10.13 10.13 
20 6 9.66 13.50 13.50 
50 15 24.15 33.75 33.75 
80 24 38.65 54.01 54.01 
 
Note: the concentrations of free CDDP and MWCNTs alone were comparable to the 
corresponding concentration of CDDP and MWCNTs in MWCNT-CDDP. The molar 
concentration is the molar concentration of CDDP. 
 
Free CDDP, MWCNTs alone, uncapped MWCNT-CDDP, and capped MWCNT-
CDDP solutions were prepared by dissolving the samples in plain DMEM and the 
solutions were sonicated briefly to ensure an even suspension. 
For the MTT assay, the cultured cells were seeded on 96-well plates at a density of 
5,000 cells per well and the plates were incubated at 37 °C and 5% CO2 for 24 h prior 
to drug treatment. Before treating the cells, the medium was removed from each well. 
MWCNTs, CDDP, uncapped MWCNT-CDDP, and capped MWCNT-CDDP 
solutions were added into each designated well at 100 µL while wells without any 
treatment were used as negative controls. The cells were then incubated for further 6 
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h. After 6 h of drug treatment, the drug solutions were replaced with FBS 
supplemented DMEM and the cells were allowed to grow further for 66 h. 
Assessment of cell viability was done using 0.5 mg/mL solution of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Alfa Aesar) prepared by 
dissolving MTT in sterile PBS and filtering through 0.2 µm PES filter. After 
incubation for 72 h, the solution in each well was aspirated and MTT solution (100 
µL) was added and the plates were incubated for additional 4 h to enable MTT 
reduction to water-insoluble blue formazan crystals [321, 322]. Subsequently, MTT 
solution was thoroughly aspirated out and DMSO was added to dissolve the formazan 
crystals. The plates were shaken for 3 min to ensure homogeneity and aid proper 
solubilization of the dye prior to absorbance measurement. The absorbance at 595 nm 
was recorded using Microplate Reader Infinite Series M200 (TECAN). The readings 
were converted into survival (%) and the concentrations were transformed 
logarithmically. The data were analysed by non-linear regression and plotted via 
GraphPad Prism. 
 
4.4 Results and discussion 
4.4.1 Synthesis of capped MWCNTs loaded with CDDP 
Carbon nanotubes can easily undergo chemical modifications in order to introduce 
suitable functional groups at their surface. However, this procedure is associated with 
loss of the aromaticity at the benzene rings and concomitant decrease of the 
characteristic high aspect-ratio of the tubes. On the contrary, the inner encapsulation 
of molecules inside the hollow space of nanotubes is based on different strategies, 
which rely on favorable binding energies towards adsorption of molecules and do not 
affect the integrity of nanotubes. Therefore, in our case pristine, non-functionalized 
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MWCNTs were either used directly as control or subjected to nano-extraction [270] 
to incorporate CDDP and further seal the open extremities with surface-modified gold 
nanoparticles (ODT-f-AuNPs). The successful preparation of ODT-f-AuNPs was 
confirmed using UV-vis and FT-IR spectroscopy [323]. UV-visible spectra showed a 
red shift once 1-octadecanethiol (ODT) was bound to AuNPs. Indeed, ODT-f-AuNPs 
showed a slight increase in surface plasmon resonance (SPR) λmax for ODT-f-AuNPs 
(Appendix I). Moreover, the absence of the peaks at about 2,400 cm-1, attributable to 
S-H stretching in the IR spectrum of ODT-f-AuNPs, provided further evidence that 
ODT were attached to the AuNP surface via the formation of Au-S bond (Appendix 
II). To confirm that CDDP was successfully encapsulated inside MWCNTs, 
MWCNT-CDDP sample was observed under TEM. CDDP, which appeared as black 
dots, was found inside the nanotubes (Fig. 4.1a). The identity of black dots was 
verified using TEM-EDX analysis. The presence of chlorine and platinum peaks in 
the TEM-EDX spectrum (Fig. 4.1b) confirmed that the black dots inside the 
MWCNTs were indeed CDDP. 
 
Fig. 4.1 (a) TEM image showing encapsulated CDDP inside an uncapped nanotube; 
and (b) EDX spectrum of MWCNT-CDDP. Al and Cu peaks could be attributed to 
the TEM supporting grid, which was made of aluminium and copper. 
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The ODT-f-AuNPs-filled MWCNTs were observed under TEM. Unlike CDDP, 
which was distributed along the inner cavities of MWCNTs, ODT-f-AuNPs were 
mostly found at the tips (Fig. 4.2). TEM-EDX analysis confirmed the identity of these 
black circles to be ODT-f-AuNPs (Fig. 4.3). We postulated that the migration of 
ODT-f-AuNPs into the middle part of MWCNTs was not favorable due to their larger 
particle size. In addition, the hydrophobic C18 ODT chain, which surrounded the 
AuNPs made the surface of the AuNPs sticky by increasing the affinity of AuNPs for 
MWCNTs’ wall. Consequently, the ODT-f-AuNPs readily adsorbed on the internal 
walls and occupied the narrow space in the tubes, preventing adsorption of other 
ODT-f-AuNPs. Based on qualitative evaluation of the TEM images, we estimated that 
at least 30% of the tubes were capped with ODT-f-AuNPs. 
 
Fig. 4.2 TEM images of ODT-f-AuNPs at the tips of MWCNTs without CDDP. 
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We also observed that ODT-f-AuNPs did not completely block the MWCNT 
openings (Fig. 4.4). Considering that CDDP is less than 1 nm in diameter, we 
expected that it could still pass through the gaps formed among the ODT-f-AuNPs to 
exit the MWCNTs. Their rate of discharge, however, would be slower in comparison 
to uncapped MWCNTs since the exits were partially blocked. In other words, ODT-f-
AuNPs were expected to narrow the exit openings, resulting in a reduced rate of 
release. 
 
Fig. 4.3 EDX spectrum of MWCNTs containing ODT-f-GNPs, without CDDP. Al 
and Cu peaks could be attributed to the TEM supporting grid, which was made of 
aluminium and copper. 
 
The loading of CDDP in MWCNTs was evaluated through TGA and ICP-OES 
according to the procedures reported in Chapter 3. First, MWCNT-CDDP was 
combusted by TGA, and the remaining residue was dissolved and analysed by ICP-
OES to determine the amount of elemental platinum. 
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Fig. 4.4 TEM images of ODT-f-AuNPs in MWCNT-CDDP. Red arrows denote the 
possible passage for the exit of encapsulated CDDP. 
 
In TGA analysis of MWCNTs alone and pure CDDP, the residues collected after 
heating up to 1000 °C were 4.1% w/w and 67% w/w of initial weight, respectively 
(Fig. 3.7a and Fig. 3.7b). The value of CDDP is comparable to the theoretical 
platinum content in CDDP (65% w/w). In contrast, the residue obtained from 
uncapped MWCNT-CDDP was 41.3% w/w of its initial weight (Fig. 3.7c). The 
platinum content accordingly in our formulation and as obtained from ICP-OES 
measurements was 43.9% w/w, thus corresponding to 0.621 mg of CDDP for each 1 
mg of MWCNT-CDDP sample (i.e. 62.1% w/w). 
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Fig. 4.5 TGA of capped MWCNT-CDDP. TGA graph is labeled with the wt% of 
metal residue after ramping the sample up to 1000 °C at a rate of 10 C/min in air. 
 
The loading of CDDP in this capped-sample was also evaluated by TGA and ICP-
OES. The residue obtained from capped MWCNT-CDDP after incineration was 57.5% 
w/w of its initial weight (Fig. 4.5), which included both the elemental platinum from 
CDDP and elemental gold from ODT-f-AuNPs. The platinum content obtained from 
ICP-OES measurements indicated 0.444 mg of CDDP for each 1 mg of capped 
MWCNT-CDDP sample. In the case of capped MWCNT-CDDP, the co-localization 
of ODT-f-AuNPs at the tips of the nanotubes decreased the levels of CDDP that could 
be encapsulated inside the nanotubes. In comparison with uncapped nanotubes, the 
procedure required an additional washing step after the co-encapsulation of ODT-f-
AuNPs, further decreasing CDDP loading inside the nanotubes while increasing the 
total weight of the nano-bottles (capped-sample). Nevertheless, CDDP levels 
quantitated within the capped MWCNT-CDDP corresponded to 44.4% w/w of the 
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Table 4.2 CDDP loading in various carbon nanomaterials. 
 





Pure CDDP — — 67% 103%a — 
MWCNT-
CDDP 




0.3~10 μm 30~40 nm 28.9% 44.4% — 
NHox-CDDPb about 40 nm 0.5~1.5 nm 12.3% 18.9% [158, 161] 
NHh-CDDPc about 40 nm 0.5~1.5 nm 11.4% 17.6% [161] 
SWCNT-
CDDPd 
up to several 
microns 




1.4 nm 3.4~8.7% 5.2~13.4% [163] 
 
aTheoretical value: 100%. 
bCDDP encapsulated into carbon nanohorns with oxygen-containing functional 
groups at the hole edges. 
cCDDP encapsulated into carbon nanohorns with hydrogen-terminated edges. 
dCDDP encapsulated into SWCNTs. 
eCDDP encapsulated into ultra-short SWCNTs under different loading solvent and 
washing conditions. 
 
4.4.2 In vitro release of CDDP from capped MWCNT-CDDP 
Our previous study showed a fast release of CDDP from uncapped MWCNT-CDDP 
(Fig. 3.9), which was independent of the pH values of release medium. Therefore, 
ODT-f-AuNPs were incorporated inside MWCNTs to narrow the channel width and 
thus slow down the rate of release. The release study of capped MWCNT-CDDP was 
carried out in PBS, i.e. similar to physiological conditions. The presence of caps 
decreased the rate of CDDP release from MWCNTs sealed by ODT-f-AuNPs 
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especially in the first 1 hour, and finally approximately 95% of encapsulated CDDP 
was released following 8 h immersion in PBS (Fig. 4.6). 
 
Fig. 4.6 Release of [Pt] from capped MWCNT-CDDP as assayed by ICP-OES; 
measurements were taken in triplicates. 
 
This result suggested that ODT-f-AuNP caps reduced the release rate of CDDP. It is 
possible that the passage of exit was partially blocked and thus the encapsulated 
CDDP could not pass through this narrow exit opening freely. This is in agreement 
with the ODT-f-AuNPs-filled MWCNTs observed under TEM. To further elucidate 
the reason behind a slower release of CDDP, caps of different dimensions and 
material could be investigated. For example, pH-sensitive polymers that shrink only 
in case of acidic pH could represent a valuable alternative to our structurally-rigid 
AuNPs. 
In addition, due to C18-alkyl chains on the surface of the AuNPs, these caps were 
hydrophobic in nature and insoluble in water. Therefore, we did not expect them to be 
displaced from the MWCNTs by water. To validate this hypothesis, we characterised 
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the MWCNTs by TEM after the 96 h drug release experiment. Indeed, the ODT-f-
AuNPs remained at the tips of the MWCNTs, suggesting that they were not removed 
(Fig. 4.7). 
 
Fig. 4.7 TEM image showing ODT-f-AuNPs caps remained at the tip of the nanotube 
after the in vitro drug release experiment. The grey layer surrounding the nanotube 
was a trace from the release medium. 
 
4.4.3 Cell viability assay on MCF-7 cells treated with capped and uncapped 
MWCNT-CDDP samples 
Nine concentrations (0.1~80 μM) of free CDDP were initially chosen for the MTT 
assay against MCF-7 cells [319, 320]. The corresponding concentrations of uncapped 
MWCNT-CDDP and capped MWCNT-CDDP, as well as MWCNTs alone were 
calculated based on our results that CDDP content in MWCNT-CDDP samples were 
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62.1% w/w and 44.4% w/w for uncapped MWCNT-CDDP and capped MWCNT-
CDDP, respectively.  
The results on cell viability are illustrated in Fig. 4.8. At lower concentrations of 
CDDP (0.1~1 µM), cell viability was maintained across the samples, suggesting that 
cells could tolerate these low doses of CDDP. We found in our previous study that 
several influencing factors were responsible for MWCNTs potential cytotoxicity, 
such as nanotubes length, surface functionalization, purity and dispersibility [275]. 
Although ultrapure MWCNTs were used for entrapment of CDDP and subsequent 
drug delivery, the lack of functionalization still led to 30% reduction in cell viability 
for concentrations of ultrapure pristine MWCNTs above 4 μg/mL. This effect, most 
probably due to lower dispersibility of the nanotubes in aqueous media, remained 
quite constant across several concentrations of MWCNTs. On the basis of our 
cytotoxicity study, in future studies it will be possible to minimize such a decrease in 
cell viability by functionalizing the surface of MWCNTs (e.g. through PEGylation), 
which can also increase MWCNTs dispersibility. 
On the other hand, we observed a remarkable reduction in cell viability as the cells 
were exposed to higher concentrations of CDDP, uncapped MWCNT-CDDP, and 
capped MWCNT-CDDP. The IC50 of CDDP alone, uncapped MWCNT-CDDP, and 
capped MWCNT-CDDP were 11.74 μM, 12.92 μM, and 7.74 μM, respectively. 
Uncapped MWCNT-CDDP did not exhibit significant difference compared to free 
CDDP in terms of their pharmacological profile. This could be attributed to the 
findings of in vitro release experiment, showing that around 90% of CDDP was 
leaked out from inner space of MWCNTs by 2 h. These leaked CDDP would behave 
like free CDDP in the medium and therefore no significant difference was observed 
in their IC50 values. 
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Fig. 4.8 Graph showing percentage of cell viability after 6 h treatment with nine 
different molar concentrations of CDDP and corresponding w/v concentrations of 
MWCNTs alone and MWCNT-CDDP (capped and uncapped) on MCF-7 cells as 
determined by MTT assay. 
 
Importantly, for the capped MWCNT-CDDP treatment, there was a slight left shift in 
the curve, indicating that the pharmacological actions of CDDP had been augmented. 
Additionally, the enhanced pharmacological characteristic of encapsulated CDDP 
could stem from the role of capped nano-bottles as an effective drug depot. The 
slower release of CDDP from capped MWCNT-CDDP enabled the nanotubes to 
bring greater amount of therapeutic molecules into cells instead of releasing them into 
the medium as free drug, and the freshly released CDDP would be able to exert its 
pharmacological effects while the un-released CDDP would be protected inside 
MWCNT against possible inactivation. Moreover, for cells exposed to free CDDP, 
when the drug treatment solution was replaced by fresh growth medium at 6 h, the 
uptake of CDDP was finished; in other words, the intracellular amount of CDDP 
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could not increase. In contrast, if one cell internalised a few capped MWCNT-CDDP 
nano-bottles and brought them close to nucleus via intracellular trafficking, the drug 
depot could continue releasing CDDP during the period of 6~72 h despite the 
replacement of nano-bottles treatment solution, since there was a certain amount of 
CDDP (5~6%) remaining inside the capped nano-bottles after 6 h incubation. The 
follow-up release of CDDP from capped nano-bottles in cells is equivalent to 
extended exposure time. Meanwhile, in the treatment with uncapped MWCNT-CDDP, 
nearly all the encapsulated CDDP was released within 6 h. The cytotoxicity result 
suggested that this limited CDDP (about 2%) between 6 h and 72 h likely had no 
remarkable influence on the increase in intracellular amount of CDDP after the 
replacement of treatment solution, despite the internalization of nanotubes. Therefore, 
the intracellular CDDP of cells treated with capped MWCNT-CDDP could probably 
increase even after the treatment solution was replaced and this would enhance the 
cellular bioavailability of CDDP for its therapeutic action, in comparison with CDDP 
alone and uncapped MWCNT-CDDP. Furthermore, the lack of a surge in the initial 
release in the capped MWCNT-CDDP might be advantageous as there would be less 
excessive reactive form of CDDP at the initial stage to attack other proteins and 
enzymes non-specifically and this might confer a decrease in unwanted side effects. 
Such enhanced pharmacological properties and the capacity of CDDP to decrease or 
delay in vitro tumor cell growth in several nano-carriers has also been shown [324, 
325]. 
Overall, these findings supported the concept of employing MWCNTs as a drug 
delivery system. First, capped nano-bottles could act as a ‘‘depot’’ to store the drug 
and shield it from the environment to enhance stability (although the demonstration of 
this point was beyond the scope of this thesis). Second, the encapsulated drug could 
be released at physiological pH with retention of its pharmacological activity. The 
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results obtained at a dose as low as 7.74 μM suggest that it is possible to use less 
amount of drug, with concomitant lower side-effects. Also, current direct 
administration of high amount of drugs into cancer tissues is not possible as the drugs 
may not be able to penetrate the cancer cells fast enough. As a result, any unabsorbed 
drugs would be distributed to other tissues, causing toxicity. With MWCNTs, direct 
administration into cancer tissues may become feasible as MWCNTs have shown to 
penetrate cells [326]. Coupled with the possibility of adding targeting molecules on 
the external walls of MWCNTs, we can increase the specificity towards cancer cells. 
Another possible application is to anchor MWCNTs outside the cells, rather than 
letting them enter the cells. With “caps”, we can regulate the amount of drug released 
per unit time to be similar to the rate of drug taken up by cancer cells. Thus, we could 
prevent any excessive build-up of drug, which will result in the distribution of any 
unabsorbed drugs into surrounding tissues. 
 
4.5 Conclusion 
In this study, we have achieved a few important goals such as successful synthesis of 
“carbon nanotube bottle”, higher amount of drug loading inside the nanotubes in 
comparison with published literature, showing that “carbon nanotube bottle” does not 
prevent the release of encapsulated drug while improving its pharmacological effects. 
On the basis of these results, we could conclude that “carbon nanotube bottle” 
remains a promising alternative drug delivery system. Future investigations would 
focus on the use of caps that could be removed, rather than permanently blocking the 
tips of MWCNTs, under specific temperature or pH conditions [327]. This would 
increase the specificity of anticancer therapy as encapsulated anti-cancer drugs will 
only be released in acidic tumor tissues, but not in normal tissues. 
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Chapter 5 Covalent Capping of Carbon Nano-bottles 





5.1.1 Chemical modification of carbon nanotubes 
The rapid development of chemical modification of CNTs in recent years has 
effectively addressed many biocompatibility and toxicity related issues, extending the 
range of biomedical opportunities in areas such as therapeutic nano-devices, drug 
delivery systems, diagnostic imaging techniques, etc. It has been demonstrated that 
CNTs can undergo chemical reactions through interaction with various chemical 
species [328-333], thus making them more soluble and/or biocompatible. Generally, 
the main approaches to the covalent modification of those pseudo-one-dimensional 
structures include cycloadditions, sidewall halogenation, radical additions, 
functionalization at oxidised defect sites, etc. (Scheme 5.1) 
Many cycloaddition reactions that are derived from those traditionally used for 
graphite surfaces or established for fullerenes have been applied to the 
functionalization of CNTs. Haddon’s group first performed carbene [2+1] 
cycloadditions to pristine CNTs [334-336], generating carbine in situ using a 
chloroform/sodium hydroxide mixture or a phenyl(bromodichloro methyl)mercury 
reagent (Scheme 5.1, route d). Hirsch et al. achieved nucleophilic addition of 
carbenes to form zwitterionic 1:1 adducts rather than cyclopropane systems (Scheme 
5.1, route a) [329, 337]. In addition, Prato’s group added azomethine ylides, which 
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were thermally generated in situ by condensation of an α-amino acid and an aldehyde, 
to the graphitic surface of CNTs via a 1,3-dipolar cycloaddition reaction, forming 
pyrrolidine-fused rings (Scheme 5.1, route b) [338, 339]. 
 
Scheme 5.1 Surface functionalization of CNTs: (a) carbene addition; (b) 1,3-dipolar 
cycloaddition of azomethine ylides; (c) fluorination of nanotubes; (d) cycloaddition 
reaction with in situ generated dichlorocarbene; (e) derivatization by reduction of aryl 
diazonium salts. Adapted from “Crucial Functionalizations of Carbon Nanotubes for 
Improved Drug Delivery: A Valuable Option?” by Pastorin, G., 2009, Pharmaceutical 
Research, 26(4), p. 746-769. 
 
Alternatively, CNTs were subjected to sidewall halogenations to obtain attachment of 
halogen and further substitution. Highly pure SWCNTs were fluorinated by treatment 
with elemental fluorine and heated at 150~600 °C (Scheme 5.1, route c) [340]. 
Mickelson et al. found that the optimal temperature for the fluorination reaction was 
in the range 150~400 °C [341], as the graphitic network decomposes at higher 
temperatures. The fluorinated CNTs could undergo further substitution [342], where 
the fluorine atoms could be replaced by alkyl groups using Grignard or organolithium 
reagents [343, 344]. Furthermore, it was reported that several diamines or diols 
reacted with fluoronanotubes via nucleophilic substitution reactions [345, 346]. 
Sidewall halogenations of CNTs also involved chlorination or bromination reactions 
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through electrochemical oxidation that afforded the coupling of halogen atoms on the 
graphitic network [347]. 
The reaction of radical additions on the walls of CNTs was demonstrated by classical 
molecular dynamics simulations [348]. Two types of coupling reactions, namely the 
reductive coupling of aryl diazonium salts and the oxidative coupling of aromatic 
amines, were proposed in the attachment of substituted phenyl groups to CNTs via 
electrochemical modification (Scheme 5.1, route e) [349-351]. A diazonium salt-
based strategy is devised to form first a covalently attached multilayer of diphenyl 
disulfide on the surface of SWCNTs and MWCNTs. The interlayer S-S bonds are 
subsequently degraded reductively to produce essentially a single layer of thiophenols 
(or closely related derivatives) on the nanotube surface [352]. In addition, Peng et al. 
carried out the reaction of CNTs with succinic or glutaric acid acyl peroxides, 
accomplishing the addition of carboxyalkyl radicals onto the sidewalls [353]. The 
carboxyl moieties in these acid-functionalized CNTs could be further converted to 
acid chlorides and then reacted with various terminal diamines to form amides. 
 
Scheme 5.2 Derivatization reactions of oxidised nanotubes through the defect sites of 
the graphitic surface. Adapted from “Chemistry of carbon nanotubes,” by Tasis, D., 
et al., 2006, Chemical Reviews, 106(3), p. 1105-1136. 
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The acid oxidation process was reported to induce the opening of the tube caps as 
well as the formation of defects in the sidewalls, which are decorated by oxygenated 
functionalities, mainly carbonyl and carboxylic groups [354, 355] (Scheme 5.2). 
These surface defect-derived carboxylic acid moieties were targeted by acylation 
(Scheme 5.2, route a) or coupling reactions (Scheme 5.2, route b) to react with amines 
and alcohols for amide and ester linkages, respectively [356]. The amidation or 
esterification has become one of the most commonly used approaches to the 
fabrication of soluble nanotubes either in organic solvents or in water. The first 
functionalized nanotubes that are soluble in organic solvents were reported in 1998 by 
Chen et al., who covalently attached long chain alkylamines to the carboxyl moieties 
activated with SOCl2 [335]. Later, Pompeo et al. obtained water soluble short-length 
nanotubes by the attachment of glucosamine moieties [357]. Furthermore, oxidised 
CNTs were also solubilized by covalent modification with galactose and mannose 
through acyl chlorides conversion or carbodiimide activation [358, 359]. In addition 
to the modification with soluble adducts, other chemical or biological molecules were 
also attached to the oxidised CNTs to endue nanotubes with specific functions. 
Polymers and dendrimers with terminal amino or hydroxy groups were reported to 
couple with oxidised nanotubes activated with SOCl2 or carbodiimide [360-363]. Sun 
et al. succeeded in the attachment of lipophilic and hydrophilic dendrimers to 
oxidised CNTs via amidation or esterification reactions [361, 364]. Ramanathan et al. 
treated oxidised SWCNTs with ethylenediamine to link the free amino group to 
nanotubes to form an amide functionalization [365]. The amino-termination allows 
further functionalization of nanotubes and makes it possible the covalent bond to 
polymers and biological systems such as DNA and carbohydrates. On the other hand, 
similar to the acylation-esterification approach, the carboxylic groups of oxidised 
CNTs were conjugated with a base to form carboxylate salts [366]. The resulting 
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carboxylates of nanotubes reacted with alkyl halides in the presence of a phase 
transfer agent to give alkyl-modified nanotubes. 
Interestingly, it was found that the carboxyl groups created by acid oxidation mainly 
distributed at the tips of nanotubes, providing localized reactive sites. Lieber et al. 
fabricated nanotube tips by coupling basic or biomolecular probes to the carboxylic 
groups that were present at the open ends of oxidised nanotubes [367, 368]. A variety 
of fluorescent probes were attached to the acid-cut ends of nanotubes by analogous 
coupling reactions for photophysical studies [369, 370]. Moreover, Shinkai et al. 
changed the nanotubes shape from straight form to circles by making use of the 
condensation of carboxylate and other oxygenated functional groups at the ends of the 
oxidised SWCNTs, creating perfect rings [371]. Therefore, in contrast to the presence 
of active sites on the sidewalls of nanotubes generated by other functionalization 
methods, the functional groups at the acid-cut tips of oxidised nanotubes offer the 
advantage to be readily attached to “cap” materials through covalent linkage, with the 
purpose to seal the open ends of nanotubes after the incorporation of drug molecules 
into their interior. 
In this chapter, we proposed an alternative model of “carbon nano-bottle” based on 
the cleavable chemical bonds between open ends of nanotubes and gold nanoparticles 
(AuNPs). Unlike the previous “carbon nano-bottle”, which was dependent on the 
suction of small AuNPs into the cavity of nanotubes (as described in Chapter 4), the 
new approach will tether larger AuNPs to the open tips of nanotubes through the 
formation of cleavable bonds: this strategy is expected to prevent the leakage of 
encapsulate drugs, while controlled release will be activated upon the rupture of 
chemical bonds and removal of AuNPs. So far, a great number of studies have 
reported the successful conjugation of CNTs with AuNPs. The acid-cut nanotubes 
were chemically modified with thiolalkylamines through amidation reaction, 
Chapter 5 Covalent Capping of Carbon Nano-bottles with Gold Nanoparticles for 
Selective Release in Tumor Cells 
108 
 
followed by tethering AuNPs to the thiol moieties, which was confirmed by AFM 
[355]. Liu et al. demonstrated that CNTs could be linked with AuNPs using a thiol-
pyrene derivative as the cross-linker [372]. The cross-linker could be bound to the 
nanotubes surface by π-π stacking between pyrene and graphitic surface of nanotubes, 
while simultaneously the thiol moieties could conjugate with AuNPs. Moghaddam et 
al. chemically attached single-stranded DNA to sidewalls and tips of CNTs via an 
amide linkage, and then these DNA strands immobilized on CNTs were able to bind 
their partner DNA strands, which were tethered to AuNPs, with complementary base 
sequences. TEM images identified the attachment of AuNPs to CNTs [373]. 
Therefore, provided that we can control the combination between AuNPs and the 
open ends of nanotubes, as well as exploit some biologically cleavable bonds as the 
linkage, such “nano-bottles” could probably achieve selective drug release under 
specific conditions. 
 
5.1.2 Biologically cleavable bonds for drug delivery 
The cleavable bonds that could be split under physiological conditions have been 
widely used for drug delivery and receptor specific-targeting design. In general, three 
components are required in a targeting conjugate design, including a receptor 
recognition moiety/carrier, the active drug, and a suitable linkage between the carrier 
and the drug [374]. An appropriate linkage is a crucial factor in drug delivery or 
development of prodrugs, since it would guarantee the conjugates stable during 
circulation in vivo and readily cleavable upon internalization into tumor cells to 
release active cytotoxic agents in cytoplasm. So far, the studies of cleavable linkages 
for drug delivery mainly involve hydrazone bond, disulfide bond, ester bond, etc. 
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5.1.2.1 The use of hydrazone bond in drug delivery 
The pH-sensitive hydrazone linkage can undergo hydrolysis under acidic conditions, 
e.g. the tumoral environment, thereby hydrazone linkage is commonly employed to 
achieve pH-responsive drug release. Baker et al. synthesized a series of prodrugs by 
the conjugation of antimitotic colchicine derivatives with proprietary lipophilic 
molecules via hydrazone bonds, and studied the release of drug from these conjugates 
in buffered solutions at pH 4.1, 5.6, and 7.2. The results showed that the conjugates 
released 50% of the drug at rates from 0.1 h at pH 4.1 to over 3 months at neutral pH 
[375]. Chang et al. successfully conjugated the anticancer drug doxorubicin (DOX) to 
polyamidoamine (PAMAM) dendrimer via hydrazone bond to construct a pH-
responsive drug release system. The drug release rates of DOX-PAMAM conjugates 
were studied in citrate buffer (pH 5.0) and PBS buffer (pH 7.4), which simulated 
cancer cells’ pH as well as physiological pH, respectively [376]. The result showed 
that approximate 80% of the DOX was released in the pH 5.0 environment after 15 h, 
while less than 8% of the DOX was released in the pH 7.4, indicating that the release 
of DOX was controlled by the cleavage of hydrazone bond via hydrolysis under 
acidic conditions. Prabaharan et al. also constructed a targeted anticancer drug 
delivery carrier by covalently conjugating DOX onto amphiphilic block copolymer 
via hydrazone linkage, finding that only 15% of DOX was released from micelles 
after 45 h at pH 7.4, while approximately 90% and 83% of the drug was released 
within 45 h at pH 5.3 and pH 6.6, respectively [377]. Similarly, Ulbrich’s group 
presented that DOX-HPMA (N-(2-hydroxypropyl)methacrylamide) conjugates via 
hydrazone bond exhibited highly potent efficacy for chemotherapy, and the 
conjugates were stable in aqueous solution at pH 7.4, while DOX was rapidly 
released in buffers at pH 5.0~6.5 [378, 379]. In their recent study, fluorescent dye 
DY-676 was conjugated to HPMA copolymers via hydrazone bond, and the 
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distribution of conjugates was investigated by in vivo fluorescence imaging in tumor-
bearing mice. The pH-sensitive coupled model drug (DY-676) showed a much 
stronger accumulation in the tumors than the HPMA carrier polymers, probably due 
to an acidic microenvironment in the tumors where the model drug is cleaved and can 
diffuse inside the tissue [380]. 
 
5.1.2.2 The use of disulfide bond in drug delivery 
The disulfide bond is sensitive to reducing agents such as dithiothreitol (DTT), β-
mercaptoethanol and tris(2-carboxyethyl)-phosphosphine (TCEP) [381, 382], as well 
as the intracellular glutathione (GSH), although it is relatively stable in harsh 
extracellular environment [383, 384]. In mammalian cells, a high level of GSH 
(0.5~10 mM) provides greatly reductive microenvironment; whereas the GSH 
concentration decreases in blood circulation (2~20 μM), leading to extraordinarily 
weak reducing capacity [383-385]. Moreover, the variances of GSH levels between 
cancerous and non-cancerous cells/tissues have been widely reported in literature. 
Elevated levels of GSH have been found in several melphalan- or cisplatin-resistant 
ovarian cancer cell lines [386], leukemia [387], and cell lines derived from several 
carcinoma types [388]. Interestingly, higher GSH levels have been detectd in tumor 
tissue compared to the adjacent nontumor tissue in carcinomas of the oral cavity, 
cervix, and breast [389-392]. For example, cellular GSH levels were reported to be 7-
fold higher in a human lung adenocarcinoma cell line (A549) than in a normal human 
lung fibroblast line (CCL-210) [393]. GSH levels (in nmol/mg protein) doubled in 
human hepatocellular carcinoma (HCC) in compared with normal liver (normal 
liver=22.4±3.5, HCC=41.9±7.2) [394]. Human fibroblast tumor cell lines were also 
found to have higher levels of cellular GSH than normal human fibroblasts [395, 396].  
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Therefore disulfide linkage is broadly utilised to develop novel drug delivery systems 
that are stable in circulation but upon internalization inside the reducing environment 
of the cytoplasm, the linkage would undergo GSH-triggered dissociation followed by 
drug release [397]. Zhang et al. constructed a prodrug system by linking the 
anticancer drug camptothecin (CPT) to neuropeptide substance P (neurokinin-1 
receptor-specific targeting) via a disulfide carbonate linker, and found that the active 
drug was released within the cells following the cleavage of disulfide bond of prodrug 
under high GSH concentration [398]. In a recent study reported by Kelly et al., 
maytansinoid derivative was conjugated to a targeting humanised monoclonal 
antibody (huB3F6) via a cleavable disulfide linker and a non-cleavable thioether bond, 
respectively. The cleavable conjugate was able to generate maytansinoid metabolites 
after lysosomal degradation inside the reducing environment of the cytoplasm, while 
the non-cleavable conjugate was not susceptible to reduction or disulfide exchange 
[399]. 
In addition, the disulfide bond is also applied for the functionalization of nanotubes to 
deliver bioactive molecules and enable the selective release of the cargo in the 
reducing environment of endosomes, once the nano-carrier is internalised into 
intracellular compartments [400-403]. PEGylated carbon nanotubes were loaded with 
antisense oligonucleotides using a tether with a cleavable disulfide bond, and the 
cleavable nature of the disulfide linkage between oligonucleotide and nanotubes was 
confirmed by incubation with DTT followed by agarose gel electrophoresis, which 
showed that the electrophoretic mobility of oligonucleotide-nanotube conjugates were 
decreased following the dissociation of the oligonucleotide from the nanotubes by 
reducing the disulfide bond [404]. Kam et al. attached siRNA to phospholipids 
functionalized SWCNTs via cleavable disulfide linkage, and compared the silencing 
efficiency of cleavable siRNA-SWCNT conjugate with the non-cleavable conjugate 
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[402]. The cleavable siRNA-SWCNT containing disulfide bond exhibited higher 
silencing efficiency than the non-cleavable conjugate, presumably attributed to active 
releasing of siRNA from SWCNTs by enzymatic disulfide cleavage, which 
maximizes the endosome/lysosome escape of siRNA. The intended disulfide cleaving 
and releasing of molecular cargos into the cytosol as well as subsequent nuclear 
translocation of DNA were confirmed by confocal microscopic imaging. 
 
5.1.2.3 The use of ester bond in drug delivery 
The reversible nature of ester bond has also been used for controlled release of drug 
molecules from nano-carriers or prodrugs based on hydrolysis in vivo. Oh et al. 
prepared conjugate microspheres by chemically linking a model drug Fmoc-Trp(Boc) 
to PLGA via an ester linkage, and examined the drug release profiles in PBS buffer at 
37 °C [405]. Conventional microspheres without ester linkage exhibited an initial 
rapid release and their release terminated within 5 days; conversely, conjugate 
microspheres released the drug over one month at almost zero-order kinetics. This 
result suggested that conventional microspheres released free Fmoc-Trp(Boc) by the 
diffusion control, while conjugate microspheres modulated the liberation of Fmoc-
Trp(Boc)-PLGA oligomers into the medium by the chemical degradation of PLGA 
chains. Similarly, DOX was combined with PLGA via an ester linkage, and the 
comparison of DOX-PLGA conjugate nanoparticles with DOX/PLGA mixture 
nanoparticles showed that mixture nanoparticles had a large initial burst and DOX 
release duration for another 5 days, while conjugate nanoparticles displayed more 
sustained release patterns [406]. 
Furthermore, the cleavable ester linkage has been involved in the drug delivery with 
CNTs for cancer treatment. Liu et al. attached the anticancer drug paclitaxel (PTX) to 
Chapter 5 Covalent Capping of Carbon Nano-bottles with Gold Nanoparticles for 
Selective Release in Tumor Cells 
113 
 
branched PEG chains on SWCNTs via a cleavable ester bond to obtain a water-
soluble SWCNT-PTX conjugate, which afforded higher efficacy in suppressing tumor 
growth than clinical Taxol in a murine 4T1 breast cancer model [133]. The difference 
between the biodistribution of SWCNT and 3H-PTX suggested that the release of 
PTX from the nanotube carriers in the various organs and tissues was attributed to in 
vivo cleavage of the ester linkage most likely by carboxylesterases following 
internalization of SWCNT-PTX into reticuloendothelial system (RES) organs. Chen 
et al. loaded SWCNTs with pirarubicin (THP) via a cleavable ester bond to construct 
SWCNT-THP conjugate, which caused minimal side effects without loss of 
therapeutic efficacy in the treatment of bladder cancer [407]. The in vivo study 
showed that SWCNT-THP conjugate induced more apoptotic cells in bladder cancer 
tissue than in normal bladder tissue, suggesting that rapid release of THP from 
SWCNTs through cleavage of the ester linkage occurred after high uptake of 
SWCNT-THP conjugate by tumor tissue. 
 
Based on the susceptibility of these cleavable bonds under pathological conditions, 
we could construct a “nano-bottle” system that is sensitive to the intracellular or 
tumoral environment, thus resulting in the controlled release of payload from the 
nanotubes through the dissociation of “caps”. 
 
5.2 Hypothesis and objectives 
In this chapter, we construct a “carbon nano-bottle” system comprising carbon 
nanotubes, gold nanoparticles, and a cleavable linkage, to obtain specific toxicity to 
tumor cells but low toxicity to normal cells (Scheme 5.3). Indeed, the cleavable 
linkage of “nano-bottles” is expected to split under intracellular or tumoral conditions, 
Chapter 5 Covalent Capping of Carbon Nano-bottles with Gold Nanoparticles for 
Selective Release in Tumor Cells 
114 
 
thus leading to the removal of AuNP “caps” and release of encapsulated drug 
molecules. To prove this hypothesis: 
MWCNTs will be functionalized with various chemical species and subsequently 
linked to AuNPs via the formation of hydrazone bond, ester bond, or disulfide bond. 
 
Scheme 5.3 Design of cleavable bond linked “carbon nano-bottle”: the drug release is 
activated by the dissociation of cleavable linkage. 
 
5.3 Materials and methods 
5.3.1 Chemicals and reagents 
cis-Diammineplatinum(II) dichloride (cisplatin), N-hydroxysuccinimide (NHS), N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC·HCl), hydrazine 
monohydrate, N,N’-dicyclohexylcarbodiimide (DCC), N,N-diisopropylethylamine 
(DIPEA), 9-mercapto-1-nonanol, 3-mercaptopropionic acid (3-MPA), 2-hydroxyethyl 
disulfide, DL-dithiothreitol (DTT), esterase from porcine liver, and ultrapure nitric 
acid (≥ 65%, for ultratrace analysis) were purchased from Sigma Aldrich. Nitric acid 
(65%) and Sulphuric acid (98%) were purchased from Merck. Spherical Gold 
Nanoparticles (40 nm) and Conjugated Spherical Gold Nanoparticles (40 nm, 
carboxyl polymer) were purchased from NanopartzTM. The reactions were performed 
with solvents purchased from Tedia. Ultrapure water was obtained from Sartious-
Stedim biotech atrium® 611 system (18.2 MΩ-cm resistivity). Spectra Por dialysis 
membrane (12,000~14,000 MWCO) was used in the drug release experiment. 
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Omnipore hydrophilic PTFE membranes (0.2 µm) and Fluoropore hydrophobic PTFE 
membranes (0.22 µm) were purchased from Millipore. Ultrapure MWCNTs were 
kindly provided by Professor Ramaprabhu (Nano-Functional Materials Technology 
Centre (NFMTC), Indian Institute of Technology, Chennai, India). 
 
5.3.2 Instruments 
TEM was carried out using JEM 2010F HR-TEM (JEOL). UV-vis spectra were 
recorded on a BioSpec-nano (SHIMADZU). TGA using TGA-SDT 2960 
Simultaneous DTA-TGA and ICP-OES using Perkin Elmer Dual-view Optima 5300 




5.3.3.1 Functionalization of multi-walled carbon nanotubes (MWCNTs) 
5.3.3.1.1 Oxidation of MWCNTs 
Ultrapure pristine MWCNTs (10 mg) were oxidised by ultrasonication in the 
presence of acidic mixture comprising 95% sulphuric acid and 65% nitric acid (3:1 
v/v) for 6 hours (Scheme 5.4a). The acid-treated MWCNTs were diluted with 
deionized water and filtered through 0.2 μm hydrophilic PTFE membrane. The 
residue was washed exhaustively with deionized water until it turned into neutral pH 
and then dried in vacuum to yield oxidised MWCNTs (MWCNTox). 
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5.3.3.1.2 Synthesis of f-MWCNT-1 
MWCNTox (5.4 mg) was suspended in thionyl chloride (6 mL) and refluxed for 24 h 
(Scheme 5.4b). The resulting solid (1.6 mg) was dried in vacuum and redispersed in 
dry tetrahydrofuran (THF, 0.4 mL), followed by adding dropwise to mixture of 
hydrazine monohydrate (2.1 mmol) and triethylamine (TEA, 10 mmol) (Scheme 5.4c). 
The mixture was stirred at room temperature for 24 h and filtered through a 
hydrophilic PTFE membrane. The residue was washed with deionized water and 
dried in vacuum to yield f-MWCNT-1. 
 
5.3.3.1.3 Synthesis of f-MWCNT-2 
MWCNTox (4.0 mg) was suspended in THF (1 mL) under sonication. N-
hydroxysuccinimide (NHS, 28 μmol), DCC (92 μmol), and 2-hydroxyethyl disulfide 
(92 μmol) were added and the mixture was stirred at room temperature for 24 h 
(Scheme 5.4d). The MWCNTs were filtered through a hydrophilic PTFE membrane 
and washed with DMF and deionized water. The remaining solid was dried in 
vacuum to yield f-MWCNT-2. 
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Scheme 5.4 Synthetic procedure of the samples: (a) H2SO4/HNO3 (3:1 v/v), 
ultrasonication; (b) SOCl2, reflux; (c) hydrazine monohydrate, THF, TEA; (d) 2-
hydroxyethyl disulfide, DCC, NHS, THF. 
 
5.3.3.2 Functionalization of AuNPs 
5.3.3.2.1 Reaction with 4-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy)benzaldehyde 
The reaction between 4-(2-(2-(2-mercaptoethoxy)ethoxy)ethoxy)benzaldehyde 
(compound 5.1) and AuNPs was carried out as reported in Chapter 4. In brief, a 
solution of compound 5.1 (0.7 mg) in THF was added to spherical AuNPs (0.37 mg) 
colloid under sonication. The mixture was agitated for 24 h and subjected to 4 cycles 
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of washing to remove unbound compound 5.1. The modified AuNPs were suspended 
in THF to yield the colloid of f-AuNP-1 (Scheme 5.5a). 
 
5.3.3.2.2 Reaction with 9-mercapto-1-nonanol 
Solution of 9-mercapto-1-nonanol (compound 5.2, 0.28 mg) in 50% EtOH was added 
to spherical AuNPs (0.28 mg) colloid under sonication. The mixture was agitated for 
20 h and subjected to 4 cycles of washing to remove unbound compound 5.2. The 
modified AuNPs were suspended in THF to yield the colloid of f-AuNP-2 (Scheme 
5.5b). 
 
Scheme 5.5 Functionalization of gold nanoparticles: (a) coating with compound 5.1; 
(b) coating with compound 5.2. 
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5.3.3.3 Preparation of AuNP-capped nano-bottles assembled via chemical 
bonds 
5.3.3.3.1 AuNP-capped nano-bottles assembled via hydrazone bond 
We entrapped CDDP within f-MWCNT-1 using nano-extraction method in accord 
with the procedures reported in Chapter 3. To cap the open ends of f-MWCNT-1 that 
retains CDDP inside its cavity, as-prepared f-MWCNT-1 with CDDP (4.2 mg) and f-
AuNP-1 (0.37 mg) were suspended in THF (1 mL) under sonication, and then 0.01 M 
HCl (20 μL) was added. The mixture was stirred at room temperature for 4 days 
(Scheme 5.6a). The MWCNTs were filtered through a PTFE membrane and washed 
with THF, EtOH, and deionized water. The remaining solid was dried in vacuum to 
yield the capped MWCNT-CDDP nano-bottles assembled via hydrazone bond (f-
MWCNT-CDDP-1). 
 
5.3.3.3.2 AuNP-capped nano-bottles assembled via ester bond 
Encapsulation of CDDP into MWCNTox was carried out using nano-extraction 
method to obtain MWCNTox-CDDP complex. As-prepared f-AuNP-2 (0.28 mg), 
DCC (7.8 μmol), NHS (4.7μmol), and a few drops of DIPEA were added to the 
suspension of MWCNTox-CDDP in THF (1 mL). The mixture was stirred at room 
temperature for 2 days and filtered through a PTFE membrane (Scheme 5.6b). The 
residue was washed with THF and EtOH and dried in vacuum to yield the capped 
MWCNT-CDDP nano-bottles assembled via ester bond (f-MWCNT-CDDP-2). 
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5.3.3.3.3 AuNP-capped nano-bottles assembled via disulfide bond 
We entrapped CDDP within f-MWCNT-2 using nano-extraction method. After that, 
as-prepared f-MWCNT-2 with CDDP (2.8 mg) and carboxyl conjugated AuNPs (1.5 
mg) were suspended in THF (1 mL) under sonication, and then DCC (17.3 μmol), 
NHS (10.4 μmol), and DIPEA were added. The mixture was stirred at room 
temperature for 5 days (Scheme 5.6c). The MWCNTs were filtered through a PTFE 
membrane and washed with THF, EtOH, and deionized water. The remaining solid 
was dried in vacuum to yield the capped MWCNT-CDDP nano-bottles assembled via 
disulfide bond (f-MWCNT-CDDP-3). 
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Scheme 5.6 Preparation of covalently capped MWCNT-CDDP nano-bottles: (a) f-
MWCNT-CDDP-1 containing hydrazone bond; (b) f-MWCNT-CDDP-2 containing 
ester bond; (c) f-MWCNT-CDDP-3 containing disulfide bond. 
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5.3.3.4 In vitro release of CDDP from covalently capped MWCNT-CDDP 
nano-bottles 
In vitro release of CDDP from covalently capped MWCNT-CDDP nano-bottles was 
evaluated using a dialysis bag diffusion method. The procedure can be found in 
Chapter 3.  
The experiment on f-MWCNT-CDDP-1 examined the effect of pH on release, 
therefore we carried out the in vitro release in two different pH media, i.e. Tris buffer 
at pH 7.2, and MES buffer at pH 5.5. 
To investigate the release of CDDP from f-MWCNT-CDDP-2 in the presence of 
esterase, capped nano-bottles were immersed in PBS containing 5 U/mL esterase 
from porcine liver, and PBS without esterase was used as a control. 
The release of CDDP from f-MWCNT-CDDP-3 was carried out in PBS containing 1 
mM DTT, and PBS without DTT was used as a control. 
 
5.3.3.5 Cell viability assays of covalently capped nano-bottles 
5.3.3.5.1 Cell culture 
Human colon adenocarcinoma cells (HCT-116) and human foetal lung myofibroblast 
cells (IMR-90) were obtained courtesy of Prof. Victor Yu (NUS) and Prof. Mei Lin 
Go (NUS). 
HCT-116 was chosen as a prototype of cancer cell line with overexpressed GSH for 
cytotoxicity assay of f-MWCNT-CDDP-3 nano-bottles containing disulfide bond. 
IMR-90 was chosen as a non-cancerous counter-part to investigate the selectivity of f-
MWCNT-CDDP-3 nano-bottles. 
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HCT-116 cells were cultured in McCoy’s 5A (Sigma Aldrich) supplemented with 10% 
FBS (HyClone) while IMR-90 cells were cultured in Dulbecco’s Modified Eagle 
Medium (Invitrogen) supplemented with 10% FBS. 
 
5.3.3.5.2 Lactate Dehydrogenase (LDH) assay 
The efficacy of f-MWCNT-CDDP-3 against free CDDP was studied using LDH 
assay involving HCT-116 cells and IMR-90 cells. Furthermore, to evaluate the 
capping effects of f-MWCNT-CDDP-3 on selective cytotoxicity to tumor and non-
cancerous cells, MWCNTox with entrapment of CDDP (MWCNTox-CDDP) was 
included as a control group. Eight concentrations (0.1~30 μM) of CDDP were 
examined in this assay. The corresponding concentrations of f-MWCNT-CDDP-3 and 
MWCNTox-CDDP were calculated according to our results that CDDP contents were 
40.1% w/w and 59.5% w/w for f-MWCNT-CDDP-3 and MWCNTox-CDDP, 
respectively. Moreover, blank disulfide bond nano-bottles without CDDP were 
prepared as negative control to test the cytotoxicity induced by nanotubes themselves, 
and the concentrations of blank nano-bottles were in accordance with content of 
nanotubes in f-MWCNT-CDDP-3. Table 5.1 summarises the concentrations of CDDP, 
f-MWCNT-CDDP-3, MWCNTox-CDDP, and blank nano-bottles used for the 
purpose. CDDP solution, as well as f-MWCNT-CDDP-3, MWCNTox-CDDP, and 
blank nano-bottles dispersions were prepared by dissolving the samples in plain 
McCoy’s 5A medium or Dulbecco’s modified eagle medium under brief sonication to 
ensure even suspensions. 
The cultured cells were seeded at a density of 5,000 cells per well in 96-well plates 
and left to adhere at 37 °C and 5% CO2 for 24 h prior to drug treatment. Cells were 
then treated with 100 µL of CDDP solution as well as f-MWCNT-CDDP-3, 
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MWCNTox-CDDP, and blank nano-bottles dispersions for 6 h, while cells incubated 
with media were used as negative controls. After 6 h of treatment, media containing 
CDDP and/or nanotubes were replaced by FBS supplemented McCoy’s 5A medium 
or Dulbecco’s modified eagle medium and the cells were allowed to grow further for 
66 h. 
 
Table 5.1 Concentrations of CDDP, f-MWCNT-CDDP-3, MWCNTox-CDDP and 















0.1 0.03 0.075 0.045 0.05 
1 0.3 0.75 0.45 0.51 
2 0.6 1.5 0.9 1.02 
4 1.2 3 1.8 2.03 
8 2.4 6 3.6 4.07 
10 3 7.5 4.5 5.08 
15 4.5 11.25 6.75 7.63 
30 9 22.5 13.5 15.25 
 
Note: the concentrations of CDDP and nanotubes were comparable to the 
corresponding concentration of CDDP and nanotubes in f-MWCNT-CDDP-3. The 
molar concentration is the molar concentration of CDDP. 
 
A modified version of LDH assay that was validated by Ali-Boucetta et al. was used 
for assessment of cell viability to avoid any interference from nanotubes [408]. The 
LDH content was assessed in intact cells that survived the treatment, instead of 
detecting the amount of LDH released in the media upon CDDP and/or nanotubes 
induced-cell death. In brief, medium was aspirated and cells were lysed with 10 μL of 
lysis buffer (0.9% Triton X100) mixed with 100 μL serum and phenol free media for 
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45~60 min at 37 °C to obtain cell lysate, which was then centrifuged at 13,000 g for 5 
min in order to pellet down the nanotubes. 50 μL of the supernatant of the cell lysate 
was mixed with 50 μL of LDH substrate mixture prepared from LDH in 
vitro toxicology assay kit (Sigma Aldrich) in a new microtiter plate and incubated at 
room temperature for 20~30 min according to the manufacturer’s instructions. The 
absorbance was read with a microplate reader (TECAN infinite M200 PRO) at 490 
nm. The amount of LDH detected represented the number of cells that survived the 
treatment. The percentage of cell survival was calculated using the following equation: 
               
                        
                          
     
Where A490 nm is the absorbance at the wavelength 490 nm. 
 
5.3.3.6 Statistical analysis 
All statistical analyses were accomplished using Statistical Package for the Social 
Sciences (SPSS). Data are presented as mean ± standard deviation. Statistical 
significance was calculated using Student’s t-test. Differences with P< 0.05 were 
considered statistically significant. 
 
5.4 Results and discussion 
5.4.1 Synthesis of covalently capped MWCNT-CDDP nano-bottles 
Our previous work in Chapter 4 has developed capped nano-bottles that were 
dependent on the internalization of small AuNPs to narrow the open ends and 
accordingly slow down the release of CDDP from MWCNTs. These AuNPs were 
modified with hydrophobic molecules and simply entrapped within pristine 
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MWCNTs based on physical interaction; however, such capping strategy was not able 
to carry out selective release under specific conditions, which play a key role in drug 
delivery. To enhance the performance of nano-bottles, we therefore proposed another 
capping strategy: MWCNTs’ tips and AuNPs are connected by cleavable chemical 
bonds that could be split only in pathological conditions. 
 
Fig. 5.1 TEM images of (a) 40 nm spherical bare AuNPs and (b) f-AuNP-1. 
 
In contrast to capping method as described in Chapter 4, AuNPs would locate at the 
tips of MWCNTs to completely block the open ends from the external environment, 
but would not be entrapped within the inner cavity, thus larger AuNPs (40 nm 
diameter, Fig. 5.1a) were used for capping in view of the MWCNTs’ size (30~40 nm 
diameter). Three kinds of cleavable bonds, i.e. hydrazone bond, ester bond, and 
disulfide bond, were attempted in this study, hence AuNPs were modified to generate 
functional groups that are essential to the formation of these cleavable bonds. In the 
design of nano-bottles connected by hydrazone bond, spherical AuNPs were 
functionalized with compound 5.1 that has a benzaldehydic group. The diameter of 
spherical AuNPs prior to functionalization was about 40~45 nm (Fig. 5.1a), while the 
particle size increased to approximately 50 nm with a core-shell structure following 
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the combination with compound 5.1 (Fig. 5.1b). TEM images of these functionalized 
nanoparticles (f-AuNP-1) showed that a black core was enwrapped by a grayish shell 
with the thickness of 4 nm, suggesting that the shell structure was presumably due to 
the conjugation with compound 5.1. The size increase of AuNPs after coating was 
supported by the UV-vis spectra analysis showing a shift of SPR λmax from 527 nm 
for spherical AuNPs to 536 nm for f-AuNP-1 (Fig. 5.2). Moreover, to fabricate nano-
bottles connected by ester bond, spherical AuNPs were functionalized with 
compound 5.2 to generate hydroxyl groups, and the size increase of the resulting f-
AuNP-2 were observed using TEM and UV-vis. On the other hand, commercial 
carboxyl conjugated AuNPs were directly used for the fabrication of nano-bottles 
connected by disulfide bond. 
 
Fig. 5.2 UV-vis spectra of spherical AuNP (black line) and f-AuNP-1 (red line). λmax: 
1—527 nm; 2—536 nm. 
 
As the reservoir of drug molecules, MWCNTs were also functionalized to generate 
corresponding functional groups for the formation of cleavable bonds prior to the 
entrapment of CDDP. Pristine MWCNTs were first oxidised by acid treatment to 
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generate carboxyl groups that could be diversified by further reactions. The length of 
MWCNTox was much shorter than pristine MWCNTs and only a few defects 
appeared on their external surface following 6 h oxidation (Fig. 5.3), thus the multi-
layered walls were still firm to retain encapsulated drug molecules inside the cavity 
and prevent their leakage from defects of sidewalls. It should be noted that the 
carboxyl groups were introduced mainly at the extremities of MWCNTox, since the 
carbon atoms at that position were more reactive in the oxidation process in 
comparison with those on the sidewalls [409]. Considerable studies of CNTs’ 
functionalization have demonstrated that attachment of decorative molecules mainly 
occurred at the tips of CNTs [360, 410, 411]. Such tip-oxidation is beneficial to our 
covalent capping strategy followed by encapsulation of CDDP and final sealing of the 
tubes’ open ends. The carboxylic acid groups on MWCNTox could be directly 
utilised to form ester linkage with f-AuNP-2: indeed, carboxylic acid groups on 
MWCNTox were attached to f-AuNP-2 that had hydroxyl groups via carbodiimide 
coupling, and the ester linkage was expected to be cleaved by esterase. To produce 
nanotubes suitable for hydrazone bond connecting nano-bottles, carboxylic acid 
functionalities on MWCNTox were converted to acyl chlorides and then the activated 
nanotubes reacted with hydrazine monohydrate to generate hydrazide groups (f-
MWCNT-1) that located at the same positions as carboxyl groups. The hydrazide 
groups on f-MWCNT-1 reacted with benzaldehyde groups on f-AuNP-1 in the 
presence of HCl as catalyst to construct nano-bottles that had pH-sensitive hydrazone 
bond (f-MWCNT-CDDP-1). In the fabrication of nanotubes for disulfide bond 
connection, compound 5.2, which contains disulfide bond in its chain structure and 
hydroxyl groups at both extremities, was attached to carboxylic acid functionalities 
on MWCNTox via carbodiimide coupling. The resulting f-MWCNT-2 had reactive 
hydroxyl groups available for subsequent connection. 
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Fig. 5.3 TEM images of (a) pristine MWCNTs and (b) MWCNTox. 
 
Under TEM, the large functionalized AuNPs used for capping were observed at the 
open tips as well as sidewall defects of most of nanotubes, assembling the “nano-
bottle” structure of f-MWCNT-CDDP-2 and f-MWCNT-CDDP-3 comprising ester 
linkage and disulfide linkage, respectively (Fig. 5.4), although there was still a 
minority of tips left open without capping. This combination structure is analogous to 
the observations reported by Zhao et al., who found that the amine functionalities of 
nitrogen-doped carbon nanotube cups (NCNCs) preferentially distributed at the open 
edges of the cups and further, by thiolating the amine groups with 3-MPA, effectively 
corked the isolated cups using AuNPs with commensurate diameters [412]. Their 
micrographs showed that, when incubating thiolated NCNCs with 40 nm AuNPs, one 
AuNP could fit the open rim of the cup and confine the residual material inside. 
Therefore in our study the encapsulated CDDP could be safely retained inside the 
interior of nanotubes, whose open tips were blocked by the large AuNPs with 
diameter of around 40~50 nm, while the drug release was anticipated to occur when 
the linkage between nanotubes and AuNPs was split under certain conditions. 
Chapter 5 Covalent Capping of Carbon Nano-bottles with Gold Nanoparticles for 




Fig. 5.4 TEM images of (a) f-MWCNT-CDDP-2 composed of MWCNT, AuNP, and 
ester linkage; and (b) f-MWCNT-CDDP-3 composed of MWCNT, AuNP, and 
disulfide linkage. 
 
5.4.2 In vitro release from covalently capped nano-bottles 
The three kinds of covalently capped nano-bottles were designed for controlled 
release of encapsulated drug molecules under specific conditions, hence in vitro 
release was carried out to evaluate the effects of capping via cleavable bonds (Fig. 
5.5). The f-MWCNT-CDDP-1 (with hydrazone bond) nano-bottles were examined in 
Tris buffer (pH 7.2) and MES buffer (pH 5.5) that simulated neutral environment in 
normal cells and mildly acidic environment in tumor cells, respectively. The 
hydrazone bond, which was used to connect nanotubes with AuNPs, would rupture 
upon the pH-responsive hydrolysis [413]. The results showed that only a small 
portion of elemental platinum from f-MWCNT-CDDP-1 was released in aqueous 
media at both pH values following 72 h dialysis (Fig. 5.5 A & B). In our previous 
study, uncapped MWCNT-CDDP showed fast and almost complete release of 
encapsulated CDDP within a short period of time, therefore the limited platinum 
content in release media was attributed to hydrazone bond capping, which blocked 
most of the nanotubes’ open tips and restricted the movement of entrapped CDDP; on 
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the other hand, leakage from those uncapped nanotubes occurred as they were 
immersed in aqueous media, thus leading to a small amount of elemental platinum in 
release media. However, the release from f-MWCNT-CDDP-1 under mildly acidic 
condition was almost the same as that under neutral condition. The hydrazone bond 
linkage of f-MWCNT-CDDP-1 nano-bottles seemed insusceptible to mildly acidic 
condition, hereby CDDP molecules were not able to move out by the removal of 
AuNP caps from the tips. Although hydrolysis of hydrazone in the presence of acid as 
catalyst has been confirmed in literature [414, 415] and we also verified the 
hydrolysis of a few hydrazones (without CNTs) under acidic conditions, the low 
concentrations of CDDP in release media, which simulated the in vivo dosage, 
disabled the cleavage of hydrazone bond, since the corresponding concentrations of 
hydrazone bond were below the threshold of hydrolysis. Most probably, as the 
hydrolysis process is reversible and concentration-dependent, the release slowed 
down and reached soon an equilibrium, because the concentration of hydrazones was 
low. In addition, the high steric hindrance of both AuNPs and CNTs could have an 
effect on the dissociation of these cleavable bonds [374]. Therefore, the f-MWCNT-
CDDP-1 nano-bottles were not as good as we expected for pH-responsive release in 
pathological conditions. 
The in vitro release from f-MWCNT-CDDP-2 nano-bottles (with ester bond) was 
carried out in PBS with and without esterase to evaluate the feasibility of capping 
strategy based on rupture of ester bond. The ester bond capping was able to limit the 
release of platinum compound from f-MWCNT-CDDP-2 nano-bottles in aqueous 
media, although their sealing effect was not as excellent as f-MWCNT-CDDP-1 
nano-bottles. However, the presence of esterase did not lead to a significant increase 
in the platinum release from nano-bottles compared with the release in PBS without 
esterase, suggesting that ester bond linkage was not efficiently cleaved in 5 U/mL 
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esterase (Fig. 5.5 C&D). The hydrolysis of such ester bond probably has to occur in 
higher concentrations of esterase that might exceed the extent of physiological 
conditions. In addition, the low efficiency of caps removal, which depended on 
reversible hydrolysis of ester bond, was limited by the low concentrations of f-
MWCNT-CDDP-2 nano-bottles in release media as well as the high steric hindrance 
of MWCNTs and AuNPs. Therefore the design of nano-bottles assembled via ester 
linkage confronted the same problems that occurred to nano-bottles assembled via 
hydrazone linkage. 
 
Fig. 5.5 Release of [Pt] from covalently capped nano-bottles of f-MWCNT-CDDP-1, 
f-MWCNT-CDDP-2, and f-MWCNT-CDDP-3 under various conditions. A: Tris 
buffer at pH 7.2; B: MES buffer at pH 5.5; C: PBS; D: PBS containing 5 U/mL 
esterase from porcine liver; E: PBS; F: PBS containing 1 mM DTT. 
 
f-MWCNT-CDDP-3 nano-bottles contained both ester bond and disulfide bond, 
although we merely focused on the effect of disulfide bond, hence the release from f-
MWCNT-CDDP-3 nano-bottles was performed in PBS containing DTT (1 mM), a 
mercaptan generally used to reduce the disulfide bonds of proteins, to simulate thiol-
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rich environment in tumor cells. It has been reported that the concentrations of thiol 
levels in tumor cells is much higher compared with normal cells [416-418]. We 
accordingly took advantage of this variance to design f-MWCNT-CDDP-3 nano-
bottles for controlled release. The platinum content detected in the release medium 
was remarkably higher in the presence of 1 mM DTT compared with PBS control, 
suggesting that DTT played a part in the removal of caps and enabled the release of 
encapsulated CDDP, although the concentration of disulfide bond nano-bottles in 
release medium was comparable to hydrazone bond and ester bond nano-bottles. The 
success in caps removal was presumably attributed to the sensitivity of disulfide bond 
in nano-bottles to DTT, as well as the thiol-disulfide exchange reactions, in which 
a thiolate group attacks a sulfur atom of a disulfide bond to form a new disulfide bond 
and the other sulfur atom of original disulfide bond is released as a new thiolate [419, 
420]. In the study of CNT-based stimuli-responsive controlled-release system 
described by Chen et al., the fluorescein-filled CNTs, whose ends were plugged by 
the addition of thiol-silica nanospheres via the formation of a disulfide linkage, 
displayed a selective discharge process triggered by exposure to DTT or at elevated 
temperature; moreover, the release rate of encapsulated fluorescein could be 
controlled through increased DTT concentration or temperature, respectively [421]. 
On the other hand, some encapsulated CDDP was also found to leak from f-
MWCNT-CDDP-3 nano-bottles in PBS as observed in f-MWCNT-CDDP-1 and f-
MWCNT-CDDP-2 nano-bottles, due to the incomplete capping of nanotubes; such 
extent of leakage was acceptable in our study, and future work will attempt to 
enhance the sealing efficiency. The f-MWCNT-CDDP-3 nano-bottles thereby were 
better choice for controlled release in comparison with the other two nano-bottles. 
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5.4.3 Cytotoxicity of CDDP, f-MWCNT-CDDP-3, MWCNTox-CDDP, and 
blank nano-bottles to HCT-116 and IMR-90 
The nano-bottles containing cleavable bonds are expected to exert various cytotoxic 
effects on tumor cells and normal cells due to the rupture of linkage between 
nanotubes and AuNPs in tumoral environment, which subsequently leads to release of 
encapsulated drug molecules. Based on the in vitro release of the three kinds of nano-
bottles, only f-MWCNT-CDDP-3 was examined in the cell viability assay, since there 
was no significant difference in drug release from f-MWCNT-CDDP-1 and f-
MWCNT-CDDP-2 by incubation within in vitro simulated tumoral and physiological 
conditions. To investigate the selective cytotoxicity of f-MWCNT-CDDP-3 nano-
bottles due to GSH-triggered cleavage of disulfide bond followed by drug release, 
HCT-116 and IMR-90 were chosen as prototypes of tumor cells with overexpressed 
GSH as well as normal cells with relatively low GSH level, respectively. 
The treatment with free CDDP induced striking cytotoxicity to HCT-116 cells, 
leading to rapid decrease of cell viability with higher CDDP concentrations (Fig. 
5.6a). This tendency is in agreement with the IC50 value 1.25~7.5 μM reported in 
literature [422, 423]. By contrast, IMR-90 was insensitive to free CDDP treatment at 
low concentrations (0.1~4 μM), and its viability was remarkably higher than HCT-
116 following treatment within the range of 0.1~30 μM. However, the survival level 
of IMR-90 showed significant decrease when subjected to treatment with higher 
concentrations of CDDP, thereby nano-bottles were expected to control the cytotoxic 
effect of CDDP on IMR-90 cells. In order to investigate the biocompatibility of nano-
bottles, which is an important aspect in the highly debated safety of nano-carriers, cell 
viability assay of HCT-116 and IMR-90 was carried out following incubation with 
capped blank nano-bottles (Fig. 5.6b). This result suggested that blank nano-bottles 
had very low cytotoxicity to both cell lines, although there was a slight decrease in 
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cell survival at higher concentrations (6.75 and 13.5 μg/mL). Moreover, IMR-90 was 
likely less sensitive to blank nano-bottles compared with HCT-116, and this variance 
is beneficial to the selective killing of tumor cells. Thus the low cytotoxicity could 
allow nano-bottles to act as a biocompatible carrier to deliver therapeutic agents. 
 
Fig. 5.6 Cell viability of IMR-90 and HCT-116 treated with (a) free CDDP; (b) 
capped blank nano-bottles without CDDP; (c) capped nano-bottles f-MWCNT-
CDDP-3 with CDDP inside; and (d) uncapped MWCNTox-CDDP, respectively. *P< 
0.05 compared with IMR-90 (Student’s t-test). 
 
The capped f-MWCNT-CDDP-3 nano-bottles induced more cell death of HCT-116 
compared with IMR-90, although the decrease in cell viability of both cells at lower 
concentrations (< 15 μM) was not as remarkable as those treated with corresponding 
concentrations of free CDDP (Fig. 5.6c). The low cytotoxicity was likely attributed to 
the GSH-triggered removal of caps with low efficiency inside cells, which prevented 
the discharge of most CDDP from nano-bottles, and the slight release of CDDP into 
cytoplasm was insufficient to cause significant toxicity. Interestingly, a great decrease 
in cell viability of HCT-116 occurred at concentration of 30 μM, while IMR-90 still 
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remained at a high survival level after the treatment. We postulated that the total 
amount of released active CDDP could increase to an adequate level for cytotoxicity 
as HCT-116 tumor cells were incubated with high concentration of nano-bottles 
despite the low efficiency of caps’ removal, whereas the low GSH level in IMR-90 
cells was incapable of cleaving the disulfide linkage between nanotubes and AuNPs, 
thus the small amount of CDDP released from nano-bottles had less impact on IMR-
90 cells’ survival. By contrast, the uncapped MWCNTox-CDDP exhibited 
comparable cytotoxicity to both HCT-116 and IMR-90 cell lines within the overall 
range of concentrations (Fig. 5.6d). Therefore the f-MWCNT-CDDP-3 nano-bottles 
could be internalised into tumor cells and release the encapsulated CDDP by the 
cleavage of disulfide linkage in GSH-rich tumoral environment; on the other hand, 
the uptake by normal cells did not induce significant cytotoxic effect, since the GSH 
level was not high enough to remove the AuNP caps. These AuNP-sealed nano-
bottles, which are assembled through disulfide linkage, provide a proof-of-concept on 
the development of novel drug delivery systems to achieve GSH-triggered controlled 
release in tumoral environment, thus allowing to exert selective toxicity against 
tumors while prevent healthy cells or tissues from side effects. 
 
5.5 Conclusion 
We presented a novel “nano-bottle” drug delivery system by attaching AuNPs to the 
open-tips of MWCNTs via cleavable bonds. The in vitro release of nano-bottles 
showed that CDDP could be discharged from f-MWCNT-CDDP-3 after incubation in 
aqueous medium containing 1 mM DTT, while the extent of drug release was 
relatively low under thiol free condition. To validate the selective cytotoxicity of 
nano-bottles, f-MWCNT-CDDP-3 was examined by incubation with HCT-116 and 
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IMR-90 cells, and the result showed that the capped f-MWCNT-CDDP-3 nano-
bottles exerted stronger cytotoxic effect on HCT-116 than IMR-90 especially at high 
concentrations. Therefore the nano-bottles assembled through cleavable linkage could 
be a promising nano-carrier to obtain selective release of payload in tumor cells while 
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The information contained in this chapter has been collated in the following 
article: 
 Li Jian et al., Platinum(IV) prodrugs entrapped within multiwalled 
carbon nanotubes: Selective release by chemical reduction and 
hydrophobicity reversal. Chemical Science, 2012. 3(6): p. 2083-2087. 
 
6.1 Introduction 
FDA-approved platinum-based anticancer drug cisplatin and its analogues carboplatin 
and oxaliplatin are some of the most effective chemotherapeutic agents available and 
used to treat a wide range of malignancies (Fig. 6.1) [424, 425]. Cisplatin in particular 
is applied as first-line therapy in the treatment of testicular cancer, against which it 
displays remarkable curative properties [426, 427]. Its mechanism of action is 
postulated to be mediated by a combination of processes including cell entry, 
activation and DNA binding. Cisplatin forms mainly 1,2-intrastrand DNA-adducts 
with purine nucleosides and these adducts trigger cellular responses that ultimately 
result in apoptotic cell death [428, 429]. One of the main limitations of platinum-
based chemotherapy is the high toxicity and severe side-effects associated with 
treatment, resulting from non-specific binding with essential plasma proteins, as well 
as its inability to discriminate between healthy and diseased cells. It is therefore the 
goal of platinum-based therapy to be able to selectively target cancer cells while 
leaving healthy cells unscathed. 
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Fig. 6.1 FDA-approved platinum(II) drugs and hydrophobic platinum(IV) prodrug 6.1. 
 
One approach to mitigate this poor selectivity is to deliver platinum drugs to the 
target tissue using macromolecular drug delivery agents [430-433]. The use of a 
macromolecular carrier is advantageous since the vessel can be readily modified with 
multiple functional groups for targeting and serves as a protective shell to improve 
the pharmacological profile and drug efficacy. Platinum drugs have been either 
covalently tethered or non-covalently encapsulated within carriers, such as polymers 
or liposomes, as macromolecular drug formulations and targeting was achieved via 
surface modification of the macromolecules using folate, peptides or aptamers 
targeting groups. These macromolecular formulations typically entered the cells via 
receptor-mediated endocytosis and intracellular release of the cytotoxic Pt(II) moiety 
was achieved via different mechanisms depending on the nature of the delivery agent. 
These release mechanisms included diffusion of the Pt-drug from the carrier, 
degradation/disintegration of the delivery agent or chemical cleavage of the Pt(II) 
pharmacophore by aquation. 
Recently, carbon nanotubes (CNTs) and nanohorns (CNHs) were used as drug 
delivery agents for platinum drugs [158, 434]. Their high aspect ratios allowed them 
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to breach and penetrate the cellular membrane to release the cytotoxic Pt(II) payload 
directly. In one approach, cisplatin and carboplatin were encapsulated within the 
inner cavity of CNTs and CNHs, which provided a protective barrier, and release was 
achieved by diffusion. However, since both cisplatin and carboplatin are hydrophilic, 
confining them within the CNT/CNH hydrophobic cavities would be inherently 
problematic as they can be rapidly displaced by solvent water molecules and therefore, 
their release cannot be easily controlled. 
In another approach, the [cis-Pt(NH3)2]-moiety was covalently attached to CNTs 
containing surface-modified carboxylic groups. Targeting was achieved by vascular 
endothelial growth factor (VEGF) conjugated to the CNTs and release of the 
cytotoxic Pt(II) moiety was accomplished by aquation [435]. A potential 
complication is that Pt(II) complexes are inherently reactive and unwanted 
interactions with other biomolecules in the solvent environment cannot be prevented. 
Therefore, they risk being prematurely released from their carrier and could bind non-
specifically to endogenous nucleophiles away from the target. This challenge was 
addressed elegantly using stable Pt(IV) prodrugs, instead of reactive Pt(II) complexes, 
conjugated to the surface of single-walled CNTs [128, 436]. After internalization, 
these Pt(IV) complexes were then cleaved from their macromolecular carrier by 
chemical reduction to yield cytotoxic Pt(II) species. 
In order to address these aforementioned limitations, we conceived of an approach 
using CNTs as the macromolecular carrier that would exploit the chemical inertness 
of the Pt(IV) scaffold, as well as the shielded environment afforded by the inner 
cavities of the CNTs. The strategy entailed the entrapment of stable Pt(IV) complexes 
within CNT cavities and their release upon chemical reduction. However, entrapment 
of drug molecules in the hydrophobic confines of a rigid macromolecular carrier, 
such as a CNT, can be a double-edged sword; the hydrophobic-hydrophobic 
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interactions that favor their entrapment can also prevent their efficient release from 
the carrier in an aqueous environment. To be able to fully exploit this approach, a 
manner of controlling the hydrophobic interactions between the carrier and the drug 
was required. 
Our strategy was to engineer a means of reversing hydrophobicity into the design of 
the platinum drug. In its inactive hydrophobic Pt(IV) form, the drug can be stably 
contained within the CNTs. However, upon chemical reduction by endogenous 
reductants such as glutathione after cell penetration, it would be converted to its 
active hydrophilic Pt(II) form and could no longer be trapped within the hydrophobic 
channels. In this manner, controlled release of cytotoxic Pt(II) species can be 
achieved intracellularly upon reduction and a concomitant change in hydrophobicity, 
where it would be able to exert its cytotoxic activity (Scheme 6.1). As a proof-of-
concept, we demonstrate the entrapment of hydrophobic Pt(IV) prodrugs within 
CNTs, their stable containment, their controlled release by way of chemical reduction 
and subsequent binding to a DNA model as Pt(II) species. 
 
Scheme 6.1 Design concept on based on hydrophobic entrapment of platinum(IV) 
prodrug within MWCNTs. 
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6.2 Hypothesis and objectives 
The hypothesis of this study is that a specifically designed nanotube carrier is able to 
achieve selective release of anticancer platinum-based molecules on the basis of a 
drastic reversal in hydrophobicity of entrapped Pt(IV) complexes. 
To prove this hypothesis, we will: 
(1) Prepare hydrophobic Pt(IV) prodrug, which could be entrapped within MWCNTs 
via nano-extraction method and it is stably retained within the MWCNTs and 
selectively released in the presence of a reductant (which simulates the 
environment of cancer cells) due to its conversion to hydrophilic Pt(II) species. 
(2) Assess whether the MWCNTs carrier is capable of delivering the Pt(IV) prodrug 
into cancer cells and releasing the reactive Pt(II) species upon reduction in GSH-
rich environment. 
 
6.3 Materials and methods 
6.3.1 Chemicals and reagents 
cis-Diammineplatinum(II) dichloride (cisplatin), sodium diethyldithiocarbamate 
(DDTC), 5’-guanosine-2’-deoxymonophosphate (dGMP) and ascorbic acid were 
purchased from Sigma Aldrich. The reactions were performed with solvents 
purchased from Tedia. Ultrapure water was obtained from Sartious-Stedim biotech 
atrium® 611 system (18.2 MΩ-cm resistivity). Spectra Por dialysis membrane 
(12,000~14,000 MWCO) was used in the drug release experiment. Omnipore 
hydrophilic PTFE membranes (0.2µm) were purchased from Millipore. cis,cis,trans-
Pt(NH3)2Cl2(CO2C6H5)2 (compound 6.1) was kindly provided by Assistant Professor 
Wee Han Ang (Department of Chemistry, National University of Singapore, 
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Singapore). Ultrapure MWCNTs were kindly provided by Professor Ramaprabhu 
(Nano-Functional Materials Technology Centre (NFMTC), Indian Institute of 
Technology, Chennai, India). 
 
6.3.2 Instruments 
SEM-EDX analysis was carried out using JSM-6700 Field Emission Scanning 
Electron Microscope. Thermogravimetric analysis was performed using TGA-SDT 
2960 Simultaneous DTA-TGA and ICP-OES using Perkin Elmer Dual-view Optima 
5300 DV Inductively Coupled Plasma Optical Emission Spectrometer by CMMAC 
(NUS). The chromatogram of Pt-dGMP adducts was analysed on Agilent 1200 HPLC. 




6.3.3.1 Encapsulation of cis,cis,trans-Pt(NH3)2Cl2(CO2C6H5)2 (compound 6.1) in 
MWCNTs via nano-extraction method 
6.3.3.1.1 Solubility test of compound 6.1 
Compound 6.1 was weighed and added to different solvents, and sonicated for 15 min. 
The samples were centrifuged at 13,300 g to ensure complete solubility. The volume 
of solvent was increased until no observable solid remained in the solution, and this 
concentration was considered as the solubility of compound 6.1 in a certain solvent. 
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6.3.3.1.2 Encapsulation of compound 6.1 in MWCNTs via nano-extraction 
method 
Compound 6.1 (6.0 mg) was dispersed in CHCl3 (2 mL) under sonication for 10 min. 
MWCNTs (2.0 mg) were added and the suspension was sonicated for 15 min. The 
mixture was stirred at room temperature for 5 days in the dark and filtered through a 
hydrophilic PTFE membrane. The residue was washed extensively with washing 
solvent (2:2.41:1 v/v CHCl3:MeOH:water) and dried in vacuum to yield MWCNT-
Pt(IV). The composition of the washing solvent was determined empirically by the 
method of Fu et al., which allowed surface-bound Pt(IV) complex to be washed away 
without displacing the Pt(IV) complex trapped within the cavity [273]. Controls were 
prepared using the same procedure but in the absence of compound 6.1. 
These as-prepared MWCNT-Pt(IV) complex were analysed using SEM-EDX, and 
loading of Pt(IV) was evaluated using TGA as well as ICP-OES as reported 
previously. 
 
6.3.3.2 Reactivity of platinum complexes 
6.3.3.2.1 Reactivity with DDTC 
Solutions containing CDDP (3.3 mM, 100 μL water), compound 6.1 (1.8 mM, 100 μL 
1:1 v/v water:DMSO), or compound 6.1 (1.8 mM) incubated in 100 μL of 3 mM 
ascorbic acid aqueous solution were treated separately with 250 μL DDTC (5% in 0.2 
M NaOH) and incubated at 37 °C for 1 h. The solutions were extracted with ethyl 
acetate (2 mL) and evaporated. The residue was dissolved in 1.5 mL acetonitrile 
before analysis with RP-HPLC. The column used was Phenomenex Gemini C18 
column (5 μm, 100 Å, 150 mm×4.6 mm). The detection UV was at 254 nm. Mobile 
phase consisted of 75:25 v/v methanol:water at a flow rate of 0.6 mL/min. The 
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column was maintained at 23°C. In sample containing CDDP and compound 6.1 
treated with 3 mM ascorbic acid, Pt(DDTC)2 was detected at Rt=13 min and was 
confirmed using ESI-MS on collected fractions (m/z = 492 [M+H]+). 
 
6.3.3.2.2 Analysis of Pt-dGMP adduct formation 
Solutions containing CDDP (3.3 mM, 100 μL water), compound 6.1 (1.8 mM, 100μL 
1:1 v/v water:DMSO), or compound 6.1 (1.8 mM) incubated in 100 μL of 3 mM 
ascorbic acid aqueous solution were treated separately with dGMP (2 mg/mL, 250 μL 
water ) and incubated at 37 °C for 24 h. The reaction mixture was analysed directly 
by RP-HPLC. The column used was Phenomenex Luna C18 column (5 µm, 100 Å, 
250 mm×4.6 mm). The detection UV was at 254 nm and 280 nm. The mobile phase 
was 5~7% solvent B in 20 min at flow rate of 0.6 mL/min where solvent A is 10 mM 
ammonium acetate and solvent B is methanol. Pt-dGMP adducts were observed only 
with solutions containing CDDP and compound 6.1 treated with ascorbic acid. 
 
Scheme 6.2 Reactions between dGMP and the aqua ligands of cispaltin. 
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6.3.3.3 Controlled release of platinum from MWCNT-Pt(IV) complex 
6.3.3.3.1 Release from MWCNT-Pt(IV) complex 
MWCNT-Pt(IV) (containing 1.0 mg of compound 6.1) was dispersed in H2O (400 µL) 
and transferred to two separate dialysis buttons (200 µL each). One button was 
immersed into PBS as the release medium (400 mL) while the other was immersed 
into PBS (400 mL) containing 3 mM ascorbic acid as the bio-reductant. An aliquot (2 
mL) of sample was collected from the release medium at regular intervals and their 
platinum contents were determined using ICP-OES. 
 
6.3.3.3.2 Binding to DNA target upon release from MWCNT-Pt(IV) 
Dialysis buttons containing MWCNT-Pt(IV) (containing 1.0 mg of compound 6.1) 
was immersed either into PBS (40 mL) containing 0.11 mM dGMP or PBS (40 mL) 
containing 3 mM ascorbic acid and 0.11mM dGMP for 24 h. The solution was 
analysed directly on RP-HPLC using Phenomenex Luna C18 column (5 µm, 100 Å, 
250 mm×4.6 mm). The mobile phase was 5~7% solvent B in 20 min at flow rate of 
0.6 mL/min where solvent A is 10 mM ammonium acetate and solvent B is methanol. 
 
6.3.3.4 Platinum uptake in A2780 ovarian carcinoma cells 
Human ovarian carcinoma cells A2780 were cultured in RPMI-1640 medium 
supplemented with 10% FBS and 1% antibiotics.  
Three MWCNT samples were prepared: (a) pristine MWCNTs as negative control, (b) 
MWCNT-Pt(IV) which contained entrapped compound 6.1, and (c) mixture of 
MWCNTs and compound 6.1 to model a MWCNT system containing un-
encapsulated compound 6.1. Platinum levels in MWCNT-Pt(IV) was previously 
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ascertained using TGA/ICP-OES and used to guide the preparation of 
MWCNTs/compound 6.1 mixture. Two different exposure conditions were prepared 
at two platinum concentrations of 48 μg/L (condition A) and 240 μg/L (condition B). 
The samples were dialysed in water for 16 h pretreatment to simulate exposure to 
bodily fluids prior to arrival at targeted cell site. 
A2780 cells were seeded in 100 mm cell culture dishes at a density of 1.3×107 cells 
per dish and the dishes were incubated at 37 °C with 5% CO2 for 48 h prior to 
MWCNT treatment. During treatment, the medium was replaced with incubation 
media containing either (a) pristine MWCNTs, (b) MWCNT-Pt(IV), or (c) 
MWCNT/compound 6.1 mixture, in RPMI-1640 (5 mL, without FBS or antibiotics) 
at 37 °C for 1 h, as well as control dishes without MWCNT exposure. After 1 h 
incubation, the medium in each dish was replaced with 5 mL fresh RPMI-1640 
medium supplemented with 10% FBS and 1% antibiotics, and incubated for further 7 
h. No obvious cell death in the treated cells was observed compared to the untreated 
controls. 
To collect cells, the dishes were placed on ice and cell monolayer was washed with 
ice-cold PBS (2×5 mL). PBS (1 mL) was added to each dish, and cells were collected 
with a scraper. The cells were pelleted by centrifugation for 15 min at 4 °C. To 
extract cytoplasm from cells, 100 μL lysis buffer (1% Triton/PBS) was added to each 
tube, and incubated on ice for 40 min. After centrifugation for 30 min at 4 °C, 100 μL 
supernatant was collected for analysis. Protein content of each sample was 
determined using the Bradford assay (Bio-Rad) in accordance to manufacturer’s 
instructions. 
The platinum content in the cell lysate was determined using ICP-MS. Prior to 
platinum analysis, the cell lysate was dried in vacuum, and the remaining residue was 
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digested in 100 μL 65% HNO3 at room temperature for 24 h. The digested solution 
was diluted with MilliQ water (3 mL) prior to ICP-MS analysis. 
 
6.4 Results and discussion 
6.4.1 Solubility test of compound 6.1 
Using hydrophilic cisplatin (CDDP) as a template, a hydrophobic prodrug derivative 
was designed by attaching benzoate functional groups to the axial positions of the 
Pt(IV) scaffold [437]. Cleavage of the axial ligands triggered by chemical reduction 
should result in a drastic reversal in hydrophobicity and the efficient release of the 
Pt(II) moiety from the CNTs. The logP value of compound 6.1 was determined to be 
2.19 based on RP-HPLC measurements, indicating its high hydrophobicity in 
comparison to CDDP and precursor cis,cis,trans-[Pt(NH3)2Cl2(OH)2], which were 
reported to be -2.28 and -2.81, respectively [166]. As anticipated, compound 6.1 was 
poorly soluble in water, in contrast to CDDP or its precursor cis,cis,trans-
[Pt(NH3)2Cl2(OH)2]. To find suitable solvents for entrapment of compound 6.1 within 
MWCNTs, the solubility test was performed with a number of polar and non-polar 
solvents. The solubility of compound 6.1 in EtOH, MeOH and EA was estimated to 
be 74, 320 and 29 µg/mL, respectively (Table 6.1). Solubility in CHCl3 was too poor 
to be estimated by this method. Moreover, the synthesis procedures of compound 6.1 
suggested its remarkably good solubility in DMSO, DMF, and THF. 
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Table 6.1 Solubility of Pt(IV) complex in polar and non-polar solvents. 
 
Solvents Solubility of compound 6.1 
Polar 
Ethanol 74 µg/mL 
Methanol 320 µg/mL 
Water < 280 µg/mL 
   
Non-polar 
Chloroform < 84 µg/mL 
Ethyl acetate 29 µg/mL 
 
6.4.2 Characterization of MWCNT-Pt(IV) 
6.4.2.1 Quantification of compound 6.1 entrapped within MWCNTs using 
TGA and ICP-OES 
The excellent solvation properties of compound 6.1 in organic solvents makes nano-
extraction a suitable method for incorporating the Pt(IV) complex into CNTs. 
Ultrapure MWCNTs with a diameter of 30~40 nm and a length of up to a few 
microns were used instead of SWCNTs since they have a higher internal diameter and 
therefore a higher drug loading capacity [270]. Platinum content in MWCNT-Pt(IV) 
was determined using ICP-OES on samples that were incinerated at 1000 °C (Fig. 6.2) 
and their residues reconstituted in 2% HNO3. The measurements indicated the 
MWCNT-Pt(IV) contained 51.7% w/w Pt(IV) compound 6.1, while controls gave 
background values. It is noteworthy that earlier attempts to incorporate CDDP into 
MWCNTs (MWCNT-CDDP) resulted in higher levels of entrapment, corresponding 
to 62.1% w/w CDDP. The lower entrapment levels of compound 6.1 were 
presumably due to the greater steric encumbrance resulting in poorer mobility within 
the CNT cavity. 
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Fig. 6.2 TGA of MWCNT-Pt(IV). TGA graph is labeled with the wt% of metal 
residue after ramping the sample up to 1000 °C at a rate of 10 C/min in air. 
 
6.4.2.2 SEM-EDX characterization of MWCNT-Pt(IV) 
SEM was performed repeatedly at eight different positions on the grid on ultrapure 
pristine MWCNTs, as well as on several batches of MWCNT-Pt(IV). The SEM 
indicated that compound 6.1 was not present on the surface of the MWCNTs since no 
remarkable differences were noticeable from the evaluation of the images in the 
absence and in the presence of Pt(IV) prodrug (Fig. 6.3a and Fig. 6.3b, respectively) 
and from the EDX analysis on the CNTs’ surface (Fig. 6.3c and Fig. 6.3d, 
respectively). The comparison between overall platinum content obtained using ICP-
OES and surface-bound platinum content detected using SEM-EDX suggested that 
only a minority of compound 6.1 adsorbed on MWCNTs’ external surface while the 
majority of prodrug was entrapped within the inner cavity of MWCNTs. Indeed, 
hydrophobic molecules can easily adhere to the external surface of CNTs. In our case, 
the crucial step to keep the external surface clean was to wash these MWCNT-Pt(IV) 
with the washing solvent comprising CHCl3:MeOH:water (2:2.4:1 v/v) (Table 6.2). 
The rationale of washing solvent has been described in Chapter 3. 
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Fig. 6.3 SEM images (30 keV) of (a) ultrapure pristine MWCNTs and (b) MWCNT-
Pt(IV); EDX spectrum of (c) MWCNTs showing C (93.36%) peak, while the other 
peaks are assigned to O (6.47%), and Si (0.17%) peaks; EDX spectrum of (d) 
MWCNT-Pt(IV) showing C (77.21%), Cl (1.98%), Pt (6.51%), while the other peaks 
are assigned to O (12.57%), and Si (1.73%) peaks; all the elements were measured by 
weight. 
 
Table 6.2 “Washing solvents” screening for Pt(IV) compound 6.1 (“√” miscible, “×” 
immiscible). 
 
Mixture   Solubility 
CHCl3:MeOH:water (v/v)  Miscibility  
1:1.96:1  × — 
1:1.97:1  √ 0.66 mg/mL 
2:2.40:1  × — 
2:2.41:1  √ 0.86 mg/mL 
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6.4.3 Release of platinum from MWCNT-Pt(IV) complex 
In the release study of MWCNT-Pt(IV) we first investigated whether compound 6.1 
could be stably trapped within the MWCNTs without leakage into the solvent 
environment. It had been previously ascertained using 
1
H-NMR that compound 6.1 
was stable in polar solvents, such as DMSO, for 2 weeks. In contrast, CDDP 
degraded in DMSO, with the ammine ligands displaced and chemically altering the 
Pt(II)-pharmacophore. MWCNT-Pt(IV) was suspended and agitated in phosphate 
buffer. At regular intervals over a period of 4 days, samples were taken and analysed 
for platinum content by ICP-OES. No significant levels of platinum were detected in 
the buffer solution (Fig. 6.4). In contrast, when MWCNT-CDDP was subjected to the 
same conditions, significant levels of platinum were detected within 5 min and more 
than 70% of the drug was released from the carrier in 2 h. The rapid release of CDDP 
from the carrier would be problematic in therapy since the macromolecular drug 
needs to be reformulated in saline before application. 
To achieve release of compound 6.1 from the carrier, MWCNT-Pt(IV) was agitated in 
3 mM ascorbic acid as a bio-reductant for a period of 4 days to simulate a reductive 
environment and samples of the buffer were analysed as before. Compound 6.1 was 
released at a slower rate and completed only after 8 h. A slower rate of release was 
achieved because the reduction can only occur at the cavity entrance at the exposed 
solvent interface. This provided a validation on our hypothesis that hydrophobic 
Pt(IV) complexes can be stably stored within hydrophobic cavities and selectively 
released by chemical reduction. 
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Fig. 6.4 Release of [Pt] from MWCNT-Pt(IV) as assayed by ICP-OES; MWCNT-
Pt(IV) in PBS (red line); MWCNT-Pt(IV) in 3 mM ascorbic acid (blue line); 
MWCNT-CDDP in PBS (black line); measurements are taken in triplicates. 
 
6.4.4 Reactivity of platinum complex with dGMP upon release from 
MWCNT-Pt(IV) 
To evaluate MWCNT-Pt(IV) as a potential drug delivery vehicle, we studied the 
nature of the Pt(II) species released upon reduction and whether they could still bind 
DNA, their putative biological target. We carried out a drug release experiment in the 
presence of deoxyguanosine monophosphate (dGMP) as a model for DNA-binding to 
examine the type of Pt-dGMP formed upon binding. Experiments were conducted to 
determine the conditions in which compound 6.1 could bind dGMP. ESI-MS showed 
that compound 6.1 was stable in the presence of dGMP, but reacted to form Pt-dGMP 
adducts after treatment with 3 mM ascorbic acid (Fig. 6.5). Analytical RP-HPLC 
identified these adducts to be monofunctional [cis-Pt(NH3)2(dGMP)Cl] and 
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bifunctional [cis-Pt(NH3)2(dGMP)2], which were confirmed by ESI-MS analysis on 
isolated fractions. The same adducts were formed when CDDP was treated with 
dGMP, indicating that compound 6.1 was functionally similar to CDDP after 
reduction. 
 
Fig. 6.5 RP-HPLC chromatograms (280 nm wavelength) showing the activity of 
CDDP and reduced Pt(IV) compound 6.1: (a) dGMP alone as control; (b) the reaction 
of dGMP with CDDP; (c) the reaction of dGMP with compound 6.1; (d) the reaction 
of dGMP with compound 6.1 in the presence of 3 mM ascorbic acid; labels indicate 
unreacted dGMP plus its oxidised form (*), [Pt(NH3)2(dGMP)Cl] (♦) and 
[Pt(NH3)2(dGMP)2] (●) as analysed by ESI-MS. 
 
Similar Pt-dGMP adducts were also detected after MWCNT-Pt(IV) was treated with 
3 mM ascorbic acid and dGMP, indicating that selective release from the MWCNT 
yielded functionally analogous Pt(II) species capable of DNA-binding (Fig. 6.6). In 
contrast, no Pt-dGMP adducts were formed when MWCNT-Pt(IV) was incubated 
with dGMP in the absence of the bio-reductant. From these results, we conclude that 
platinum release from MWCNT-Pt(IV) can only be achieved upon chemical 
reduction as reactive Pt(II) species capable of DNA-binding. 
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Fig. 6.6 RP-HPLC chromatograms (280 nm) showing the reactivity of reduced 
platinum complex from MWCNT-Pt(IV): (a) dGMP alone as control; (b) the reaction 
of dGMP with MWCNT-Pt(IV) alone; (c) the reaction of dGMP with MWCNT-Pt(IV) 
in the presence of 3 mM ascorbic acid; labels indicate unreacted dGMP plus its 
oxidised form (*), [Pt(NH3)2(dGMP)Cl] (♦) and [Pt(NH3)2(dGMP)2] (●) as analysed 
by ESI-MS. 
 
6.4.5 Cellular uptake of platinum in A2780 ovarian carcinoma cells treated 
with MWCNT-Pt(IV) 
As the next step, we investigated whether MWCNT-Pt(IV) was capable of delivering 
compound 6.1 into cancer cells in vitro. The ability of CNTs to penetrate and 
internalise within cells had previously been documented, using MWCNTs covalently 
labelled with fluorophores, leading to the notion of using them as “nano-needles” or 
“nano-syringes” [120, 438-441]. In this study, we treated A2780 ovarian carcinoma 
cells with dialysed samples of pristine MWCNTs, MWCNTs/compound 6.1 mixture, 
as well as MWCNT-Pt(IV) to ascertain if entrapment of compound 6.1 was essential 
for drug delivery. The samples were subjected to dialysis to simulate the exposure to 
bodily fluids after intravenous administration. After dialysis, the cells were exposed 
to MWCNT samples for 8 h, after which they were harvested and analysed for 
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platinum content using ICP-MS. The normalised platinum content, as a function of 
protein levels, after two independent experiments at different exposure conditions (48 
μg/L [Pt] and 240 μg/L [Pt]) were plotted in Fig. 6.7. Baseline platinum values were 
observed in samples treated with pristine MWCNTs, as well as the 
MWCNTs/compound 6.1 mixture. In the case of MWCNTs/compound 6.1 mixture, 
MWCNTs were not able to keep compound 6.1 within their tubular structure in the 
dialysis process and drag it into A2780 cells, since compound 6.1 simply leaked out 
the dialysis membrane and was not found inside the cells. In contrast, significant 
platinum levels were detected in cells treated with MWCNT-Pt(IV), which was 
dependent on the administered dosage. This experiment confirmed the stable 
entrapment of compound 6.1 within the MWCNTs and its efficient delivery into 
cancer cells and showed that when compound 6.1 was not entrapped within the 
MWCNTs, it rapidly dissipated into the ambient environment. This result provided 
further validation of the proposed hydrophobic entrapment strategy by MWCNTs as 
drug-nanocapsules, which could be expanded to other hydrophobic prodrug 
molecules, leading to new advances in the field of nanomedicine. 
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Fig. 6.7 Intracellular platinum content (per mg of proteins) extracted from A2780 
cells treated with pristine MWCNTs (blue), mixture of MWCNTs and Pt(IV) (orange), 
and MWCNT-Pt(IV) (green); A corresponds to delivery of 48μg/L [Pt] and B to 240 
μg/L [Pt]; readings are taken in triplicates. 
 
6.5 Conclusion 
Platinum drugs remain some of the most important chemotherapeutic drugs. With 
improved and targeted delivery, the main limitations of platinum-based therapies can 
be mitigated. This article provides a proof-of-concept on a macromolecular delivery 
system, in the form of MWCNTs capable of entrapping hydrophobic Pt(IV) 
complexes and selectively releasing them as cytotoxic Pt(II) species upon chemical 
reduction. The strongly hydrophobic Pt(IV) complex was designed to be trapped 
within MWCNTs via hydrophobic-hydrophobic interactions and to achieve a drastic 
reversal in hydrophobicity upon reduction to facilitate drug release. Our data showed 
that compound 6.1 could be stably contained within the MWCNTs, in contrast to 
CDDP, and be selectively released in the presence of a reductant. The drug was 
released in the form of Pt(II) species that were functionally analogous to cytotoxic 
CDDP, capable of forming similar monofunctional and bifunctional Pt-dGMP 
adducts. When treated in vitro, this MWCNT-Pt(IV) nanocapsule was capable of 
delivering the platinum payload into cancer cells. This simple method of hydrophobic 
entrapment and selective release by chemical reduction and hydrophobicity reversal, 
exploiting the Pt(IV) scaffold as a prodrug, could form the basis of other delivery 
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Platinum-based drugs have been extensively used in monotherapies or combination 
therapies for numerous solid malignancies. Cisplatin (Platinol®, CDDP), carboplatin 
(Paraplatin®), and oxaliplatin (Eloxatin®) are three main platinum drugs approved by 
FDA and applied to clinical therapies for ovarian [442, 443], lung [444, 445], 
testicular [446], colorectal [447], gastric [448], lymphomas [449], etc. Platinum drugs 
induce DNA interstrand cross-links formed by Pt-DNA adducts following uptake of 
drugs into nucleus of cells. The formation of cross-links interfere with DNA 
replication and transcription, which consequently cause critical cytotoxic lesions and 
lead to apoptotic cell death involving prolonged cell cycle (G2) arrest [450]. 
However, a major concern about the therapeutic efficacy is the biodistribution of 
platinum drugs, which may limit their accumulation in diseased tissues and induce 
toxicity in normal tissues. In previous studies, platinum distribution in plasma, 
kidneys, liver, and lung was investigated following intraperitoneal (i.p.) bolus 
injection of CDDP, showing that platinum concentrations in liver and kidneys were 
markedly higher than in lung and plasma during 21 days pharmacokinetic study (Fig. 
7.1) [451]. Apart from Pt(II) analogues, the biodistribution study of Pt(IV) derivatives 
also revealed that elemental platinum mostly accumulated in kidney and liver, 
followed by lung, jejunum, skin, spleen, heart, brain, and muscle, where the 
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concentrations were less or similar when compared to the plasma Cmax values [452, 
453]. Furthermore, it has been demonstrated that platinum chemo drugs have some 
side effects; for example, besides common toxicities including nausea and vomiting 
in chemotherapy, nephrotoxicity, ototoxicity and neurotoxicity are found in the 
treatment with CDDP [454, 455]. Carboplatin causes bone marrow suppression and 
thrombocytopenia [456, 457], while the use of oxaliplatin results in stomatitis, 
diarrhea, neutropenia and peripheral neuropathy [458, 459]. Taking into account the 
distribution propensity of platinum-based drugs in some specific organs and tissues, 
these adverse effects may aggravate damage to certain normal tissues, especially 
kidney and liver, which have higher platinum concentrations in comparison with 
other tissues. A severe tubular necrosis was microscopically observed in the kidneys 
of rats and pigs, where the highest platinum concentration was detected after i.v., i.p., 
or intra-abdominal pressure (IAP) CDDP treatment, suggesting that both animals 
developed renal failure after receiving the highest doses of CDDP [460]. Therefore, 
efforts to alter the biodistribution of platinum-based drugs are necessary to enhance 
their antineoplastic effects and reduce side effects on normal tissues. 
 
Fig. 7.1 The total Pt concentration-time profiles in plasma (●), kidneys (△), liver (□) 
and lung (○) after i.p. bolus injection of CDDP. Reprinted from “Organ distribution 
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of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres,” by 
Tamura, T., et al., 2002, Eur J Pharm Biopharm, 54(1), p. 1-7. 
 
Towards that purpose, in the present study we performed the entrapment of platinum-
based compounds within pristine and modified MWCNTs, as well as examined the 
tissue distribution of elemental platinum in mice in the presence of various MWCNTs. 
Thus far, a number of biodistribution studies on pristine or functionalized CNTs have 
been published. Yang et al. studied Tween 80 dispersed SWCNTs labeled with 
isotope 13C by measuring the 13C abundance, finding that they were easily recognized 
by macrophages and thereby captured by reticuloendothelial system (RES) in liver 
and spleen [197, 461]. Similar findings were observed in the study of Pluronic F108 
dispersed SWCNTs that mainly accumulated in the liver and were rarely detected in 
pulmonary uptake by measuring the characteristic NIR fluorescence of individual 
SWCNTs [174]; in contrast, in another study on functionalized CNTs, it was found 
that serum dispersed MWCNTs mainly resided in liver and lung [462]. The reason at 
the basis of such differences could be found in the investigation of the effects of 
covalent functionalization on CNTs’ biodistribution. Yang et al. showed that even 
short PEG1500 chains inserted through covalent functionalization could efficiently 
reduce the RES capture of PEG1500-SWCNTs, that is, the uptake by RES was 28% ID 
(% of injected dose) for PEG1500-SWCNTs [463] in comparison with 80% ID and 37% 
ID in case of the taurine-functionalized [464] and pristine SWCNTs dispersed in 
Tween 80 [179], respectively. In another study on covalent PEGylation, Liu et al. 
investigated the biodistribution of SWCNTs functionalized with linear (l) 
PEG2000/5000 and branched (br) PEG7000, finding clearly reduced levels of liver 
and spleen uptake for SWCNT-l-5kPEG and SWCNT-br-7kPEG compared with 
SWCNT-l-2kPEG, although dominant uptake was still detected in the liver and spleen 
of the RES (Fig. 7.2) [180]. This result suggested that higher degree of surface 
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PEGlyation of SWCNTs might contribute to lower RES uptake, which is in accord 
with the findings that the difference in organ distribution and excretion profiles was 
mainly dependent on the degree of chemical functionalization [465]. Moreover, it has 
been found that amino-derivatized CNTs were mainly trapped in liver, spleen, kidney 
and skin [233, 466, 467]. 
 
Fig. 7.2 Biodistribution of SWCNT-l-2kPEG, SWCNT-l-5kPEG, and SWCNT-br-
7kPEG, respectively, at 1 day post-injection, measured by Raman spectroscopy. The 
SWCNT concentrations in most organs are below detection limit. Reprinted from 
“Circulation and long-term fate of functionalized, biocompatible single-walled 
carbon nanotubes in mice probed by Raman spectroscopy,” by Liu, Z., et al., 2008, 
Proc Natl Acad Sci U S A, 105(5), p. 1-7. 
 
In our investigation, we carried out a study on the influence of CNTs’ surface 
functionalization on the incorporation of drugs or prodrugs (such as platinum 
derivatives) as well as their biodistribution in vivo. Therefore, the drug prototypes 
were entrapped within pristine, oxidised (MWCNTOX) and amino-functionalized 
MWCNTs (MWCNTTEG) which, in view of their larger diameter in comparison with 
SWCNTs, provide the advantage of accumulating a higher amount of drug molecules 
in their inner cavity. After that, mice were treated with these various nanotubes 
loaded with drugs by intravenous injection, to evaluate the effect of nanotube delivery 
on the distribution of encapsulated drugs in vivo. 
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7.2 Hypothesis and objectives 
In this study, we design a series of CNT-based drug delivery systems that, in view of 
their sidewall functionalizations and/or propensity to localize in specific organs and 
tissues, should influence the biodistribution of both the hydrophilic CDDP and the 
hydrophobic Pt(IV) compound 6.1 in vivo. To prove that hypothesis: 
(1) We will synthesize two kinds of nanotubes, namely MWCNTOX and MWCNTTEG, 
in which the various functionalities are expected to affect the distribution and 
clearance of nanotubes in vivo. 
(2) Hydrophilic CDDP and hydrophobic Pt(IV) compound 6.1 will be encapsulated 
into these various nanotubes at high loading efficiency. These MWCNT-drug 
complexes will be intravenously injected into mice to assess the distribution of 
elemental platinum in vivo, as well as immune and histopathological responses. 
If the hypothesis is proven, we will demonstrate that functionalized nanotubes with 
good biocompatibility are able to enhance the drug content in tissues as well as alter 
the tissue distribution in vivo, thus acting as a promising vehicle to carry therapeutic 
agents into specific tissues or organs. 
 
7.3 Materials and methods 
7.3.1 Chemicals and reagents 
Tetramethylammonium hydroxide (TMAH), 25% w/w aqueous solution was 
purchased from Alfa Aesar. 2,2’-(Ethylenedioxy)diethylamine, formaldehyde 
solution (36.5~38% in H2O), and Platinum Standard for ICP (1000 mg/L Pt in 
hydrochloric acid) were purchased from Sigma Aldrich. The reactions were 
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performed with solvents purchased from Tedia. Mouse IL-1β, IL-6, TNF-α ELISA 
‘Ready-SET-Go!’ kits were purchased from eBioscience. 
 
7.3.2 Instruments 
TEM was carried out using JEM 2010F HR-TEM (JEOL). UV-vis absorbance was 
measured using SHIMADZU UV-1800 Spectrophotometer. ICP-MS was carried out 
using Agilent 7500A Inductively Coupled Plasma Mass Spectrometer. 
 
7.3.3 Animals 
Female BALB/c mice, 6-8 weeks old, were obtained from Center for Animal 
Resources (CARE) in Comparative Medicine, National University of Singapore 
(NUS). The animals were housed in plastic cages (5 mice/cage) and allowed free 
access to sterile food pellets and water. The animal holding room kept a 12 h 
light/dark cycle. All animal studies (protocol number IACUC 063/11) were 
performed in compliance with guidelines set by NUS Institutional Animal Care and 
Use Committee (IACUC). 
 
7.3.4 Methods 
7.3.4.1 Samples preparation 
7.3.4.1.1 Synthesis of MWCNTOX and MWCNTTEG 
Pristine MWCNTs were oxidised and purified as described in Chapter 5 to obtain 
MWCNTOX. As-prepared MWCNTOX (9.7 mg) were dispersed in 1 mL of 
dimethylformamide (DMF) under sonication, and then NHS (45 μmol), EDC·HCl 
(112 μmol), 2,2’-(ethylenedioxy)diethylamine (TEG, 111 μmol), and DIPEA (112 
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μmol) were added in the suspension (Scheme 7.1). The mixture was heated at 60 °C 
for 24 h and filtered through a hydrophilic PTFE membrane with a cut-off of 0.22 μm. 
The residue was washed with DMF and deionized water, and after that, was dried in 
vacuum to yield MWCNTTEG. The degree of amino-functionalization per gram of 
MWCNTTEG (amino-loading) was calculated through quantitative Kaiser Test [468]: 
about 100 μg of as-prepared MWCNTTEG was incubated with 75 μL of 4 g/mL phenol 
in ethanol, 100 μL of 0.02 mM KCN in pyridine, and 75 μL of ninhydrin in ethanol at 
100 °C for 7 min; after heating, the reaction was diluted with 60% ethanol to 5 mL, 
and the absorbance was read with SHIMAZU UV-1800 Spectrophotometer at 570 nm. 
The amount of –NH2 groups (μmol/g in MWCNTTEG) was calculated using the 
following equation: 
              μ       
             
       
 
 
Where A570 nm is the absorbance at the wavelength 570 nm; W is the weight of 
analysed nanotube sample (mg). 
 
Scheme 7.1 Synthetic procedure of amino-functionalized MWCNT (MWCNTTEG). 
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7.3.4.1.2 Entrapment of CDDP in MWCNTOX and MWCNTTEG via nano-
extraction 
The preparation of MWCNTOX-CDDP and MWCNTTEG-CDDP complexes was 
carried out as reported previously. In brief, CDDP (7.5 mg) was mixed with 
MWCNTOX (3.0 mg) or MWCNTTEG (3.0 mg) in ethyl acetate (EA, 1.5 mL) for 24 h 
and filtered through a hydrophobic PTFE membrane. The residue was washed 
extensively with a washing mixture (2.6:1:1 v/v EA:EtOH:water) and dried in 
vacuum to yield MWCNTOX-CDDP or MWCNTTEG-CDDP. Platinum content of 
MWCNTOX-CDDP and MWCNTTEG-CDDP was determined using ICP-OES on 
samples that were prepared by incineration at 1000 °C followed by reconstituting the 
residue in 2% HNO3. 
 
7.3.4.1.3 Entrapment of Pt(IV) compound 6.1 in MWCNTOX and MWCNTTEG 
via nano-extraction 
The preparation of MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) complexes was in 
accordance with the procedure for MWCNT-Pt(IV) reported in Chapter 6. In brief, 
compound 6.1 (4.5 mg) was mixed with MWCNTOX (1.7 mg) or MWCNTTEG (1.6 mg) 
in CHCl3 (1 mL) for 5 days and filtered through a hydrophilic PTFE membrane. The 
residue was washed extensively with the washing mixture (2:2.41:1 v/v 
CHCl3:MeOH:water) and dried in vacuum to yield MWCNTOX-Pt(IV) and 
MWCNTTEG-Pt(IV). Platinum content of MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) 
was determined using ICP-OES on samples that were prepared by incineration at 
1000 °C followed by reconstituting the residue in 2% HNO3. 
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7.3.4.2 In vivo injection of Pt-MWCNT complexes in mice 
Mice of each group were i.v. injected via tail vein with 200 μL of CDDP aqueous 
solution, compound 6.1 in 0.5% DMSO aqueous solution, various MWCNT-
CDDP/Pt(IV) complexes or blank nanotubes aqueous suspensions. Mice treated with 
PBS were used as negative control group. The injected doses were normalized to be 4 
mg/kg CDDP, which is the previously reported maximum tolerated dose (MTD) of 
CDDP in mice [469], or 1.5 mg/kg compound 6.1. The injected dose of compound 
6.1 was decided based on a preliminary investigation, in which mice were treated 
with increasing concentrations of compound 6.1 to assess the MTD (data not shown). 
At post-injection of 1 h, 4 h and 24 h, mice were euthanized for collection of blood 
and removal of vital organs (brain, heart, kidney, liver, lung, spleen). Serum samples 
were separated from blood, which was obtained by intracardiac puncture, by 
centrifugation at 3,000 rpm for 10 min. Tissues for elemental platinum determination 
were collected and weighted for organ indices (organ weight/body weight) calculation. 
Urine was collected only after 24 h through metabolic cages. Organs, serum and urine 
samples were stored at -80 °C before assays. Tissues for histopathological 
morphology studies were fixed in 10% buffered formalin and processed for routine 
histology with hematoxylin and eosin (H&E) stain by Institute of Molecular and Cell 
Biology, Agency for Science Technology and Research (Singapore). Microscopic 
observation of tissues was carried out with an Olympus BX41 microscope (Olympus 
Corporation, Shinjuku, Tokyo, Japan) coupled with a digital camera. 
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7.3.4.3 Determination of platinum content in the organs, serum, and urine 
7.3.4.3.1 Serum analysis [470] 
0.1 ml of serum samples were decomposed by the addition of 0.1 ml TMAH (25%) in 
each tube. These mixtures were shaken at room temperature for 4 days in closed 
centrifuge tubes until complete digestion. The volume of decomposed serum was 
adjusted to 1 mL with deionized water and then solutions were centrifugated at 
17,000 rpm for 5 min. The supernatant was diluted with deionized water to suitable 
concentrations for analysis. Platinum concentrations of serum samples were 
determined using ICP-MS. 
 
7.3.4.3.2 Organs analysis [470] 
Organs (brain, heart, kidney, liver, lung, spleen) were heated at 105 °C overnight to 
make the organs completely dry. The dried organs were decomposed by adding an 
aliquot of TMAH (25%) and deionized water at a ratio of 1:1 directly in each tube. 
The decomposition was carried out at room temperature for 4 days while shaking 
until complete digestion. Deionized water was added to adjust the volume of 
decomposed organs to 1 mL and then solutions were centrifugated at 17,000 rpm for 
5 min. The supernatant was diluted with deionized water to suitable concentrations 
for analysis. Platinum concentrations of various organ samples were determined using 
ICP-MS. 
 
7.3.4.3.3 Urine analysis 
0.1 mL of urine samples were directly diluted 100-fold with deionized water for 
analysis. Platinum concentrations in urine samples were determined using ICP-MS. 
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7.3.4.3.4 Standard samples preparation 
The blank serum, organs, and urine samples, which were harvested from naïve group, 
were subjected to decomposition in accordance with the procedures carried out in 
experimental groups. The five-point calibration curves for each matrix were obtained 
by spiking with platinum standard solutions (1000 mg/L elemental platinum in HCl). 
The platinum concentrations in the calibration curves ranged between 1 and 50 μg/L. 
ICP-MS reading was repeated three times and the respective mean values were used 
for the construction of the calibration curves. 
 
7.3.4.4 ELISA assay 
To determine the secretion of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α) 
and interleukin-6 (IL-6) levels in plasma, ELISA was performed using ‘Ready-SET-
Go!’ kits from eBioscience according to manufacturer’s instructions. The absorbance 
was measured on a microplate reader (TECAN infinite Series M200) at 450nm. 
Results were presented as mean pg/mL ± SD of triplicates. 
 
7.3.4.5 Statistical analysis 
All statistical analyses were performed using Statistical Package for the Social 
Sciences (SPSS). Statistical comparisons were performed using one-way analysis of 
variance (ANOVA). Significant ANOVAs were further analysed using Bonferroni, 
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7.4 Results and discussion 
7.4.1 Characterization of nanotubes 
In this chapter, we present the in vivo biodistribution of platinum-based compounds 
upon their encapsulation in the interior of various nanotubes including pristine 
MWCNTs, oxidised MWCNTs, and amino-functionalized MWCNTs. Theses 
nanotube samples were produced by oxidation experiment and further carbodiimide 
coupling reaction, and then analysed through different techniques in order to evaluate 
morphology, extent of functionalization and drug loading. More precisely, pristine 
MWCNTs, MWCNTOX and MWCNTTEG were observed under TEM (Fig. 7.3). As 
expected, MWCNTOX and MWCNTTEG were much shorter than pristine MWCNTs, 
since oxidation by acid treatment is able to cut nanotubes at the tips and at the sites of 
sidewall defects. 
Moreover, in order to evaluate the functionalization degree of nanotubes, 
MWCNTTEG was examined through quantitative Kaiser Test, showing a value of 322 
μmol of NH2 groups/g of MWCNTTEG. 
The loading of CDDP or compound 6.1 in these samples was determined using the 
method described in Chapter 3. The results showed that the content of CDDP was 59% 
w/w in MWCNTOX-CDDP and 58% w/w in MWCNTTEG-CDDP samples, 
respectively; similarly, 45% w/w of compound 6.1 was found in both MWCNTOX-
Pt(IV) and MWCNTTEG-Pt(IV). This suggested that the functionalization of 
MWCNTs still maintained a high loading efficiency of CDDP and compound 6.1; 
drug loading was comparable with the results obtained from the encapsulation into 
pristine MWCNTs (62.1% w/w and 51.7% w/w for CDDP and compound 6.1, 
respectively), therefore both pristine MWCNTs and their functionalized forms could 
be powerful vehicles capable of carrying high payload. 
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Fig. 7.3 TEM images of (a) pristine MWCNTs, (b) carboxylated MWCNTOX, and (c) 
amidated MWCNTTEG. 
 
7.4.2 Tissue distribution of elemental platinum in mice 
7.4.2.1 Biodistribution of elemental platinum from the administration of 
CDDP alone, MWCNT-CDDP, MWCNTOX-CDDP, and MWCNTTEG-
CDDP in mice 
The comparative tissue distribution study of free CDDP and CDDP entrapped within 
various nanotubes (MWCNT-CDDP, MWCNTOX-CDDP and MWCNTTEG-CDDP) 
was investigated in female BALB/c mice following intravenous administration of the 
maximally tolerated doses of CDDP (4 mg/kg) via tail vein [469]. Platinum content in 
tissues showed similar distribution patterns following treatment with either CDDP 
alone or its MWCNT complexes, and no remarkable variations of platinum content 
were found in most tissues (Fig. 7.4). It is conceivable that water-soluble CDDP 
rapidly leaked out from the restriction within nanotubes’ inner cavities when they 
entered the bloodstream, and thus those CDDP molecules that were released from 
nanotubes behaved similarly to free CDDP molecules, whereas the nanotubes could 
not really play a role in the transportation of CDDP. This result is consistent with 
previous in vitro release experiment of MWCNT-CDDP in PBS medium, which 
indicated that most of encapsulated CDDP was released from nanotubes within 1 h 
(Chapter 3). 
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Fig. 7.4 Tissue distribution of CDDP alone, MWCNT-CDDP, MWCNTOX-CDDP, 
and MWCNTTEG-CDDP in female mice at (a) 1 h post-exposure, (b) 4 h post-
exposure, and (c) 24 h post-exposure. Data are presented as Mean ± SD (n=3). 
*Significantly different from CDDP alone at P< 0.05 (one-way ANOVA with Tukey 
post-hoc test). 
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The distribution was further analysed based on platinum concentrations per gram of 
tissues, which represented the affinity of platinum-based molecules for a particular 
tissue (Fig. 7.5). MWCNTOX-CDDP and MWCNTTEG-CDDP groups exhibited higher 
platinum concentrations in spleen compared with CDDP alone group following 4 h 
and 24 h administration (P< 0.05), and such disparity seemed to have a time-
dependent increase. In other words, the longer was the delay from the i.v. injection, 
the lower the accumulation in liver and kidney, while the higher the accumulation in 
the spleen for MWCNTOX-CDDP and MWCNTTEG-CDDP samples. This tendency is 
probably due to the internalization of shorter MWCNTOX-CDDP and MWCNTTEG-
CDDP into macrophages and subsequent transportation to immune organ spleen [191], 
while macrophages may have difficulties in engulfing longer MWCNT-CDDP nano-
bottles (Fig. 7.3) [223]. Interestingly, despite the fast leakage of CDDP from 
nanotubes at physiological conditions, a small amount of CDDP still remained inside 
nanotubes and these nano-bottles could keep discharging CDDP after transportation 
to the spleen, which contributed to the slight increase of platinum concentrations in 
the spleen. 
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Fig. 7.5 Percentage of platinum dosed per gram of tissue collected from female mice 
that were treated with CDDP alone, MWCNT-CDDP, MWCNTOX-CDDP, and 
MWCNTTEG-CDDP at (a) 1 h post-exposure, (b) 4 h post-exposure, and (c) 24 h post-
exposure. Data are presented as Mean ± SD (n=3). 
*Significantly different from CDDP alone at P< 0.05 (one-way ANOVA with Tukey 
post-hoc test). 
Chapter 7 Biodistribution of Intravenously Administered 
MWCNT-CDDP and MWCNT-Pt(IV) in Mice 
174 
 
7.4.2.2 Biodistribution of elemental platinum from administration of Pt(IV) 
compound 6.1 alone, MWCNT-Pt(IV), MWCNTOX-Pt(IV), and 
MWCNTTEG-Pt(IV) in mice 
7.4.2.2.1 Increased platinum levels in vivo through MWCNTOX or MWCNTTEG 
The tissue distributions of free compound 6.1 and compound 6.1 entrapped within 
various nanotubes (MWCNT-Pt(IV), MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV)) 
were also compared following 1 h, 4 h, and 24 h post-administration (Fig. 7.6). In this 
case, it was observed a significant increase of platinum content in tissues obtained 
from mice that were exposed to MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) groups in 
comparison with compound 6.1 alone group. In compound 6.1 alone group, the tissue 
distribution showed that a small amount of platinum content was indeed detected in 
plasma, organs, and urine. The low platinum level is probably attributed to the 
insolubility of hydrophobic compound 6.1 in aqueous solution, which might be 
unfavorable to the movement of compound 6.1 in the bloodstream. Similarly, such 
insolubility might have caused adhesion to blood vessel wall and combination with 
blood cells or proteins to a great extent. By contrast, carboxylated MWCNTOX and 
amidated MWCNTTEG have a more hydrophilic surface, which may enhance the 
dispersibility of nanotubes, thus enabling the pervasion of MWCNTOX-Pt(IV) and 
MWCNTTEG-Pt(IV) complexes in physiological systems as well as preventing the 
entrapped compound 6.1 from the contact with blood vessel and blood cells. On the 
other hand, pristine MWCNTs with relatively poor dispersibility could not efficiently 
diffuse compound 6.1 in physiological systems, hence there was no remarkable 
difference between the tissue distribution of platinum in MWCNT-Pt(IV) group and 
that in compound 6.1 alone group. Besides, it was expected that the strong 
hydrophobicity of compound 6.1, which is contrary to the water-soluble property of 
CDDP, allowed it to remain inside the CNT cavities without leakage under normal 
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aqueous conditions, whereas its release could be promoted in the presence of 
reducing agents inside the cells. Therefore, most of the compound 6.1 was able to 
enter systemic circulation along with MWCNTOX and MWCNTTEG rather than 
behaving like free molecule. This selective release has been proven in our previous in 
vitro release experiments (Chapter 6), suggesting that MWCNTOX and MWCNTTEG 
had a greater impact on the tissue distribution of compound 6.1 than that of CDDP. 
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Fig. 7.6 Tissue distribution of Pt(IV) compound 6.1 alone, MWCNT-Pt(IV), 
MWCNTOX-Pt(IV), and MWCNTTEG-Pt(IV) in female mice at (a) 1 h post-exposure, 
(b) 4 h post-exposure, and (c) 24 h post-exposure. Data are presented as Mean ± SD 
(n=3). 
*Significantly different from Pt(IV) compound 6.1 alone at P< 0.05 (one-way 
ANOVA with Tukey post-hoc test). 
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7.4.2.2.2 Variations in distribution tendency of Pt(IV) compound 6.1 through 
MWCNTOX or MWCNTTEG 
MWCNTOX and MWCNTTEG not only enhanced the platinum levels in most tissues 
following administration of MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) in 
comparison with free compound 6.1, but also altered the distribution tendency in 
certain tissues. Among all the tissues analysed in the comparative study, platinum 
levels in the lungs showed the largest improvement in comparison with the other 
tissues. In Pt(IV) compound 6.1 alone group, the amount of platinum detected in the 
lungs at 1 h and 4 h post-injection was only 0.7% and 0.2% of overall administered 
platinum, respectively; conversely, platinum distribution in the lungs drastically 
increased to 14.4% at 1 h and 9.9% at 4 h in MWCNTTEG-Pt(IV) group, and 
MWCNTOX-Pt(IV) group also had a remarkable increase to 4.7% at 1 h and 1.7% at 4 
h post-injection. 
To investigate the effect of nanotubes on distribution tendency of compound 6.1, 
platinum contents in tissues were converted into the platinum concentrations per gram 
of tissues (Fig. 7.7). In MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) groups, platinum 
concentration in the lungs was much higher than that in the other tissues at 1 h and 4 
h post-injection, whereas the highest platinum concentrations were detected in kidney 
and liver when mice were treated with free compound 6.1. This variance suggests that 
delivery by MWCNTOX and MWCNTTEG seems favorable to the transportation of 
platinum-based drugs to the lungs for lung carcinoma treatment. Interestingly, the 
increasing trend of elemental platinum accumulation in the lungs was dependent on 
the functionalization of MWCNTs. This result is in good agreement with previous 
distribution studies of oxidised MWCNTs in mice, showing that most oxidised 
MWCNTs were accumulated in the lungs, with just a small amount of retention in the 
liver and spleen after intravenous administration [471]. It was considered that 
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pulmonary capillary bed captured oxidised MWCNTs and subsequently retained them 
in the lungs, but a little part of oxidised MWCNTs could be cleared and could enter 
into the circulatory system with the passage of time. Moreover, the carboxylation of 
MWCNTOX and amidation of MWCNTTEG reduced the length of nanotubes and 
increased their hydrophilicity as well (especially with the TEG chain); as a result, 
these shorter and hydrophilic nanotubes could be readily and safely taken up by 
alveolar epithelial cells. In contrast, the hydrophobic pristine nanotubes would 
assemble as long bundles like asbestos fibers, as they entered physiological 
environment; these large aggregates of nanotubes would prevent them from being 
engulfed by cells [189, 208, 225]. Therefore functionalization probably enhanced the 
affinity of MWCNTOX and MWCNTTEG for the lungs in comparison with pristine 
MWCNTs. Platinum-based antitumor drugs are currently used as first-line 
chemotherapy for non-small-cell lung cancer (NSCLC) [472, 473], whereas clinical 
studies suggested that reduced platinum accumulation might be an important 
mechanism of platinum resistance, which is a major limitation in the treatment of 
advanced NSCLC [474]. Therefore MWCNTOX and MWCNTTEG could be a 
promising carrier to achieve higher accumulation of therapeutic molecules in the 
lungs and lessen the adverse effects on normal tissues. 
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Fig. 7.7 Percentage of platinum dosed per gram of tissue collected from female mice 
that were treated with Pt(IV) prodrug 6.1 alone, MWCNT-Pt(IV), MWCNTOX-Pt(IV), 
and MWCNTTEG-Pt(IV) at (a) 1 h post-exposure, (b) 4 h post-exposure, and (c) 24 h 
post-exposure. Data are presented as Mean ± SD (n=3). 
*Significantly different from Pt(IV) prodrug 6.1 alone at P< 0.05 (one-way ANOVA 
with Tukey post-hoc test). 
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Interestingly, the proportion of platinum content in kidney decreased the most among 
all the tissues when compound 6.1 was entrapped within MWCNTOX and 
MWCNTTEG. Indeed, nephrotoxicity is one of the most common side effects 
associated with platinum-based chemotherapeutics [265, 454]. Fig. 7.7 showed that 
kidney had the highest platinum concentration in Pt(IV) compound 6.1 alone group, 
while platinum levels in lungs, liver and spleen transcended that in kidneys when 
mice were treated with MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV). This variation 
suggested that delivery by MWCNTOX and MWCNTTEG might be helpful in reducing 
the nephrotoxicity of platinum-based drugs during the process of tumor treatment. 
 
7.4.2.2.3 Time-dependent variations of platinum levels in tissues 
The tissue distributions of elemental platinum at various time-points were compared 
to evaluate the relationship between platinum content and time in MWCNTOX-Pt(IV) 
and MWCNTTEG-Pt(IV) groups; the comparison presented time-dependent variances 
in certain tissues. In MWCNTTEG-Pt(IV) group, a decreasing trend of platinum level 
was found in the lungs over the time; the platinum content in the lungs dropped to 3.2% 
at 24 h time-point, which is as much as 1/5 of the amount at 1 h time-point and 1/3 of 
the amount at 4 h time-point, respectively. Although MWCNTTEG-Pt(IV) group 
showed much higher platinum content in the lungs compared with pristine MWCNT-
Pt(IV) and MWCNTOX-Pt(IV) groups, the MWCNTTEG internalized in the lungs 
probably promoted their clearance by macrophages, which could engulf MWCNTTEG 
along with entrapped compound 6.1 and then transfer them to immune organs, thus 
resulting in the fast decrease of platinum level in the lungs. Once again, this result 
suggests that MWCNTTEG might be useful at promoting drug release to the lungs 
while avoiding an excessive accumulation in the target organ. Future studies could 
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address this clinically relevant aspect, i.e. the optimal transition time of platinum-
based drugs in the lungs for a desirable therapeutic effect against NSCLC. 
In contrast to the decline of platinum levels in the lungs, MWCNTTEG-Pt(IV) group 
had a slight rise of platinum content in spleen over time; in a similar manner, a higher 
platinum content in spleen was detected at 24 h time-point than earlier time-points in 
MWCNTOX-Pt(IV) group. This increase is in accord with the observations reported in 
the biodistribution studies of CDDP encapsulated into liposomes [475, 476], where it 
was shown that the maximum CDDP uptake in spleen was achieved at 1 h and 12 h 
post-injection with free CDDP and stealth pH-sensitive liposomes containing 
cisplatin (SpHL-CDDP), respectively. Similarly, intravenously administrated 
nanotubes, as xenogenous materials, might activate the immune response, hereby 
these nanotubes distributed throughout the body were likely trapped in certain 
macrophages, such as alveolar macrophages and Kupffer cells, and then transported 
to lymph nodes and spleen [197]. Moreover, Al-Jamal et al. observed translocation of 
functionalized MWCNTs from lung to spleen [465], which is explained by the 
transportation process of overloaded MWCNTs from the lungs to the afferent 
lymphatics and then to the spleen [179, 464]. On the other hand, a great number of 
nanotubes, whether functionalized or pristine, would be directly captured by RES (e.g. 
sinus histiocytes in spleen) when they passed through the spleen, which is the largest 
unit of RES, resulting in the enhanced uptake of nanotubes in the spleen [471]. The 
retention of nanotubes in the spleen was expected to be subsequently cleared through 
the renal pathway [175]. This observed behavior is comparable to the findings 
reported by Wu et al. showing that the dose of Fe in the spleen did not reach a 
maximum until 8 h after intravenous injection of MWCNT/Fe3O4 hybrid and 
subsequently, the Fe concentration in the spleen declined significantly [477]. 
Therefore the increase of platinum level in the spleen at the primary stage of 
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clearance is expected in view of the spleen’s major role in immunomodulation. 
Furthermore, a similar increase of platinum level at 24 h post-injection was observed 
in liver, which is also an RES organ, in both MWCNTTEG-Pt(IV) groups and 
MWCNTOX-Pt(IV). In addition, there was no significant variation (P> 0.05) of 
platinum levels in most of the other tissues, with the exception of blood, which 
exhibited a slight decrease in platinum levels over time. 
The variances of platinum levels in MWCNTOX-Pt(IV) group were not as remarkable 
as that in MWCNTTEG-Pt(IV) group, even though a slight increase in platinum levels 
was found in spleen and liver at 24 h time-point compared with 1 h and 4 h time-
points. Unlike the striking change in MWCNTTEG-Pt(IV) group, platinum level in the 
lungs was relatively steady in the MWCNTOX-Pt(IV) group. The distribution of 
MWCNTOX-Pt(IV) showed only 4.7% platinum content detected in the lungs at 1 h 
time-point, which was much lower than 14.4% in MWCNTTEG-Pt(IV) group. It was 
speculated that such lower level of accumulation/deposition in the lungs likely 
avoided the intense immune response and escaped from rapid phagocytose by 
macrophages, which might be activated by a much larger uptake of MWCNTOX [478]. 
At 24 h time-point, MWCNTOX-Pt(IV) group still maintained 2.8% platinum content 
in the lungs, which is close to that in MWCNTTEG-Pt(IV) group. Therefore, we 
postulated that the clearance rate of MWCNTOX-Pt(IV) and MWCNTTEG-Pt(IV) from 
the lungs might be correlated with the amount internalized in this specific organ, 
while their final retention was comparable over the same period of time (i.e. 24 h). 
 
7.4.3 Production of inflammatory cytokines in serum 
To evaluate the effect of CDDP, Pt(IV) compound 6.1, MWCNTOX-CDDP/Pt(IV), 
and MWCNTTEG-CDDP/Pt(IV) complexes on inflammatory cytokine production, 
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which indicates the immune response, IL-1β, IL-6, and TNF-α levels in serum were 
measured by ELISA (Appendix III). Exposure to these compounds and complexes 
induced a slight increase in IL-1β level in serum compared with PBS control at 1 h 
and 4 h post-injection, although it was not statistically significant (P> 0.05). The 
increasing trend of IL-1β level in MWCNTOX-CDDP/Pt(IV) and MWCNTTEG-
CDDP/Pt(IV) groups is consistent with that in CDDP alone and Pt(IV) compound 6.1 
alone groups, except for 4 h treatment with MWCNTOX-Pt(IV) and MWCNTTEG-
Pt(IV), which produced higher IL-1β level in serum. This difference is probably 
associated with the persistent release of platinum-based compound from MWCNTOX 
and MWCNTTEG, as well as the resulting higher platinum concentrations in overall 
tissues compared with Pt(IV) compound 6.1 alone group. We also observed that the 
IL-1β level at 24 h post-injection in all treated groups declined to the same level as 
PBS control. This decrease might be attributed to the clearance of platinum-based 
compounds from mice, which has been shown in the biodistribution study (Fig. 7.6). 
We thereby postulated that the stimulation for IL-1β production mainly stemmed 
from the injection of platinum-based compounds. Moreover, MWCNTOX and 
MWCNTTEG as carriers did not result in any increased effect on the IL-1β production 
when they were co-administered with CDDP or compound 6.1, suggesting that the 
oxidised and amino-functionalized nanotubes themselves did not induce any 
additional inflammatory reaction once injected in mice. In addition, no significant 
changes were observed in the production of IL-6 and TNF-α in serum (P> 0.05) for 
all the samples, therefore indicating that the injection of the drugs alone or in 
combination with nanotubes was unable to increase the IL-6 level and TNF-α level. 
This observation is coincident with the results that no treatment-related microscopic 
findings were noticed in the exposed mice in additional histopathological 
investigations (as elaborated in the following paragraph). 
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7.4.4 Histopathology of mice tissues 
Each group of mice was sacrificed at 24 h post-injection with free CDDP or 
compound 6.1, various MWCNT-CDDP/Pt(IV) complexes, blank nanotubes, as well 
as PBS. The organs, including heart, lungs, liver, spleen, kidneys, and brain, were 
collected and processed with H&E staining for histological observation. There were 
no abnormalities (such as necrosis, inflammation, etc.) observed in all examined 
sections of tissues (Fig. 7.8). We postulated that such good biocompatibility of 
nanotubes and MWCNT-CDDP/Pt(IV) complexes in our study was likely due to the 
low-dose and short-period exposure, since the tissue injuries caused by nanotubes 
were reported both dose- and time-dependent [171, 205, 206, 213]. Therefore neither 
nanotubes (pristine MWCNTs, MWCNTOX, and MWCNTTEG) nor MWCNT-
CDDP/Pt(IV) complexes as drug carriers induced acute toxicity to mice during 24 h 
exposure in our study. 
 
Fig. 7.8 The histology of H&E stained liver, spleen, and kidney tissues (× 20) from 
mice treated with CDDP alone, MWCNTTEG-CDDP, and PBS at 24 h post-injection. 
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It was difficult to distinguish the aggregates of carbon nanotubes in tissue sections 
processed with H&E staining, since nanotubes in the tissues were agglomerated into 
large black maculas that appeared analogous to the dark pigment with H&E stain. 
However, occasionally, black aggregates were observed within Kupffer cells 
suggesting uptake of nanotubes (Fig. 7.9). In order to obtain a clear background for 
nanotubes observation, the sections of tissues were stained with only eosin. The 
results showed that the nanotubes, which assembled in the form of brown spots 
(similarly to the observations reported by Wu et al. [134]), could be found in the 
histological sections from the experimental groups treated with various nanotubes or 
MWCNT-CDDP/Pt(IV) complexes, while there was no such spot in sections from 
control group treated with PBS (Fig. 7.10). These results confirmed that the 
nanotubes could spread around the organs including heart, lungs, spleen, and kidneys, 
following 24 h exposure, which was in accordance with the results of the 
biodistribution study. 
 
Fig. 7.9 The histology of H&E stained liver showing Kupffer cells. 1—Kupffer cell 
with dark brown pigment; 2—Kupffer cell without pigment. 
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Fig. 7.10 The histology of only eosin stained liver tissues (× 20) from mice treated 
with (a) pristine MWCNTs alone, (b) MWCNTTEG-Pt(IV), and (c) PBS at 24 h post-
injection. The arrows point to the aggregates of nanotubes in the slices of liver. 
 
7.5 Conclusion 
In this chapter, CDDP and Pt(IV) compound 6.1 were entrapped within pristine 
MWCNTs, MWCNTOX, and MWCNTTEG to obtain a high drug loading inside the 
cavity of nanotubes. In order to investigate the effects of various nanotubes on the 
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biodistribution of platinum-based compounds, female BALB/c mice were exposed to 
free CDDP or compound 6.1, as well as MWCNT-CDDP/Pt(IV) complexes. The 
results showed that functionalized MWCNTs could significantly enhance the 
platinum content in almost all tissues and efficiently alter the tissue distribution in 
mice when co-administration with Pt(IV) compound. In addition, the nanotubes as 
drug carriers did not induce any additional inflammatory reaction or necrosis when 
injected in mice. Therefore functionalized nanotubes could be exploited as a 
promising nano-carrier to improve accumulation of therapeutic molecules in the lungs 
for an eventual therapeutic treatment. 
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In summary, we have optimized the encapsulation of anticancer drug cisplatin (CDDP) 
inside multi-walled carbon nanotubes (MWCNTs) using ethyl acetate via nano-
extraction method, obtaining a great drug loading of over 60% w/w, which allows 
MWCNTs to act as an efficient vehicle to carry drug molecules with high efficiency, 
in comparison with the previously reported encapsulation inside single-walled carbon 
nanotubes (SWCNTs). In vitro release of cisplatin, which was simulated in media of 
pH 7.4 and pH 5.5 (to mimic physiological conditions and tumoral environment, 
respectively), showed comparable and fast release from MWCNTs (approximately 89% 
and 93% of encapsulated cisplatin were released following 6 h immersion in media at 
pH 7.4 and pH 5.5, respectively), indicating that MWCNT-CDDP conjugate was not 
able to achieve a pH-responsive release. On account of the fact that the release rate of 
entrapped payload is correlated with the nanotubes’ diameter, we have proposed a 
“nano-bottle” strategy for controlling or slowing down the release by using “caps” to 
block the open ends of nanotubes. 
To accomplish the “nano-bottle” design, we have used 4 nm small gold nanoparticles 
(AuNPs) as “caps” to plug the open tips of nanotubes after encapsulation of cisplatin. 
Micrographs showed that these AuNPs were located at the tubes’ extremities, and in 
vitro release displayed a slower release rate of cisplatin from the capped nanotubes 
than the uncapped ones. Therefore this “nano-bottle” could prolong the period of drug 
release and avoid premature release in bodily fluid, allowing enhanced cellular uptake 
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of cisplatin by tumor cells. Cytotoxicity assays against MCF-7 breast cancer cells 
showed a remarkably improved antitumor efficacy of capped MWCNT-CDDP (IC50 
value 7.74 µM), in comparison with cisplatin alone (IC50 value 11.74 µM) and 
uncapped MWCNT-CDDP (IC50 value 12.92 µM). 
We have also designed an alternative “nano-bottle” strategy based on the attachment 
of 40 nm large AuNPs to the open-tips of MWCNTs via cleavable bonds. Among the 
3 explored strategies (namely hydrazine bonds, ester bonds and disulfide bonds) the 
entrapped cisplatin could be readily released from “nano-bottles” containing disulfide 
linkage in 1 mM DTT aqueous medium (to mimic reductive environment inside 
tumor cells); conversely, relatively less drug was discharged under thiol free 
conditions. The cell viability assays of HCT-116 tumor cells and IMR-90 normal 
cells suggested that the capped disulfide “nano-bottles” exerted stronger cytotoxic 
effect on HCT-116 than IMR-90 especially at high concentrations. Therefore the 
cleavable “nano-bottles” provide a proof-of-concept on “smart” drug delivery system 
capable of attaining selective release of payload in tumor cells while avoiding 
harmful effects in normal cells. 
We have involved platinum-based prodrug (which has poor water solubility and 
displays inertness in its prodrug form) in the study on controlled-release drug delivery 
system. The highly hydrophobic Pt(IV) complex (logP value 2.19) was engineered to 
be encapsulated inside MWCNTs using CHCl3 via nano-extraction method and to 
achieve a selective release as cytotoxic Pt(II) species upon chemical reduction (in the 
presence of 3 mM ascorbic acid) that elicits a drastic reversal in hydrophobicity. The 
released Pt(II) species were functionally analogous to cytotoxic cisplatin, capable of 
forming similar Pt-dGMP adducts. The intracellular platinum level of A2780 cells 
treated with this MWCNT-Pt(IV) complex suggested that nanotubes were able to 
penetrate cell membrane and transport the platinum payload into cancer cells. This 
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simple method for utilising Pt(IV) prodrug to obtain controlled release by chemical 
reduction and hydrophobicity reversal, could provide the framework for future studies 
on targeted delivery of platinum drugs into cancer cells. 
With the purpose to investigate the effect of delivery through nanotubes on the 
distribution of platinum-based drugs in vivo, cisplatin and Pt(IV) prodrug were 
encapsulated inside various nanotubes (i.e. pristine MWCNTs, oxidised MWCNTox, 
and amidated MWCNTTEG, respectively), and mice were treated with these MWCNT-
drug complexes via intravenous injection. The platinum levels in vital organs 
suggested that functionalized nanotubes could significantly enhance the drug content 
of Pt(IV) compound in some tissues and efficiently alter the tissue distribution in 
mice, especially the increased accumulation tendency in the lungs. Moreover, the 
nanotubes as vehicle for drug delivery did not induce any abnormal immune or 
histopathological responses. Therefore, the functionalized nanotubes could be a safe 
and efficient nano-carrier to improve the drug accumulation in targeted tissues or 
organs. 
Overall, this study systematically investigated the entrapment of platinum-based 
drugs within MWCNTs, and the consequent effects on in vitro antitumor efficacy and 
in vivo drug distribution, providing a basis for the research on nanotubes as a carrier 
in drug delivery. 
 
8.2 Future perspectives 
Although a “nano-bottle” construct has been engineered to achieve high-performance 
drug delivery, we will make much effort to promote further advance in exploiting 
nanotubes as drug delivery system. Future work should therefore include the 
following parts: 
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(1) We will tether targeted ligands or peptides to “nano-bottles” to improve their 
targeting delivery to diseased sites, thus more efficiently enhancing the potency 
of entrapped drugs against cancers and reducing side effects in normal tissues. 
(2) The treatment effect of CNT-based drug delivery system will be compared with 
other nanomaterials (e.g., nanoparticles, liposomes, micelles, dendrimers) used 
for drug delivery. 
(3) The “nano-bottles” will be labelled with fluorophore to track them in cells or 
animals, hence allowing more specific biodistribution study. 
(4) We will investigate the toxicity of CNTs and drug-loaded “nano-bottles” to mice 
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Appendix I UV-vis spectra of 4 nm bare (left) and functionalized (right) AuNPs. 
UV-vis spectra analysis confirmed the successful surface functionalization of AuNPs 
with ODT, by showing an increase in SPR λmax (i.e. a red shift) from 528 nm (for 4 






Appendix II FT-IR spectra of (a) ODT and (b) ODT-f-AuNPs. The IR spectrum of 
ODT-f-AuNPs resembled the spectrum of ODT closely. This suggests that ODT 
molecules were successfully attached to the AuNPs. The IR vibrational bands at 
approximately 1,260 cm-1 corresponded to CH2-S wagging, while the weak intensity 
peaks at approximately 2,380 cm-1 could be attributed to S-H stretching. The absence 
of the peaks at 2,380 cm-1 in the spectrum of ODT-f-AuNPs supported the idea that 
ODT molecules were attached to the AuNPs via the formation of Au-S bond, which 
resulted in the dissociation of S-H bond and hence the loss of S-H stretching vibration 









Appendix III Serum immunological indicator levels of the control mice and the 
MWCNT/Pt-based drug exposed mice at 1 h, 4 h, and 24 h post- exposure. (a) IL-1β 
levels; (b) IL-6 levels; (c) TNF-α. Data are represent as Mean ± SD (n=3). 
 
